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THE SURPRISING REACH OF FDA 
REGULATION OF CANNABIS,  
EVEN AFTER DESCHEDULING 
SEAN M. O’CONNOR* 
ERIKA LIETZAN** 
As more states legalize cannabis, the push to “deschedule” it from the 
Controlled Substances Act is gaining momentum.  At the same time, the Food 
and Drug Administration (FDA) recently approved the first conventional drug 
containing a cannabinoid derived from cannabis—cannabidiol (CBD) for two 
rare seizure disorders.  This would all seem to bode well for proponents of full 
federal legalization of medical cannabis.  But some traditional providers are 
wary of drug companies pulling medical cannabis into the regular small 
molecule drug development system.  The FDA’s focus on precise analytical 
characterization and on individual active and inactive ingredients may be 
fundamentally inconsistent with the “entourage effects” theory of medical 
cannabis.  Traditional providers may believe that descheduling cannabis would 
free them to promote and distribute their products free of federal intervention, 
both locally and nationally.  Other producers appear to assume that descheduling 
would facilitate a robust market in cannabis-based edibles and dietary 
supplements.  In fact, neither of these things is true.  If cannabis were descheduled, 
the FDA’s complex and comprehensive regulatory framework governing foods, 
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drugs, and dietary supplements would preclude much of this anticipated 
commerce.  For example, any medical claims about cannabis would require the 
seller to complete the rigorous new drug approval process, the cost of which will 
be prohibitive for most current traditional providers.  Likely also unexpected to 
some, there is no pathway forward for conventional foods containing cannabis 
constituents, with the (probably exclusive) exception of certain hemp seed 
ingredients, if those foods cross state lines.  And it will certainly come as a shock 
to many that federal law already prohibits the sale of dietary supplements 
containing CBD—including those already on the market as well as those made 
from “hemp,” which has recently been descheduled under the 2018 Farm Bill.  
This Article describes in detail the surprising reach of the FDA and then outlines 
three modest, but legal, pathways forward for cannabis-based products in a 
world where cannabis has been descheduled. 
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INTRODUCTION 
As a number of states have legalized cannabis—at least for state law 
purposes—a quasi-licit above-ground industry has emerged.1  This 
industry is enormous, with estimates into the billions of dollars of 
annual revenues.2  Along with this economic opportunity, one of the 
selling points of legalization for voters is that an illicit and often 
dangerous underground industry will be transformed into a safe and 
well-regulated one.3 
Yet, “marihuana”—defined to include much of what is derived from 
the plant Cannabis sativa L.4—is still illegal under the federal 
Controlled Substances Act (CSA).5  “Marihuana” is expressly listed in 
Schedule I of the CSA,6 which means there were government findings, 
credible or not,7 that:  (1) it “has a high potential for abuse”; (2) it “has 
                                               
 1. State Medical Marijuana Laws, NAT’L CONF. ST. LEGISLATURES (Oct. 17, 2018), 
http://www.ncsl.org/research/health/state-medical-marijuana-laws. 
 2. See, e.g., Thomas Pellechia, Legal Cannabis Industry Poised for Big Growth, in North 
America and Around the World, FORBES (Mar. 1, 2018), https://www.forbes.com/ 
sites/thomaspellechia/2018/03/01/double-digit-billions-puts-north-america-in-the-w 
orldwide-cannabis-market-lead (estimating North American industry revenues in 2017 
at $9.2 billion). 
 3. See, e.g., 2013 Wash. Legis. Serv. Ch. 3 § 1 (West) (“The people intend to stop 
treating adult marijuana use as a crime and try a new approach that: . . . (3) Takes 
marijuana out of the hands of illegal drug organizations and brings it under a tightly 
regulated, state-licensed system similar to that for controlling hard alcohol.”). 
 4. 21 U.S.C. § 802(16) (2012).  For further details on the origin and exact scope 
of this definition, see infra Part II. 
 5. 21 U.S.C. §§ 801–904. 
 6. See § 812(c), Schedule I(c)(10). 
 7. Am. Coll. Physicians, Supporting Research into the Therapeutic Role of 
Marijuana:  An Addendum by the Health and Public Policy Committee 17 (2008) 
(“Considering the evidence available today about the potential therapeutic benefits 
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no currently accepted medical use in treatment in the United States”; 
and (3) “[t]here is a lack of accepted safety” for use of the drug or 
other substance under medical supervision.8  Tetrahydrocannabinols 
(THC) and cannabimimetic agents (compounds that mimic the effects of 
cannabinoids) are also listed in Schedule I.9  Manufacturing, distributing, 
dispensing, or possessing with the intent to do any of the foregoing is 
allowed under the CSA only for individuals who have been issued a so-called 
“Schedule I license.”10  These licenses are rare and hard to come by.11 
The Department of Justice (DOJ), and more specifically, the Drug 
Enforcement Agency (DEA) generally enforce the CSA.12  Their 
actions with regard to illicit trade in drugs are usually perceived to be 
straightforward criminal prosecutions:  “Miami Vice”- or “Cops”-style 
drug busts.13  There is a misperception that such enforcement is not 
available in states with recreational or medical marijuana laws, at least 
with regard to state law-compliant cannabis enterprises.14  The reality 
                                               
and risks associated with marijuana and its cannabinoids, ACP believes that it is time 
to review the evidence to determine whether reclassification is appropriate.”). 
 8. § 812(b)(1)(A)–(C); see also infra Part II. 
 9. See § 812(c); § 812(d)(2)(A). 
 10. §§ 821–823; Synthetic Drugs, Real Danger:  Hearing Before the Subcomm. on 
Crime, Terrorism, Homeland Sec. & Investigations of the H. Comm. on the Judiciary, 
114th Cong. 4 (2016) (statement of David Earl Nichols, Ph.D., Adjunct Professor of 
Chemical Biology and Medicinal Chemistry at the University of North Carolina at 
Chapel Hill, NC) (“Obtaining a Schedule I license is not a trivial matter . . . .  [T]he 
investigator must have a strong personal belief that something useful will be discovered 
by their research that is of sufficient importance to justify the regulatory demands of a 
Schedule I license.  To wit, a researcher must submit an application to the DEA that 
includes the investigator’s scientific credentials, the description of the laboratory, a 
precise description of the work to be carried out, listing the specific substance to be 
used, and a calculation of how much substance will be needed and for how long.  If 
the DEA determines that the . . . license is justified, there is then an inspection of the 
storage facility . . . to ensure that the controlled substance cannot be easily 
diverted . . . .  Inventory and use must be documented, and there is a license fee for 
most non-public institutions.”). 
 11. See NAT’L ACADS. SCIS. ENG’G & MED., THE HEALTH EFFECTS OF CANNABIS AND 
CANNABINOIDS:  THE CURRENT STATE OF EVIDENCE AND RECOMMENDATIONS FOR RESEARCH 
378–84 (2017) [hereinafter THE HEALTH EFFECTS OF CANNABIS]. 
 12. BRIAN YEH, CONG. RESEARCH SERV., RL34635, THE CONTROLLED SUBSTANCES 
ACT:  REGULATORY REQUIREMENTS 1 (2012). 
 13. See Sean M. O’Connor & Jason Liu, The Risks of Clouded Property Title for Cannabis 
Business Owners, Investors, and Creditors, 3 TEX. A&M J. PROP. L. 67, 68 (2016). 
 14. See id. (“[B]ecause federal law does not distinguish between shadowy 
underworld drug deals and the clean, well-lit places licensed and regulated under the 
new state-legal regimes, all of the forfeiture rules apply equally to both.  Accordingly, 
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here again is further complicated by current DOJ policy and by an 
annual congressional appropriations rider prohibiting the use of funds 
for cannabis prosecution.15  Aside from cannabis drugs approved by 
the Food and Drug Administration (FDA), and cannabis production 
and research licensed by the National Institute of Drug Abuse (NIDA), 
all cannabis production, distribution, or sale violate federal criminal 
law under the CSA. 
State decriminalization of medical marijuana (MMJ) in the 1990s 
began flipping this dynamic.16  At the same time, even the federal 
government was forced to provide cannabis to some patients under 
“compassionate use” programs.17  Accordingly, the DOJ and the DEA 
did not act as aggressively as they could have in relation to cooperatives 
and dispensaries operating under first California’s, and then other 
states’, MMJ quasi-legal frameworks.18  An uneasy partial truce was 
established for patients who grew their own MMJ for personal use 
because this was a grey area under the CSA as it did not involve 
distributing or dispensing the substance to others, and the 
“manufacturing” and possession was not for the purpose of distributing 
or dispensing to others either. 
This was the opening for cooperatives, and ultimately, dispensaries:  
if a patient can grow cannabis for her own personal use, then she 
should also be able to share resources for growing with other MMJ 
patients.  Accepting this premise, courts also had difficulty settling on 
anything like a uniform minimum level of patient-member 
participation, and so soon, effectively non-working members were 
allowed.19  All that was needed was the minor formality of a member 
card showing one had joined the co-op, perhaps with a doctor’s note 
recommending cannabis to alleviate some symptoms.20 
                                               
the façade of legitimacy and regularity rapidly attaching to the most well-intentioned 
state-legal cannabis businesses is, of course, quite illusory.”). 
 15. See infra Part II. 
 16. See id. at 71–72. 
 17. See infra Part III. 
 18. See infra Part II. 
 19. See Alex Kreit, Reflections on Medical Marijuana Prosecutions and the Duty to Seek 
Justice, 89 DENV. U. L. REV. 1027, 1041–44 (2012) (discussing various court decisions 
on how much participation is required of a member of a marijuana cooperative). 
 20. See Gerald Caplan, Medical Marijuana:  A Study of Unintended Consequences, 43 
MCGEORGE L. REV. 127, 144 (“Routinely identifying individuals who are growing more 
than the number of plants legally allowed, who purchased a fake recommendation or 
forged one themselves . . . is impossible, except by happenstance.”).  Thus, case law 
soon established a free-speech right for doctors to recommend, but not necessarily 
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With state MMJ laws enabling these quasi-licit cannabis enterprises—
effectively commercial businesses—and DOJ and DEA restraining their 
enforcement efforts under the CSA, other federal regulatory agencies 
began treating these operations as any other (licit) businesses.  
Nevertheless, cannabis and illicit drug operations can violate a host of 
other federal laws and regulations beyond the CSA—e.g., dumping 
pollutants, dangerous work environments (to put it mildly), using 
banned or improper pesticides, and discriminatory employment and 
business practices.21  However, the respective federal agencies 
enforcing these laws traditionally have not been on the front lines with 
the DEA, busting down doors of derelict warehouses.22  To be clear, 
many MMJ co-ops and dispensaries appear to be well-run and 
compliant with laws and regulations.  And some that were not fully 
                                               
“prescribe,” cannabis to clients.  E.g., Conant v. Walters, 309 F.3d 629, 639 (9th Cir. 
2002) (“[W]hether a doctor-patient discussion of medical marijuana constitutes a 
‘recommendation’ depends largely on the meaning the patient attributes to the 
doctor’s words.  This is not permissible under the First Amendment.”).  Excellent 
summaries of this history can be found elsewhere.  See generally DOUGLAS A. BERMAN & 
ALEX KREIT, MARIJUANA LAW AND POLICY (forthcoming 2019); ROBERT A. MIKOS, 
MARIJUANA LAW, POLICY, AND AUTHORITY (2017); Kathleen Ferraiolo, From Killer Weed to 
Popular Medicine:  The Evolution of American Drug Control Policy, 1937–2000, 19 J. POL’Y. 
HIST. 147 (2007). 
 21. Stephen Lee, Workplace Violations Found in Marijuana Sector, BLOOMBERG L.:  
OCCUPATIONAL SAFETY (Aug. 27, 2015), https://www.bloomberglaw.com/document/ 
X60LREIK000000 (reporting on workplace hazards associated with the marijuana 
industry); Bart Schaneman, Costly Employment-Related Lawsuits on the Rise in Cannabis 
Industry as MJ Workforce Grows, MARIJUANA BUS. DAILY (Oct. 18, 2017), 
https://mjbizdaily.com/costly-employment-related-lawsuits-rise-cannabis-industry-mj-
workforce-grows (reporting on “an increasing number of lawsuits over everything from 
wrongful termination and discrimination to sexual harassment”); Shannon Service, 
Pot:  Not so Green After All?, PBS:  NEED TO KNOW (May 21, 2010), http://www.pbs.org 
/wnet/need-to-know/environment/pot-not-so-green-after-all (discussing the marijuana 
industry’s environmental impact, including diesel spills and toxic pesticides that wash 
into rivers). 
 22. See Lee, supra note 21 (explaining that “because marijuana remains an illegal 
narcotic at the federal level, the EPA hasn’t taken action, leaving growers in murky 
legal terrain,” and reporting that the Occupational Safety and Health Administration 
is collaborating with Colorado’s health department on “advisory efforts”).  The 
exception might be the Internal Revenue Service (IRS), which has had a surprisingly 
prominent role taking down gangsters and criminals for tax evasion since the early 
twentieth century.  See, e.g., United States v. Hurley, 957 F.2d 1, 2, 7–8 (1st Cir. 1992) 
(upholding a jury verdict that found two lawyers guilty of conspiracy to defraud the 
Internal Revenue Service because they had helped a drug smuggler hide millions of 
dollars earned from distributing marijuana and hashish). 
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compliant may have been the result of good faith lack of knowledge, 
especially given their largely unregulated status.  
At the same time, MMJ regime enterprises were fairly restrained 
affairs with little open advertising or public promotion.  The physical 
sites of dispensaries were generally nondescript, with little to indicate 
what was going on inside other than the ubiquitous green crosses seen 
in robust MMJ states like California, Oregon, and Washington.  
Accordingly, federal agencies of all kinds took a hands-off approach to 
these ventures, leaving regulation to the states.  
Our focus here is on the FDA.  Under MMJ regimes, whatever 
medical or health claims were being made occurred either in semi-
private conversations in dispensaries, among users in person, or in 
chat-room-type environments on the internet.  With little evident 
interstate activity—mandated, in fact, by the state MMJ laws 
themselves—the FDA’s jurisdiction under the Federal Food, Drug, and 
Cosmetic Act (FDCA)23 was limited.  Enacted under the Commerce 
Clause,24 the FDCA permits the FDA to regulate only products that 
travel or have traveled in interstate commerce, as discussed in more 
detail in Part III.  However, with both recreational and medical 
cannabis businesses emboldened by state legalization, overt marketing 
and sales activities in interstate commerce prompted the FDA to take 
enforcement action, also as reviewed in Part III.  One of the Authors 
has had significant discussions with the state-legal recreational and 
medical industries and can report that FDA regulation is poorly 
understood and largely ignored for the time being.25 
At the same time, this grey market for medical cannabis under state 
MMJ regimes was highly advantageous for those who wished “to do 
good and do well” in the industry.26  While recent state regimes for 
legal recreational cannabis have heavily taxed various levels of the 
production value chain, state MMJ regimes generally did not tax 
                                               
 23. 21 U.S.C. §§ 301–399h (2012). 
 24. U.S. CONST. art. I, § 8, cl. 3 (“The Congress shall have Power . . . [t]o regulate 
Commerce with foreign Nations, and among the several States, and with the Indian 
Tribes . . . .”). 
 25. See Lee, supra note 21 (“Because growers, processors and sellers in states where 
marijuana is now legal have operated outside the law for so long, they have learned to 
ignore federal and state regulations . . . .”). 
 26. See Terra Carver, Executive Director, Humboldt County Growers Alliance, INFOCAST 
(Oct. 3, 2018), https://infocastinc.com/market-insights/cannabis/terra-carver-
humboldt-county-growers-alliance (commenting that “the combined medical and 
adult-use [marijuana] market may be worth $5 billion by 2019 in California alone,” 
and mentioning that cannabis use appears to displace opioid use to some extent). 
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medical cannabis.27  Part of this was because no sales of goods were 
supposed to be occurring:  again, the idea was that all patients would 
participate in a co-op-type structure to produce communally the product 
they all used, or patients would produce solely for their personal medical 
cannabis use.28  Nonetheless, with low tax, little to no regulations that 
regular commercial businesses are subject to, and a growing influx of 
essentially recreational users, the dispensaries did quite well.29  Further, 
long-standing loyalty to producers and dispensaries that provided 
consistent strains with perceived or quantifiable effects—for both 
medical and recreational purposes—ensured stable customer bases.30 
Unsurprisingly then, many of these enterprises were wary of—or 
actively opposed—legalization efforts for recreational use.31  Correctly, 
they sensed that legalization would bring full regulation and taxation,32 
not to mention broad free-market competition and a commoditized 
vice approach to cannabis (in which cannabis would be regulated and 
                                               
 27. See, e.g., Taxes Due on Marijuana, WASH. DEP’T OF REVENUE, 
https://dor.wa.gov/print/46568 (last visited Feb. 5, 2019).  But see Lisa Rough, 
Cannabis Tax Rates:  A State by State Guide, LEAFLY, https://www.leafly.com/news 
/industry/marijuana-tax-rates-by-state (listing Alaska, California, Delaware, District of 
Columbia, Maine, Massachusetts, New Hampshire, New Mexico, North Dakota, 
Oregon, Vermont, and West Virginia among the states that did not tax medical 
cannabis as of late 2017). 
 28. See, e.g., WASH. REV. CODE § 69.51A.085 (2011) (repealed 2016) (providing that 
“qualifying patients” could participate in collective gardens for growing cannabis, but 
prohibiting more than ten qualifying patients per garden along with the delivery of 
cannabis to anyone other than the collective garden’s qualifying patients). 
 29. From Less than $100K to Millions of Dollars, Annual Marijuana Dispensary Revenues 
Run the Gamut, MARIJUANA BUS. DAILY (Apr. 10, 2013), https://mjbizdaily.com/from-
less-than-100k-to-millions-of-dollars-annual-marijuana-dispensary-revenues-run-the-
gamut (discussing the self-reported annual revenues of MMJ dispensaries, with 15% 
reporting less than $100,000; 27% reporting between $100,000 and $250,000; 18% 
reporting between $250,000 and $500,000; 15% reporting between $500,000 and $1 
million; and 25% reporting over $1 million). 
 30. See, e.g., What Do Marijuana Strain Names Mean?  Does it make a Difference?, 
GROWNROGUE, https://www.grownrogue.com/meaning-marijuana-strain-names (last 
visited Feb. 5, 2019) (describing how customers look for quality and consistency when 
checking their preferred strains and dispensaries, often relying on characteristics such 
as flower, aroma, taste, and how the strains make them feel). 
 31. Evan Puschak, Why the Medical Marijuana Industry Opposes Full Legalization, 
MSNBC:  THE LAST WORD WITH LAWRENCE O’DONNELL (July 29, 2013, 11:07 PM), 
http://www.msnbc.com/the-last-word/why-the-medical-marijuana-industry-opposes. 
 32. See, e.g., 2013 Wash. Legis. Serv. Ch. 3 (I.M. 502) §§ 26–27 (West). 
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sold similar to alcohol and tobacco).33  None of this would have been 
particularly helpful to medical cannabis enterprises, although one could 
argue that legalization at the federal level would remove the ongoing 
threat of prosecution under the CSA.  Some medical cannabis 
proponents thus focused on rescheduling cannabis so that it would be 
treated like a prescription drug, rather than a narcotic with “no currently 
accepted medical use.”34  Rescheduling theoretically could have kept it 
from becoming a commoditized vice substance, while also opening a path 
to federally-compliant prescriptions under FDA and DEA regulations. 
State legalization for recreational purposes has indeed not been 
great for medical cannabis businesses.  First, there has been a flood of 
commercial cannabis businesses into states that have legalized 
cannabis, which has been tempered only by limits on the number of 
grower, processor, and retailer licenses that these states are willing to 
grant.35  Second, in some states, medical cannabis businesses have had 
to become licensed for the new regulated and taxed recreational 
systems.36  Third, and most challengingly, the FDA has increased its 
enforcement in light of widespread public advertisements and 
promotions, including medical claims, by commercial medical 
cannabis outfits.37  Unlike these commercial medical cannabis outfits, 
the dispensaries had been very low-key and discrete in their public 
advertising and promotions, largely because this was also a grey area 
under state MMJ laws.38  With general legalization in various states 
allowing for a higher and more explicit level of branding, advertising, 
marketing, and promotion than was allowed in the medical cannabis 
                                               
 33. Vice Wars:  Tobacco, Alcohol and the Rise of Big Marijuana, NBC NEWS (Nov. 22, 
2014, 1:46 PM), https://www.nbcnews.com/storyline/legal-pot/vice-wars-tobacco-
alcohol-rise-big-marijuana-n253801. 
 34. 21 U.S.C. § 812(b)(1)(B) (2012); see also Grace Wallack & John Hudak, Marijuana 
Rescheduling:  A Partial Prescription for Policy Change, 14 OHIO ST. J. CRIM. L. 207, 208 (2016) 
(noting arguments that a Schedule change for marijuana might “better reflect[] the 
medical, safety, chemical, and pharmacological realities of the substance”). 
 35. See, e.g., Marijuana Licensing, WASH. STATE LIQUOR & CANNABIS BD., 
https://lcb.wa.gov/mjlicense/marijuana-licensing (last visited Feb. 5, 2019). 
 36. See, e.g., id. 
 37. See infra Part III. 
 38. See THE HEALTH EFFECTS OF CANNABIS, supra note 11, at 68–69, 72–73 (“Medical 
cannabis law and policies vary greatly in terms of the regulations governing supply and 
use . . . .  Some states protect and regulate the operation of storefronts known as 
dispensaries . . . .  Some dispensaries openly advertise their wares and services to 
patients at point of sale, with others aggressively promoting their business to the 
general public.”). 
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regimes, the race is now on to sell one’s expertise, services, and 
product attributes in whatever way one can.  
The end result may be the FDA cracking down hard—perhaps in 
conjunction with state governments—on medical claims and any 
positioning of cannabis products as medical without successful 
completion of the arduous and expensive new drug application (NDA) 
process.39  Further, given the high degree of reproductive variability of 
cannabis, as indicated by new genetic tests being done on a range of 
samples,40 it is unlikely that the psychoactive part of cannabis in its 
natural state, and the way in which it is traditionally rolled and smoked, 
would give anywhere near the predictable and quantifiable product 
and clinical test results needed to satisfy the FDA under the NDA 
process.41  While proponents of medical cannabis may assume that the 
flower could simply be marketed as a dietary supplement outside the 
new drug framework, dietary supplement options are quite limited.42  
Nor is marketing of medical cannabis in food an easy alternative, given 
the FDA’s complex framework for food regulation and its interaction 
with the new drug framework.43 
After all, there were very good reasons why Congress passed the Pure 
Food and Drugs Act in 1906,44 and its successor, the FDCA, in 1938.45  
Reformers at the turn of the last century and in the early decades of 
the twenty-first century sought to protect consumers from tainted, 
adulterated, toxic, mislabeled, or ineffective “patent medicines” and 
proverbial snake oils.46  This is not to disparage or discredit medical 
cannabis as a general matter, but rather to say that there is good reason 
to require clinical proof that any particular product or process has the 
actual therapeutic benefits that are claimed (i.e., that the product or 
process is effective), and that it is safe enough for the indicated use.  The 
question of federal regulation of medical cannabis is thus complex.   
This Article focuses only on regulation under the FDCA, in the event 
that cannabis is descheduled from the CSA, and for certain products 
                                               
 39. See infra Section III.A. 
 40. See infra Part II. 
 41. See infra Section III.A. 
 42. See infra Section III.C. 
 43. See infra Section III.B. 
 44. Pub. L. No. 59-384, 34 Stat. 768 (1906). 
 45. Pub. L. No. 75-717, 52 Stat. 1040 (1938) (codified as amended at 21 U.S.C. 
§§ 301–399h (2012)). 
 46. See Erika Lietzan, The Drug Innovation Paradox, 83 MO. L. REV. 39, 46–50 (2018) 
(cautioning that “‘patent medicines’ . . . should not be confused with ‘patented’ drugs”). 
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derived from the newly descheduled “hemp.”47  While some might 
suspect that a Congress willing to deschedule cannabis would be 
willing to amend the FDCA to allow the free-form expansion of 
medical cannabis production, marketing, and sale that some 
proponents and commentators advocate,48 this does not necessarily 
follow.  Indeed, FDA Commissioner Scott Gottlieb laid out the 
compelling reasons why FDA should continue to regulate not only 
hemp products, but any product containing substances classified as a 
drug by the FDA—which includes THC and cannabidiol (CBD)—or 
for which medical claims are made, regardless of their CSA status.49  
The Article chooses descheduling over rescheduling because it calls 
the relevant questions of FDA regulation into starker relief and 
because it may be more politically feasible than conventional wisdom 
holds—especially with both Democrats and Republicans now 
espousing states’ rights.50  Further, the analysis for rescheduling is 
effectively contained within that for descheduling.  In particular, many 
Democrats and progressives would like to see the federal government 
allow state legal cannabis systems to expand with no threat of 
intervention, even as President Trump has signaled a willingness to 
allow the states to decide for themselves (with states’ rights long a 
plank in Republican party politics).51 
                                               
 47. See supra notes 225–28, 406. 
 48. Frank Robison, Going Green:  Legal Considerations for Marijuana Investors and 
Entrepreneurs, 6 AM. U. BUS. L. REV. 57, 79–80 (2016) (“[T]he marijuana industry’s best, 
perhaps only, hope to achieve commercial parity with other industries is for the federal 
government to eliminate marijuana as a Schedule I controlled substance.  This, 
however, will alter the legal and commercial landscape altogether . . . .”). 
 49. Statement from FDA Commissioner Scott Gottlieb, M.D., on Signing of the 
Agriculture Improvement Act and the agency’s regulation of products containing 
cannabis and cannabis-derived compounds (Dec. 20, 2018) [hereinafter Statement on 
Signing of the Agriculture Improvement Act], https://www.fda.gov/NewsEvents/ 
Newsroom/PressAnnouncements/ucm628988.htm?utm; see also infra Part III. 
 50. Tom Angell, Democrats Forming Marijuana Legalization Consensus, FORBES, Feb. 
15, 2018, https://www.forbes.com/sites/tomangell/2018/02/15/democrats-forming-
consensus-on-marijuana-legalization (noting support for marijuana legalization 
among Democratic and Republican members of Congress and quoting Senate 
Democratic Leader Chuck Schumer’s statement that “the States should continue to be 
the labs of democracy when it comes to recreational & medical marijuana”). 
 51. See id.; Evan Halper, Trump Administration Abandons Crackdown on Legal 
Marijuana, L.A. TIMES (Apr. 13, 2018), http://www.latimes.com/politics/la-na-pol-
marijuana-trump-20180413-story.html (reporting that “[t]he Trump administration 
[wa]s abandoning a Justice Department threat to crack down on recreational 
marijuana in states where it is legal,” and that Republican Senator Cory Gardner of 
Colorado, who had been “incensed” by the Department’s threat, “said he was assured 
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Some notes on terminology are warranted.  First, this Article uses 
“cannabis” to cover the plant and its products except where referring 
to the defined legal category of “marihuana” under the CSA.52 
“Marijuana” has unfortunate discriminatory and racial undertones to 
many and is seen by some as imposed by anti-immigrant and, 
pointedly, anti-Mexican activists in the early twentieth century.53  
“Cannabis,” by contrast, is the older and more widely accepted name 
of the plant, and indeed forms the basis of the scientific names of the 
two major strains or species (speciation is contested):  Cannabis sativa 
L. and Cannabis indica Lam.54  Further, states, like Washington, with 
advanced medical and recreational cannabis regimes have switched 
over to “cannabis” as well.55 
                                               
that the federal government would not interfere with his state’s marijuana industry 
and that Trump would champion a new law that gives states the authority to set their 
own pot policies”). 
 52. 21 U.S.C. § 802(16). 
   53.  See Matt Thompson, The Mysterious History of ‘Marijuana,’ NAT’L PUB. RADIO:  
CODE SWITCH (July 22, 2013, 11:46 AM), 
https://www.npr.org/sections/codeswitch/2013/ 07/14/201981025/the-mysterious-
history-of-marijuana (“Numerous accounts say that ‘marijuana’ came into popular 
usage in the U.S. in the early 20th century because anti-cannabis factions wanted to 
underscore the drug’s ‘Mexican-ness.’  It was meant to play off of anti-immigrant 
sentiments.”); see also Alex Halperin, Marijuana:  Is it Time to Stop using a Word with Racist 
Roots?, GUARDIAN, (Jan. 29, 2018), https://www.thegu 
ardian.com/society/2018/jan/29/marijuana-name-cannabis-racism (“For the 
prohibitionists of nearly a century ago, the exotic-sounding word emphasized the 
drug’s foreignness to white Americans and appealed to the xenophobia of the time. 
As with other racist memes, a common refrain was that marijuana would lead to 
miscegenation.  Harry Anslinger, the bureaucrat who led the prohibition effort, is 
credited as saying back then: ‘There are 100,000 total marijuana smokers in the US, 
and most are Negroes, Hispanics, Filipinos and entertainers. Their Satanic music, jazz 
and swing result from marijuana use. This marijuana causes white women to seek 
sexual relations with Negroes, entertainers and any others.’”). 
 54. See Ethan B. Russo, Review, History of Cannabis and Its Preparations in Saga, Science, 
and Sobriquet, 4 CHEMISTRY & BIODIVERSITY 1614, 1616–19 (2007) (discussing the taxonomy 
of cannabis); Thompson, supra note 55 (“Throughout the 19th century, news reports and 
medical journal articles almost always use the plant’s formal name, cannabis.”). 
 55. For example, in 2011, the Washington legislature amended its MMJ statute, 
renaming the section “The Washington state medical use of cannabis act,” and 
replacing the word marijuana with cannabis throughout the statute.  See 2011 Wash. 
Legis. Serv. Ch. 181 (West) (including amendments to Wash. Rev. Code § 69.51A.005 
and § 69.51A.900).  However, although the legislature has retained the statute’s title—
”the Washington state medical use of cannabis act”—in 2015, an amendment switched 
cannabis back to marijuana throughout the statute.  See WASH. REV. CODE 
§§ 69.51A.005–69.51A.900 (2015); 2015 Wash. Legis. Serv. Ch. 70 (West). 
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Second, this Article uses “medical cannabis” to refer to growth, 
production, processing, sale, and use of cannabis or its derivatives for 
health or medical benefits.  Similar to “cannabis,” we use “medical 
marijuana” or “MMJ” only when referring to the legal, statutory 
categories created under state laws. 
Third, “descheduling” means congressional amendment of the CSA 
to remove “marihuana”—or at least some parts of that broad statutory 
term—from any of the restricted Schedules of controlled substances.  
Descheduling should also include DEA action to remove medically 
relevant components of cannabis, such as THC and CBD, as well as 
synthetically-produced analogues, that it has placed in any of the 
controlled substances Schedules under its statutory authority granted 
under the CSA.  Full descheduling would mean that (medical) 
cannabis is no longer a controlled substance at any level. 
Fourth, “rescheduling” means that Congress amends the CSA to 
place “marihuana” into a less restrictive Schedule.  Likewise, for full 
rescheduling, the DEA would also move any medically relevant natural 
or synthetic cannabis components that it has placed on Schedule I 
down to the same or lower Schedule as “marihuana” would now 
occupy.  Rescheduling means that (medical) cannabis would still be a 
controlled substance, but it would be easier to pursue clinical trials and 
new drug approvals with compounds derived from the plant.  Further, 
over-the-counter (non-prescription) status for those drugs would at 
least be theoretically possible (although unlikely). 
Fifth, “traditional medical cannabis” means use of the plant in more 
or less natural form with minimal processing. This includes not only 
the familiar rolling and smoking of resinous flower or buds of the 
plant, but also simple processes such as making butter, oils, or tinctures. 
It can be contrasted with what might be called the pharmaceutical 
approach in which a particular molecule is identified and then purified 
or isolated, often through more sophisticated means. 
Ultimately, we find only three pathways for “federal-legal” medical 
cannabis after descheduling, should that occur. Importantly, this 
includes CBD products that contain little to no THC and even those 
derived from “hemp.”  Many traditional medical cannabis practitioners 
will be surprised and likely caught off guard by this.  It will not be a 
free-for-all wherein providers can say or do anything they want.  At the 
same time, these pathways are likely sound and provide a useful 
roadmap for medical cannabis researchers and practitioners of all 
stripes. The first pathway is “intrastate” product produced and 
marketed or sold exclusively within a single state’s borders, which will 
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be regulated primarily by state law.  The second is small-molecule-drug 
product following completion of a conventional new drug research 
and development program and FDA approval of an NDA.  The third is 
to test and market, after a premarket submission to the FDA, an herbal 
dietary supplement that does not include any ingredient or substance 
currently approved as a drug or even in drug clinical trials—which 
rules out any products containing THC or CBD.  The relative 
distribution among these pathways will turn on factors, such as perceived 
or clinically measured efficacy, price, time to market, side effects, and 
preferences within the patient and healthcare communities.56 
This Article proceeds by giving a basic overview of the medical cannabis 
industry and its products in Part I.  The CSA’s treatment of “marihuana,” 
including the mechanisms and effects of descheduling and rescheduling, 
are covered in Part II.  The FDA and the FDCA regulations relevant to 
medical cannabis—and especially possible pathways to compliant 
production, marketing, and distribution—are covered in Part III.  Finally, 
this Article sets out the pathways and discusses ways forward for medical 
cannabis under full descheduling in Part IV. 
I.   HISTORY AND OVERVIEW OF THE MEDICAL CANNABIS INDUSTRY 
Claims are made for medical applications of cannabis plants and 
their parts going back thousands of years in different parts of the 
world.57  The Cannabis sativa L. strain may have been one of the first 
wild plants cultivated by humans.58  Early uses were through the raw 
seeds, oils, and fibers,59 with other preparations following.  There is 
controversy over whether the various suspected cannabis uses and 
references are to the same plant, however, or to different strains.60  
Ailments treated included pain, migraine, fungal infections, 
                                               
 56. For instance, for less regulated herbal products that seem more “natural” to 
consumers, or for finished pharmaceutical products known to have been tested in 
randomized controlled clinical trials.  See infra Conclusion. 
 57. See Russo, supra note 54, at 1621–41. 
 58. See id. at 1616 (noting that “sativa” was added to the name cannabis to 
designate its status as “cultivated” as early as the 1500s). 
 59. See id. at 1626–27, 1630, 1636. 
 60. See id. at 1627, 1631 (endnotes omitted) (“Cannabis has over 50 synonyms in 
India, and has been discussed in detail, along with its attendant controversy.  Some 
authorities have questioned whether bhang was a psychoactive at all, and others have 
questioned whether references to cannabis in Indian literature are reliable prior to 
the 11th century C.E . . . .  Nyberg noted that the word bang, while still signifying 
cannabis in contemporary Iran, has also been applied to other plants throughout 
history.” (citations omitted)). 
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psychological distress, anxiety or grief, ear infections, tumors, 
abscesses, and more.61  There is debate over the constituent active-
ingredient components of the plants used in these ancient times, but 
as a general matter, the selective breeding for cannabis containing 
high levels of THC—the substance that produces the “high” from 
cannabis use—is of a recent nature.62  Thus, older plants likely had a 
more balanced profile across the various substances explained below 
and would have produced different experiences from much of the 
recreational cannabis sold today.63 
Cannabis’s medical use is better documented in the Middle Ages 
and up into the modern era in different parts of the world, than it was 
for ancient use claims.64  However, with no knowledge of the 
constituent molecules, physicians had little way of precisely developing 
and administering cannabis-based remedies other than in the same 
manner as all other materia medica herbal remedies of the time.65  Over 
time, the intoxicating properties of cannabis also began creating some 
concerns for particular social or religious groups, such as under 
Muslim sharia law.66  There often seemed to be less focus on the 
intoxicating aspects of cannabis in ancient and medieval use 
references and more focus on the nutritive or medical properties of its 
seeds and oil, than we might expected today when the focus is 
primarily on the THC high.67  However, the Scythians and other 
Central Asian groups seemed to have already been burning or heating 
leaves, flowers, or seeds in open fires or on heated dishes to release 
vapors that were intoxicating.68  We now know that heating is necessary 
                                               
 61. See id. at 1624–26. 
 62. See id. at 1619–20, 1627, 1631. 
 63. Id. at 1628–37. 
 64. See id.; Antonio Zuardi, History of Cannabis as Medicine:  A Review, 28 BRAZ. J. 
PSYCHIATRY 153, 153–55 (2006). 
 65. See Russo, supra note 54, at 1628; Zuardi, supra note 64, at 153, 156; see also 
Materia medica, OXFORD ENGLISH DICTIONARY (3d ed. 2001) (defining materia medica as 
“[t]he remedial substances and preparations used in the practice of medicine”). 
 66. See Russo, supra note 54, at 1627 (“[B]y this time, Egyptian medicine had 
become Islamic medicine . . . .  [W]hile many derided its psychoactive effects on the 
basis of a ban on intoxicants in Muslim sharia law, a begrudging acknowledgement was 
frequently made of its abundant medical attributes.”). 
 67. See generally id. 
 68. See Zuardi, supra note 64, at 154. 
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to transform the relevant precursor chemicals from their natural state 
in the plant into the form that induces a high in humans.69 
Not surprisingly, substantial lore built up around medical, 
recreational, and spiritual uses of cannabis.70  This lore continues to 
provide some of the basis for today’s natural or herbal medical 
cannabis industry.71  In part, this segment of the industry has been 
bolstered by the continued interest in ancient and non-Western 
holistic medicine that began in earnest in the late twentieth century.72 
The benefits of this lore-based, medical cannabis attracted the 
attention of Western-trained physicians and scientists as early as the 
nineteenth century.  For example, an Irish doctor working in Calcutta 
in 1840 utilized the anti-convulsant properties of cannabis to treat 
tetanus.73  Additionally, a French physician treated mental disorders 
with cannabis by 1845.74  In 1851, the third edition of the United States 
Pharmacopoeia75 (USP)—then simply a compendium of recognized 
drugs—listed “extractum cannabis,” which it described as “[a]n 
alcoholic extract of the dried tops of Cannabis sativa—variety Indica.”76  
Subsequent editions explained how to prepare extracts and tinctures 
of dried cannabis flowers.77  However, as mentioned above, anti-
Mexican sentiment in the early twentieth century led to a 
                                               
 69. The scientific process is “decarboxylation,” during which a carboxyl group (-
COOH) is removed and replaced by a hydrogen atom (H).  In the process, the plant 
sheds CO2.  In addition to heating, decarboxylation can be accomplished by other 
means, including through premature aging by exposure to ultraviolet light.  See, e.g., 
Stacie Carrier, The Process of Decarboxylation, CANABO MED. CLINIC (Oct. 20, 2017), 
https://www.canabomedicalclinic.com/the-process-of-decarboxylation. 
 70. See Zuardi, supra note 64, at 154–55 (describing the medical and spiritual uses 
of cannabis by various cultures). 
 71. See, e.g., Ethan Russo, Cannabis in India:  Ancient Lore and Modern Medicine, in 
CANNABINOIDS AS THERAPEUTICS 1, 11–12 (R. Mechoulam ed., 2005). 
 72. Sneha Mantri, History of Medicine:  Holistic Medicine and the Western Medical 
Tradition, 10 AM. MED. ASS’N J. ETHICS 177, 179 (2008). 
 73. See W.B. O’Shaughnessy, New Remedy for Tetanus and Other Convulsive Disorders, 
23 BOS. MED. SURGICAL J. 153 (1840). 
 74. See Ethan Russo, Cognoscenti of Cannabis I:  Jacques-Joseph Moreau, 1 CANNABIS 
THERAPEUTICS 85, 86 (2001) (discussing the work of Moreau, including his 1845 book, 
DU HACHISCH ET DE L’ALIENATION MENTALE:  ETUDES PSYCHOLOGIQUES, which 
documented his use of cannabis to treat mental illness). 
 75. NAT’L MED. CONVENTION, THE PHARMACOPOEIA OF THE UNITED STATES OF 
AMERICA (Philadelphia, Lippincot, Grambo, & Co. 1851). 
 76. Id. at 50. 
 77. E.g., NAT’L CONVENTION FOR REVISING THE PHARMACOPOEIA, THE PHARMACOPOEIA OF 
THE UNITED STATES OF AMERICA 145, 318 (Philadelphia, J.B. Lippincott & Co. 1864). 
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demonization of “marihuana,” as the immigrants referred to it.78  This 
story is complicated by the facts that the Mexican government was 
already working to control it through criminal statutes and that the 
peasants most likely to be fleeing to the United States following 
upheaval caused by the Mexican Revolution of 1910 seemed the most 
terrified by what the drug could do.79  Thus, while there is evidence of 
news stories of the time focusing on “crazed” Mexicans committing 
violent crimes and debauchery under the influence of substances using 
terms we believe to correspond to strains or species of cannabis, there 
were also stories of other minorities, suspect groups such as “jazz 
musicians,” and other “undesirables,” engaged in such actions too.  
Whatever the actual mix of motives, it is clear that “marihuana” 
became a focal point of social, political, and legal concern in this 
period, which led to legislation. 
At the federal level, medical cannabis was regulated under the 
minimalist provisions of the Pure Food and Drugs Act of 1906.80  
Notably, Eli Lilly & Co. marketed a regulated cannabis formulation as 
an antispasmodic, sedative, and narcotic.81  But it was not until the 
Marihuana Tax Act of 193782 that cannabis was singled out as 
something more pernicious than other herbal remedies of the time.83  
Rapidly disappearing was media coverage of the medical benefits of 
cannabis.  Some individual states in fact were banning cannabis 
outright, and most made it available under prescription only.84 
                                               
 78. See, e.g., Eric Schlosser, Reefer Madness, ATLANTIC (Aug. 1994), 
https://www.theatlantic.com/magazine/archive/1994/08/reefer-madness/303476 
(describing how Texas police officers claimed that marijuana caused a lust for blood 
and incited violent crime while rumors also spread that Mexicans were distributing 
“killer weed” to American schoolchildren). 
 79. See ERIC SCHLOSSER, REEFER MADNESS:  SEX, DRUGS, AND CHEAP LABOR IN THE 
AMERICAN BLACK MARKET 19 (2003); Schlosser, supra note 78. 
 80. Pure Food and Drugs Act, Pub. L. No. 59-384, § 8, 34 Stat. 768, 770 (1906) 
(repealed by 21 U.S.C. § 1-5 (1940)) (deeming an article “misbranded” if the label 
does not include the “quantity or proportion of any . . . cannabis indica, . . . or any 
derivative or preparation of any such substances contained therein”), repealed by 
Federal Food, Drug, and Cosmetic Act of 1938, Pub. L. No. 75-717, 52 Stat. 1040 
(codified as amended at 21 U.S.C. §§ 301–399h (2012)). 
 81. See, e.g., ALISON MACK & JANET JOY, MARIJUANA AS MEDICINE?:  THE SCIENCE BEYOND 
THE CONTROVERSY 18 (2001) (reproducing images from 1913 Eli Lilly product labels). 
 82. Pub. L. No. 75-238, ch. 553, 50 Stat. 551 (1937). 
 83. Ferraiolo, supra note 20, at 148. 
 84. See id. at 153 (describing the Federal Bureau of Narcotics support for the 
Uniform Narcotic Act, which made marijuana available only by prescription); see also, 
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Nonetheless, cannabis research continued and major advances 
towards identifying and isolating important constituents of the plant 
took place in the 1930s and 1940s.85  Two key substances were isolated 
from hemp oil:  cannabinol (CBN) and CBD.86  The latter was present 
in a mixture of two THC variants that induced “marihuana-like” 
physiological results in dogs.87  The exact molecular structure of these 
variants remained elusive, however.  A single THC variant was soon 
isolated from cannabis resin.88  But in many ways, THC was still a 
predicted, and not fully realized, molecular construct. 
By the 1940s, significant segments of the population had hardened 
against “marihuana” for any use.89  Much of this resulted from the work 
of the Federal Bureau of Narcotics, which, among other things, 
released the low budget propaganda film, Reefer Madness,90 and 
publicized the “marijuana menace” through allies in the newspaper 
industry.91  In 1942, the United States Pharmacopeia Convention 
removed cannabis from the twelfth edition of the USP, a compendium 
now formally recognized under the FDCA of 1938.92  With this, the 
medical cannabis industry moved underground.93  Few mainstream 
researchers pursued it anymore.  Unfortunately, this also sent the 
traditional medical cannabis community back to the largely lore-based 
trial and error practices it had used before the nineteenth century.94 
                                               
e.g., 1913 Cal. Stat. 692, 697 §§ 8a–b (1913) (amending the California Poison Act of 
1907 and making the possession of hemp or its derivatives a misdemeanor). 
 85. See Roger G. Pertwee, Cannabinoid Pharmacology:  The First 66 Years, 147 BRIT. J. 
PHARMACOLOGY S163, S163 (2006). 
 86. Id. 
 87. THE HEALTH EFFECTS OF CANNABIS, supra note 11, at 46 (citing R. Adams et al., 
Structure of Cannabidiol, a Product Isolated from the Marihuana Extract of Minnesota Wild 
Hemp, 62 J. AM. CHEM. SOC’Y 196 (1940); R. Adams et al., Conversion of Cannabidiol to a 
Product with Marihuana Activity, 62 J. AM. CHEM. SOC’Y 2245 (1940)). 
 88. Id. (citing H.J. Wollner, Isolation of a Physiologically Active Tetrahydrocannibinol 
from Cannabis sativa Resin, 64 J. AM. CHEM. SOC’Y 26 (1942)). 
 89. See Ferraiolo, supra note 20, at 153–54 (describing the public shift in perceptions 
of drugs and marijuana, spearheaded by Anslinger, and the lack of marijuana defenders). 
 90. REEFER MADNESS (George A. Hirliman Productions 1938) (also screened under 
different titles across the United States in the 1940s–1950s). 
 91. Ferraiolo, supra note 20, at 156. 
 92. NAT’L ACAD. SCI., MARIJUANA AND MEDICINE:  ASSESSING THE SCIENCE BASE 16 
(Janet E. Joy et al. eds., 1999) [hereinafter MARIJUANA AND MEDICINE]; THE HEALTH 
EFFECTS OF CANNABIS, supra note 11, at 43. 
 93. Ferraiolo, supra note 20, at 154–55. 
 94. See supra notes 70–71 and accompanying text. 
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The next set of major advances in cannabis research came in the 
1960s and 1970s.  Overshadowing them all was the discovery of the 
elusive structure of the THC variant in cannabis that generates its 
intoxicating effect.95  The development of nuclear magnetic resonance 
imaging had enabled researchers to conclusively identify what became 
known as 9-THC.96  But such new tools also led to the discovery of exact 
molecular structures of other key cannabis substances including CBD,97 
cannabigerol (CBG),98 cannabichromene,99 cannabidivarin,100 
tetrahydrocannabivarin,101 and CBN.102  The enactment of the CSA in 
1970—with its placement of “marihuana,” THC, and “cannabimimetic 
agents” in Schedule I—erected serious barriers to research on cannabis. 
Nonetheless, in the 1980s and 1990s, the mammalian cannabinoid 
system came into view.  The idea of cannabinoid receptors on cells was 
postulated based on demonstrations of the selective binding to brain 
membranes of synthetic molecules designed to mimic the actions of 9-
THC.103  A “receptor” is a protein, typically on the surface of a cell.104  
Binding to a receptor triggers changes in the cell’s activity and, in this 
case, causes psychological changes such as euphoria and shifts in sensory 
perception.105  The actual existence of this first receptor, CB1, was 
                                               
 95. Pertwee, supra note 85, at S164. 
 96. THE HEALTH EFFECTS OF CANNABIS, supra note 11, at 46 (citing Y. Gaoni and R. 
Mechoulam, Isolation, Structure and Partial Synthesis of an Active Constituent of Hashish, 86 
J. AM. CHEM. SOC’Y 1646 (1964)). 
 97. See Ethan B. Russo, Taming THC:  Potential Cannabis Synergy and 
Phytocannabinoid-terpenoid Entourage Effects, 163 BRIT. J. PHARMACOLOGY 1344, 1345 
(2011) (citing R. Mechoulam & Y. Shvo, Hashish—I:  The Structure of Cannabidiol, 19 
TETRAHEDRON 2073 (1963)). 
 98. Id. (citing Y. Gaoni & R. Mechoulam, The Structure and Function of Cannabigerol, 
a New Hashish Constituent, 1 PROC. CHEMISTRY SOC’Y 82 (1964)). 
 99. Id. (citing Y. Gaoni & R. Mechoulam, Cannabichromene, a New Active Principle in 
Hashish, 1 CHEMICAL COMM. 20 (1966)). 
 100. Id. (citing L. Vollner et al., Hashish. XX. Cannabidivarin, a New Hashish 
Constituent, 3 TETRAHEDRON LETT. 145 (1969)). 
 101. Id. (citing E.W. Gill et al., Preliminary Experiments on the Chemistry and 
Pharmacology of Cannabis, 228 NATURE 134 (1970)). 
 102. R.E. Musty et al., Interactions of 9-Tetrahydrocannibinol and Cannabinol in Man, in 
2 THE PHARMACOLOGY OF MARIHUANA 559, 559–63 (M.C. Braude and S. Sarza, eds., 1976). 
 103. THE HEALTH EFFECTS OF CANNABIS, supra note 11, at 46 (citing William A. 
Devane et al., Determination and Characterization of a Cannabinoid Receptor in Rat Brain, 
34 MOLECULAR PHARMACOLOGY 605 (1988)). 
 104. See Receptor, TABER’S CYCLOPEDIC MEDICAL DICTIONARY 1760 (19th ed. 2001). 
 105. See, e.g., MACK & JOY, supra note 81, at 58–59 (discussing potential psychological 
changes and effects due to marijuana). 
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corroborated in 1990.106  In 1993, a second receptor, CB2, was cloned and 
identified.107  Endocannabinoids—cannabinoids produced by a mammal’s 
own body—were also discovered, suggesting that endocannabinoid systems 
are inherent to at least some mammals, and not merely a response to 
external triggers such as 9-THC or CBD.108  This discovery also led to one 
bold hypothesis that humans and cannabis co-evolved.109 
The fascination with the dramatic effects of THC unfortunately led 
to a near-exclusive research focus on that set of substances, and 
particularly 9-THC.110  This may have also stemmed from the 
dominant Western small molecule pharmaceutical approach in which 
“active ingredients” are identified, isolated, purified, and concentrated 
for therapeutic delivery, as other substances in source plants and other 
natural materials are largely ignored.111  This approach has led to many 
notable successes where modified concentrations of substances, or new 
chemicals synthesized from them, provide much greater therapeutic 
benefit than available from the naturally-occurring versions.  For 
example, acetylsalicylic acid, or aspirin, was synthesized in the mid-
nineteenth century from substances that had been identified in willow 
leaves and bark.112  The latter had been used therapeutically for 
thousands of years.113  But this success can crowd out research on the 
interactions and effects of the full range of chemicals—whether known 
or considered “active” or “inactive” ingredients—in herbal remedies 
                                               
 106. THE HEALTH EFFECTS OF CANNABIS, supra note 11, at 46 (citing Miles 
Herkenham et al., Cannabinoid Receptor Localization in Brain, 87 PROC. NAT’L ACAD. SCI. 
U.S. 1932 (1990); Lisa A. Matsudo et al., Structure of a Cannabinoid Receptor and 
Functional Expression of the Cloned cDNA, 346 NATURE 561 (1990)). 
 107. Id. (citing Sean Munro et al., Molecular Characterization of a Peripheral Receptor for 
Cannabinoids, 365 NATURE 61 (1993)). 
 108. See Russo, supra note 97, at 1354 (citing William A. Devane et al., Isolation and 
Structure of a Brain Constituent that Binds to the Cannabinoid Receptor, 258 SCIENCE 1946 
(1992); Raphael Mechoulam et al., Identification of an Endogenous 2-Monoglyceride, Present 
in Canine Gut, that Binds to Cannabinoid Receptors, 50 BIOCHEMICAL PHARMACOLOGY 83 
(1995); Takayuki Sugiura, 2-Arachidonoylglycerol:  A Possible Endogenous Cannabinoid 
Receptor Ligand in Brain, 215 BIOCHEMICAL BIOPHYSICAL RES. COMM. 89 (1995)). 
 109. See Russo, supra note 54, at 1614 (citing J.M. McPartland & G.W. Guy, The Evolution of 
Cannabis and Coevolution with the Cannabinoid Receptor—A Hypothesis, in THE MEDICAL USE OF 
CANNABIS AND CANNABINOIDS 71–101 (G.W. Guy, B.A. Whittle & P.J. Robson, eds., 2004)). 
 110. See Russo, supra note 97, at 1345. 
 111. See Si-Yuan Pan et al., New Perspectives on How to Discover Drugs from Herbal 
Medicines:  CAM’s Outstanding Contribution to Modern Therapeutics, 2013 EVIDENCE-BASED 
COMPLEMENTARY & ALTERNATIVE MED. 1, 2–3 (2013). 
 112. Dawn Connelly, A History of Aspirin, PHARMACEUTICAL J. (Sep. 26, 2014), http 
s://www.pharmaceutical-journal.com/news-and-analysis/infographics/a-history-of-aspirin. 
 113. Id. 
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generally.  In the traditional medical cannabis sector, and among some 
researchers, this holistic approach to cannabis as an herbal remedy has 
been called the “entourage effect.”114 
This dichotomy between the small molecule pharmaceutical and 
whole plant herbal approaches underlies the fundamental tension in 
medical cannabis today.  Drug companies generally seek to identify a 
single active ingredient that can be developed into a drug product, 
which in turn can be studied for safety and effectiveness in rigorously 
controlled clinical trials for purposes of the FDA’s NDA process.115  
This drug development model reflects the analytic framework in which 
most of Western science and technology has proceeded for the past 
few hundred years.  Only by carefully isolating and testing a particular 
phenomenon can we learn anything useful about it.  This approach 
has been focused to finer and finer levels of matter.  Traditional 
medical cannabis providers instead operate in a world in which not 
only do they insist that preparations from whole portions of the 
plant—such as the flower—are essential for therapeutic benefit, but 
they also believe that different strains of cannabis produce 
demonstrably different effects.116  
This Article does not seek to resolve any of these debates, but rather 
is intended to help all sides in the medical cannabis debates 
understand how the FDA will likely approach the matter.  This Article 
also seeks to sketch three pathways in which we think medical cannabis 
                                               
 114. The term and concept “entourage effect” (sometimes “ensemble effect”) refers 
to the synergy and interaction between multiple molecules and compounds within 
cannabis and the interplay these chemicals have with one another when producing 
effects on the body, as opposed to simply considering the effects of a single active 
compound, like THC, in isolation.  The term and concept were introduced to the 
scientific literature by Ben-Shabat, Mechoulam, and others.  See Shimon Ben-Shabat et 
al., An Entourage Effect:  Inactive Endogenous Fatty Acid Glycerol Esters Enhance 2-Arachidonoyl-
glycerol Cannabinoid Activity, 353 EUROPEAN J. PHARMACOLOGY 23, 136 (1998); Raphael 
Mechoulam & Shimon Ben-Shabat, From Gan-zi-gun-nu to Anandamide and 2-Arachidonoyl-
glycerol:  The Ongoing Story of Cannabis, 16 NAT. PRODUCT REP. 131, 136 (1999); see also 
Russo, supra note 97, at 1344. 
 115. See infra Part III. 
 116. A similar set of perspectives that has been in the popular media recently 
centers on the debate over “whole foods,” calories, and sugars in our diet.  See generally, 
e.g., MICHAEL POLLAN, THE OMNIVORE’S DILEMMA:  A NATURAL HISTORY OF FOUR MEALS 
(2007) (analyzing the ethos and processes behind three modes of food-chains:  
“processed,” “organic,” and “neo-Paleolithic”).  One side has taken the view that 
“calories are calories” and “sugars are sugars.”  The other side opines that the form of 
our food, and its calories, and sugars, matters tremendously for metabolism, health, 
and fitness.  Both sides can cite some current scientific research.  
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can proceed, compliant with FDA law, in the event descheduling 
occurs.  We set out these pathways in Parts III and IV, which arguably 
fall on differing sides of this debate—or at least, they may appeal in 
different ways depending on one’s place within that debate.  
The remainder of this Part reviews the current state of scientific 
understanding of cannabis, its constituents, and their effects on the 
human body.  Cannabis plants sit within the genus Cannabis and family 
Cannabaceae.117  The latter includes the genera Cannabis and Humulus 
(hops), which has led to interesting notes in the cannabis and beer 
industries about similarities.118  Most of the taxonomic debate concerns 
whether there are two or more species within the genus—usually 
cannabis sativa and cannabis indica—or simply one (cannabis sativa) with 
different strains, varietals, or subspecies.119  An alternate account finds 
at least one other type as a possible species:  Cannabis ruderalis Jan.120  
In this schema:  Cannabis sativa L. are “tall, branched plants for fiber, 
seed, or psychoactive use”; Cannabis indica Lam. are “short, broad-
leafed plants” from the Indian subcontinent; and Cannabis ruderalis 
Jan. are “short, unbranched ‘roadside’ plants usually weak in 
cannabinoids.”121 
Much of the uncertainty in classification appears to be from the 
hardy proliferation of the plant, which has resulted in many varieties, 
both cultivated and as found in the wild.122  Again, this Article does not 
seek to resolve scientific or practitioner debates, but three points 
suffice in summary.  First, the wide and distinctive varieties of 
cannabis—whether at a species level or lower—give ample grounds for 
traditional medical cannabis practitioners to promote the importance 
                                               
 117. THE HEALTH EFFECTS OF CANNABIS, supra note 11, at 44 (citing Mohammed 
Kuddus et al., Cannabis sativa:  An Ancient Wild Edible Plant of India, 25 EMIRATES J. FOOD 
& AGRIC. 736, 737 (2013)). 
 118. Id. 
 119. Id. (citing Lucas Larsen, Botany:  The Cultivation of Weed, 525 NATURE S4 (Sept. 
24, 2015); ROBERT CLARKE & MARK MERLIN, CANNABIS:  EVOLUTION AND ETHNOBOTANY 
(1st ed. 2016); Karl W. Hillig, Genetic Evidence for Speciation of Cannabis (Cannabaceae), 
52 GENETIC RESOURCES & CROP EVOLUTION 161 (2005); Ernest Small, Evolution and 
Classification of Cannabis sativa (Marijuana, Hemp) in Relation to Human Utilization, 81 
BOTANICAL REV. 189 (2015). 
 120. Russo, supra note 54, at 1616 (citing Richard Evans Schultes et al., Cannabis:  
An Example of Taxonomic Neglect, 23 BOTANICAL MUSEUM LEAFLETS HARV. U. 337 (1974); 
Loran C. Anderson, Leaf Variation Among Cannabis Species from a Controlled Garden, 28 
BOTANICAL MUSEUM LEAFLETS HARV. U. 61 (1980)). 
 121. Id. 
 122. See, e.g., id. 
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of strains and their entourage effects.123  In other words, the argument 
is not just that certain key chemicals like THC vary among strains, but 
also that many chemicals vary (i.e., that a compound may have the 
same molecular structure but work differently in the body depending 
on the varying other chemicals in the cannabis strain in which it 
appears).124  Accordingly, from this view, using whole-plant derived 
product is critical, rather than an isolated strain-specific constituent 
like THC.125  Second, as companies like Phylos Bioscience sequence 
the DNA of popular strains—and indeed seek to populate a “galaxy” 
of certified types—it has become clear that much of what is being 
passed as a particular strain in the traditional medical cannabis 
industry is far from uniform or exact.126  And third, data generated by 
these genomic sequencers should enable more definitive answers to 
the classification debate in the near future.127 
Across all cannabis plants, sophisticated traditional medical 
cannabis practitioners and researchers identify three broad classes of 
substances that may generate medical or health benefits:  
cannabinoids; terpenoids; and flavonoids.128  The first class is the most 
well-known as it contains THC and CBD.  But significant confusion 
exists, especially as to the “psychoactive” attributes of molecules within 
this class.129  The problem likely stems from the fact that all 
cannabinoids interact with the mammalian endocannabinoid system 
and other parts of the central nervous system.130  Thus, all cannabinoids 
are neurologically active.  However, THC stands out as a cannabinoid 
whose partial agonist binding to CB1 receptors causes the noted 
psychological responses of euphoria, sensory perception shifts, and 
other characteristics referred to as getting high or stoned.131  Trying to 
distinguish synonymous terms like “psychoactive” and “psychotropic” 
                                               
 123. See infra notes 177–79 and accompanying text. 
 124. Id. 
 125. See infra note 179 and accompanying text. 
 126. See Why Phylos Certified?, PHYLOS, https://phylos.bio/phylos-certified (last 
visited Feb. 5, 2019) (“Cannabis plants are currently sold under unreliable names (not 
every “Blue Dream” is the same plant variety), meaning inconsistent experiences for 
everyone—from farmers to consumers.”). 
 127. See supra notes 122–25 and accompanying text. 
 128. See THE HEALTH EFFECTS OF CANNABIS, supra note 11, at 44 (citing AMERICAN 
HERBAL PHARMACOPOEIA (2013)); Russo, supra note 97, at 1344. 
 129. See THE HEALTH EFFECTS OF CANNABIS, supra note 11, at 47. 
 130. See id. at 46–48. 
 131. Id. at 51. 
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does not help.132  Instead, this Article refers to all cannabinoids as 
“neuro-active” and to THC as “psychoactive.”  One further segmentation 
of cannabinoids is important:  “phytocannabinoids” are those produced 
by plants through natural photosynthesis; “synthetic cannabinoids” are 
those produced artificially; “cannabimimetic agents” are also produced 
artificially but are designed to produce the results of a certain 
cannabinoid (usually THC) and not necessarily replicate its exact 
structure; and, as mentioned above, “endocannabinoids” are those 
produced by the mammalian body through its own natural processes.133 
The endocannabinoid system is now seen as “one of the key 
regulatory mechanisms in the brain controlling multiple events such 
as mood, pain, perception, learning and memory among others.”134  
The system may also play protective and reparative roles in traumatic 
brain injury and neurodegeneration.135  Mammalian bodies produce 
endocannabinoids on-demand.136 
At the same time, estimates of phytocannabinoids occurring in 
cannabis range from sixty to more than 100.137  The two most 
important at the moment, THC and CBD, are generated from the 
common parent precursor CBG.138  To be accurate, the acid version of 
each of these cannabinoids is expressed in cannabis itself (e.g., 9-
tetrahydrocannabinolic acid).139  In such form, they are inert for most 
of the effects we associate them with. Ingesting in this form would not 
                                               
 132. These terms are nearly identical and trying to differentiate between them would 
not help determine how chemicals like THC and CBD work differently on a molecular 
level.  Compare Psychoactive, MERRIAM WEBSTER (defining “psychoactive” as “affecting the 
mind or behavior”), https://www.merriam-webster.com/dictionary/psychoactive (last 
visited Feb. 5, 2019), with Psychotropic, MERRIAM WEBSTER (defining “psychotropic” as 
“acting on the mind”), https://www.merriam-webster.com/dictionary/psychotropic 
(last visited Feb. 5, 2019). 
 133. See generally Vincenzo di Marzo, Opinion, New Approaches and Challenges to 
Targeting the Endocannabinoid System, 17 NATURE REVS.:  DRUG DISCOVERY 623 (2018); 
Debra A. Kendall & Guillermo A. Yudowski, Cannabinoid Receptors in the Central Nervous 
System:  Their Signaling and Roles in Disease, 10 FRONTIERS IN CELLULAR NEUROSCIENCE 1 
(Jan. 2017); see also THE HEALTH EFFECTS OF CANNABIS, supra note 11, at 44; Russo, supra 
note 97, at 1344. 
 134. Kendall & Yudowski, supra note 133, at 3. 
 135. Id. 
 136. Id. 
 137. Russo, supra note 97, at 1346; THE HEALTH EFFECTS OF CANNABIS, supra note 11, at 44. 
 138. Mei Wang et al., Decarboxylation Study of Acidic Cannabinoids:  A Novel Approach 
Using Ultra-High-Performance Supercritical Fluid Chromatography/Photodiode Array-Mass 
Spectrometry, 1 CANNABIS & CANNABINOID RES. 262, 262 (2016). 
 139. Id. at 263. 
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induce the desired effects.  They must be decarboxylated first, which 
in the case of traditional recreational and medical cannabis is generally 
accomplished through heating, resulting in the forms of THC and 
CBD that produce the sought-after effects.140 
The two different sets of cannabinoid receptors on various cells 
throughout the human body also play a key role in the effects of 
cannabinoids.  Cannabinoid binding to CB1 receptors can result in the 
psychoactive mood and perceptions shifts associated with getting high, 
as well as with therapeutic benefits.141  By contrast, CB2 receptors are 
found predominantly within cells and tissues of the immune system 
and the gut.142  Cannabinoids binding to them may regulate 
inflammation, pain, and even neurodegeneration.143  Many of the 
cannabinoids interact directly or indirectly with both CB1 and CB2 
receptors.144  Even more complexly, cannabinoids like THC and CBD 
can effectively interact with each other through the CB receptors.145  
For example, CBD appears to modulate the stronger and more 
negative effects of THC, such as anxiety.146  Notably, Sativex, approved 
in the United Kingdom and elsewhere, but not in the United States, 
contains both 9-THC and CBD.147 
                                               
 140. See Russo, supra note 97, at 1345. 
 141. See Kendall & Yudowski, supra note 133, at 1–2. 
 142. See, e.g., K.L. Wright et al., Cannabinoid CB2 Receptors in the Gastrointestinal Tract:  
A Regulatory System in States of Inflammation, 153 BRIT. J. PHARMACOLOGY 263, 263 (2008). 
 143. Id. 
 144. See Kendall & Yudowski, supra note 133, at 4. 
 145. Id. 
 146. See Russo, supra note 97, at 1348.  The mechanism and extent of this interaction 
remains the subject of considerable ongoing research with results that have not yet 
been reconciled.  See, e.g., C. Klein et al., Cannabidiol Potentiates 9-Tetrahydrocannabinol 
(THC) Behavioral Effects and Alters THC Pharmacokinetics During Acute and Chronic 
Treatment in Adolescent Rats, 218 LIBERTAS ACADEMICA 443, 443 (2011) (finding that 
pretreatment with CBD intensified all behavioral effects of THC including anxiety); 
Daniel Thomas Malone et al., Cannabidiol Reverses the Reduction in Social Interaction 
Produced by Low Dose 9-Tetrahydrocannabinol in Rats, 93 PHARMACOLOGY BIOCHEMISTRY 
BEHAV. 91, 91 (2009) (finding that pretreatment with CBD reversed THC-induced 
decreases in interactions). 
 147. Sativex is an oromucosal spray that, as noted, contains both 9-THC and 
cannabidiol.  The United Kingdom’s medicine regulator approved Sativex in June 
2010 to improve symptoms related to muscle stiffness or spasm caused by multiple 
sclerosis.  See U.K. MEDS. & HEALTHCARE PRODS. REGULATORY AGENCY, PUBLIC 
ASSESSMENT REPORT DECENTRALISED PROCEDURE:  SATIVEX OROMUCOSAL SPRAY 2 (2014).  
The drug is now approved in 25 countries but has not yet been approved in the United 
States. Sativex®, GW PHARMACEUTICALS, https://www.gwpharm.com/healthcare-
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Terpenoids, the key components of essential oils, are synthesized in 
cannabis as well.148  Cannabis contains over 200 terpenoids.149  It is 
terpenoids and not cannabinoids that give cannabis its distinctive 
aroma.150  While there is debate about the efficacy of terpenoids for 
therapeutic uses, increased interest has correlated with studies showing 
measurable benefits in this century.151  The primary terpenoids in 
cannabis that may produce beneficial effects, alone or in conjunction 
with a cannabinoid, are:  Limonene, -Pinene, -Myrcene, Linalool, -
Carophyllene, Carophyllene Oxide, Nerolidol, and Phytol.152 
Flavonoids are metabolites that play a role in pigmentation, UV 
filtration, nitrogen fixation, and other functions in plants.153  They are 
sometimes referred to as bioflavonoids.154  There appear to be twenty or 
more flavonoids in cannabis.155  Those occurring only in cannabis have 
been called “cannaflavins.”156  Flavonoids are pharmacologically active and 
some in the medical cannabis community believe they work in concert with 
terpenoids and other substances in cannabis plants.157  They are less well-
studied overall, in cannabis in particular, but have become a topic of 
interest, especially among those who promote the entourage effect.158 
                                               
professionals/sativex (last visited Feb. 5, 2019).  This Article discuss other new drug 
products derived from cannabis in Part IV. 
 148. Russo, supra note 97, at 1345, 1349 (noting that terpenoids were “previously 
conceived as the quintessential fifth element, ‘life force’ or spirit . . . , and form the 
largest group of plant chemicals”).  For more detail on the role of terpenes in essential 
oils, see Sangita Kumari et al., EssOilDB:  A Database of Essential Oils Reflecting Terpene 
Composition and Variability in the Plant Kingdom, 2014 DATABASE 1, 2 (Jan. 2014). 
 149. Russo, supra note 97, at 1349. 
 150. Id. 
 151. Id. at 1350–52 (citing studies that indicate terpenoids can act as sleep aids, 
memory aids, anticonvulsants, antimalarials, and increase serotonin). 
 152. Id. at 1351. 
 153. Ulrike Mathesius, Flavonoid Functions in Plants and Their Interactions with Other 
Organisms, 7 PLANTS 30, 30–31 (June 2018), https://www.ncbi.nlm.nih.gov/pmc/ 
articles/PMC6027123/pdf/plants-07-00030.pdf. 
 154. See, e.g., Drugs for Human Use Containing Rutin, Quercetin, Hesperidin, or 
Bioflavonoids, 33 Fed. Reg. 818 (Jan. 23, 1968). 
 155. Patrick Bennett, What Are Cannabis Flavonoids and What Do They Do?, LEAFLY (Feb. 
8, 2018), https://www.leafly.com/news/cannabis-101/what-are-marijuana-flavonoids. 
 156. Id. 
 157. See Angus Chen, Some of the Parts:  Is Marijuana’s “Entourage Effect” Scientifically 
Valid?, SCI. AM. (April 20, 2017), https://www.scientificamerican.com/article/some-
of-the-parts-is-marijuana-rsquo-s-ldquo-entourage-effect-rdquo-scientifically-valid. 
 158. Id.; see also supra note 114. 
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At the same time, scientific researchers are not opposed to studying 
other cannabis substances or even potential entourage effects,159 but 
current supply issues severely limit such efforts.160  The Schedule I 
status of much of the cannabis plant led the DEA and NIDA to restrict 
licensed research to a strain of cannabis produced by the University of 
Mississippi under contract with the federal government.161  This strain 
is not particularly potent nor high quality from traditional medical 
cannabis provider and user perspectives—even as it is deemed 
“research grade” by the government—and is not one used by 
dispensaries.162  Exacerbating this problem, NIDA research cannabis is 
often harvested and stored in a freezer for years before being 
distributed to researchers, further diminishing its potency (as well as 
likely degrading other substances such as essential oils).163  But even if 
this were a relevant strain and delivered fresh to researchers, the limit 
to a single strain precludes exactly the kind of cross-strain comparisons 
that traditional medical cannabis providers believe provides the core 
basis for their practice.164  NIDA research cannabis also traditionally 
was supplied only in plant form, precluding other important research 
avenues that would consider the forms and modes of delivery, such as 
conventional edible forms waxes for smoking or vaporizing, other 
concentrates, oils that are sometimes ingested, and topicals).165 
Changes initiated in 2016 are underway, however.  NIDA began 
working with the University of Mississippi to at least provide strains with 
different concentrations of 9-THC and CBD.166  Yet, this facilitates 
                                               
 159. See, e.g., Russo, supra note 97, at 1349–52 (citing several studies involving 
cannabis terpenoids). 
 160. See Chen, supra note 157. 
 161. See THE HEALTH EFFECTS OF CANNABIS, supra note 11, at 382 (explaining that the 
NIDA Drug Supply Program provides the only cannabis available for research); 
Alexander W. Campbell, The Medical Marijuana Catch-22:  How the Federal Monopoly on 
Marijuana Research Unfairly Handicaps the Rescheduling Movement, 41 AM. J. L. & MED. 190, 
200 (2015) (describing the oversight surrounding the marijuana manufacturer at the 
University of Mississippi and the requirements researchers must meet to use marijuana 
from there).  In 2013, the First Circuit Court of Appeals upheld the DEA’s denial of a 
license for a Massachusetts university professor to cultivate his own marijuana for medical 
research on the grounds that he failed to demonstrate that current cannabis supply was 
inadequate.  See Craker v. DEA, 714 F.3d 17, 18–19, 29 (1st Cir. 2013). 
 162. THE HEALTH EFFECTS OF CANNABIS, supra note 11, at 382. 
 163. Id. at 382–83. 
 164. See Chen, supra note 157 (describing how individual cannabis growers “have long 
been crossing plants to develop distinctive strains that purportedly do different things”). 
 165. THE HEALTH EFFECTS OF CANNABIS, supra note 11, at 383. 
 166. Id. 
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primarily research focusing on characterizing the biological activity of 
these two constituents, although it could also support research on the 
current interest in the interaction of THC and CBD.  More helpfully, 
DEA also changed its policy to begin accepting applications for other 
research-grade cannabis providers, which could result in a supply that 
more closely matches that of private dispensaries.167  However, no 
licenses have been granted as of publication.  In the meantime, this 
state of affairs appears to have driven some important medical 
cannabis research overseas.168 
Both pharmaceutical and whole flower medical cannabis 
researchers have targeted a number of therapeutic fields.  Some of 
these fields have roots in ancient practice or in the nascent 
pharmacological cannabis practices of the nineteenth and early 
twentieth century (before cannabis “prohibition”).169  Pharmaceutical 
approaches tend to orient around cannabinoids (especially THC and 
CBD) and CB receptors because cannabinoids are seen as the primary 
“active ingredients” available from cannabis.170  To be clear, the 
pharmaceutical industry is not only developing drugs derived from 
cannabis plant material, but also from synthetic cannabinoid products.171  
Traditional medical cannabis practitioners and other researchers 
tend to pursue illnesses that might benefit from the amount of 
substances occurring in naturally-hybridized strains as delivered 
through whole flower, oils, extracts, or concentrates, the latter of which 
could reach pharmaceutical type levels of “active ingredients” such as 
CBD.172  Further, not all traditional medical cannabis practitioners insist 
on whole flower-based product.  Some are fine advising pure THC 
concentrates (albeit, of course, in some form that does not deliver 100% 
THC to the patient).  At the same time, formally-trained researchers 
including Mowgli Holmes, at Phylos Bioscience, and Ethan Russo, 
formerly at GW Pharmaceuticals, are among some of the strongest 
                                               
 167. Id. at 383–84 (citing Applications to Become Registered Under the Controlled 
Substances Act to Manufacture Marijuana to Supply Researchers in the United States, 
81 Fed. Reg. 53,846 (Aug. 12, 2016)). 
 168. See, e.g., Yardena Schwartz, The Holy Land of Medical Marijuana, U.S. NEWS & 
WORLD REP. (Apr. 11, 2017), https://www.usnews.com/news/best-countries/articles 
/2017-04-11/israel-is-a-global-leader-in-marijuana-research (illustrating how Israel has 
become a prime location for cannabis research). 
 169. See supra Part I. 
 170. See Russo, supra note 97, at 1345, 1348. 
 171. See infra Section IV.B.1 (tracing the history of synthetic cannabis drug 
development in the United States). 
 172. See supra notes 57–77 and accompanying text. 
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proponents of entourage effect therapies.173  However, this does not 
always mean whole flower-based product.  It can also mean 
pharmaceutical products like Sativex, where the manufacturer 
combines multiple substances for an overall desired effect and not just 
a single active ingredient.174  Thus, there will likely be a continued focus 
on multiple cannabinoid products first, especially from the 
pharmaceutical side.175  Richer preparations including at least certain 
terpenoids may follow.  And of course, dietary supplement or whole 
flower-derived product will contain the full complement of the 
cannabinoids, terpenoids, and flavonoids in the cannabis strain’s profile. 
II.   CANNABIS AND “MARIHUANA”  
UNDER THE CONTROLLED SUBSTANCES ACT 
The CSA was enacted in 1970 as the cornerstone of a major push to 
combat what was perceived by some as an epidemic of “recreational” 
drug abuse, especially within the counterculture movement.176  It 
consolidated various federal drug laws into a cohesive system of 
regulations.177  The system created “Schedules,” or classifications, of 
controlled substances with different levels of regulation.178  All 
scheduled controlled substances are restricted in production and 
distribution under registration and licensing requirements promulgated 
by the Attorney General, ultimately delegated in large part to the 
                                               
 173. See Chen, supra note 157. 
 174. Id. 
 175. A recent report by the National Academies of Science, The Health Effects of 
Cannabis and Cannabinoids, provides a useful list of the major health and disease areas 
being pursued by researchers (although the reader should note the varying levels of 
evidence for or against each:  Chronic Pain; Cancer; Chemotherapy-Induced Nausea and 
Vomiting; Anorexia and Weight Loss; Irritable Bowel Syndrome; Epilepsy; Spasticity 
Associated with Multiple Sclerosis or Spinal Cord Injury; Tourette Syndrome; 
Amyotrophic Lateral Sclerosis; Huntington’s Disease; Parkinson’s Disease; Dystonia; 
Dementia; Glaucoma; Traumatic Brain Injury/Intracranial Hemorrhage; Addiction; 
Anxiety; Depression; Sleep Disorders; Posttraumatic Stress Disorder; Schizophrenia and 
Other Psychoses.  See THE HEALTH EFFECTS OF CANNABIS, supra note 11, at xii. 
 176. See Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970, 
Pub. L. No. 91-513, 84 Stat. 1236, 1242 (codified at 21 U.S.C. §§ 801–904 (2012)); see also 
John Hudak, How Racism and Bias Criminalized Marijuana, WASH. POST (Apr. 28, 2014), 
https://www.washingtonpost.com/news/in-theory/wp/2016/04/28/how-racism-and-bias 
-criminalized-marijuana (arguing marijuana’s scheduling comes from President Nixon’s 
contempt toward the counterculture movement and racial minorities). 
 177. See 84 Stat. at 1236–37. 
 178. 84 Stat. at 1247–52 (codified at 21 U.S.C. § 812 (2012)). 
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DEA.179  The Attorney General—through the DOJ, DEA, and NIDA—
licenses producers, distributors, and retailers, as well as health care 
providers who are able to write prescriptions for controlled 
substances.180  The primary purpose of the CSA was to control 
stimulants, depressants, and hallucinogens.181  The stated concern was 
safety and the potential for addiction and abuse.182  Five Schedules 
were included in the statute, in descending order of restrictiveness.183  
Schedule I criteria are that the substance has “a high potential for 
abuse,” “no currently accepted medical use in treatment in the United 
States,” and “a lack of accepted safety for use of the drug or other 
substance under medical supervision.”184  When initially enacted, 
Schedule I included certain enumerated opiates, opium derivatives 
(including heroin and morphine), and hallucinogens (including LSD, 
“marihuana,“ tetrahydrocannibols, mescaline, peyote, and psilocybin).185  
“Cannabimimetic agents” were later added to Schedule I and include “any 
substance that is a cannabinoid receptor type 1 (CB1 receptor) agonist as 
demonstrated by binding studies and functional assays within any of 
[certain enumerated molecular structural classes].”186 
Schedule II criteria also include “a high potential for abuse,” but the 
substances have “a currently accepted medical use in treatment in the 
United States or a currently accepted medical use with severe 
restrictions.”187  The substances also have a risk of “severe psychological 
or physical dependence” when abused.188  As initially set out, Schedule 
II included both general classes of substances (including opium and 
opiate generally, opium poppy and poppy straw, coca leaves and 
preparations from them, and injectable liquid forms of 
methamphetamines) and certain enumerated opiates (including 
fentanyl and methadone).189 
Schedule III loosened all three criteria.190  These substances have a 
potential for abuse lower than those in Schedules I and II and a risk of 
                                               
 179. See 21 U.S.C. §§ 821–831. 
 180. See § 822; see also THE HEALTH EFFECTS OF CANNABIS, supra note 11, at 378–81. 
 181. H.R. REP. NO. 91-1444, pt. 1, at 6–7 (1970). 
 182. Id. at 1. 
 183. 21 U.S.C. § 812. 
 184. §§ 812(b)(1)(A)–(C). 
 185. See Pub. L. No. 91-513, 84 Stat. 1236, 1248–49 (1970). 
 186. 21 U.S.C. § 812(c), Schedule I(d)(2)(A). 
 187. §§ 812(b)(2)(A)–(B). 
 188. § 812(b)(2)(C). 
 189. See 84 Stat. at 1250. 
 190. See 21 U.S.C. § 812(b)(3). 
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only “moderate or low physical dependence or high psychological 
dependence.”191  Initial classes of substances included stimulants 
(amphetamine, phenmetrazine, non-injectable methamphetamine, 
and methylphenidate), certain enumerated depressants, nalorphine, 
and certain enumerated substances with quantified narcotic levels.192 
Schedule IV lowered the abuse and risk factors further. These substances 
have a low potential of abuse and limited physical or psychological 
dependence relative to substances in Schedule III.193  A list of specific 
substances, including phenobarbital, was included in the initial Schedule.194 
Schedule V contains the lowest set of criteria.  Abuse potential and 
risk factors are set to a level below all Schedule IV substances.195  A 
single class of substances that include no more than certain quantified 
concentrations of narcotics along with other active medical ingredients 
was included in the original act.196  An example would be cough 
medicine with not more than 200 milligrams of codeine per 100 
milliliters or per 100 grams of the overall substance.197 
The definition of “marihuana” in the CSA was simply that which had 
already been codified in federal statutes since the Marihuana Tax Act: 
[A]ll parts of the plant Cannabis sativa L., whether growing or not; the 
seeds thereof; the resin extracted from any part of such plant; and 
every compound, manufacture, salt, derivative, mixture, or preparation 
of such plant, its seeds or resin.  Such term does not include the mature 
stalks of such plant, fiber produced from such stalks, oil or cake made 
from the seeds of such plant, any other compound, manufacture, salt, 
derivative, mixture, or preparation of such mature stalks (except the 
resin extracted therefrom), fiber, oil, or cake, or the sterilized seed of 
such plant which is incapable of germination.198 
But with the advances in chemical and genetic research on cannabis 
taking place during the 1960s, the time was ripe for challenges as to 
whether “Cannabis sativa L.” in fact included all kinds of cannabis in the 
market.  Fittingly, in a 1969 decision involving LSD and hallucinogenic 
drug pioneer, Dr. Timothy Leary, the Supreme Court cautiously opined 
in dicta that “it seems that there is only one species of marihuana,” 
                                               
 191. §§ 812(b)(3)(A), (C). 
 192. See 84 Stat. at 1251–52. 
 193. 21 U.S.C. §§ 812(b)(4)(A), (C). 
 194. See 84 Stat. at 1252. 
 195. 21 U.S.C. §§ 812(b)(5)(A), (C). 
 196. See 84 Stat. at 1252. 
 197. See id. 
 198. 84 Stat. at 1244 (codified at 21 U.S.C. § 802(16)); see also Marijuana Tax Act of 
1937, Pub. L. No. 75-238, 50 Stat. 551 (codified at 26 U.S.C. § 4761(2)). 
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although the case was decided under the earlier Marihuana Tax Act 
statute and did not involve a direct challenge to the definition.199 
A decision the next year in a Pennsylvania federal court also decided 
under the earlier statute, expressly rejected the defendant’s argument 
that “marihuana”—tied to Cannabis sativa L.—did not include 
Cannabis “indicia.”200  In its examination of the legislative history of 
marijuana law, the court quoted Henry J. Anslinger, the Commissioner 
of Narcotics, when he spoke during congressional hearings on the 
taxation of marijuana: 
[M]arihuana is the same as Indian hemp, and is sometimes found as 
a residual weed, and sometimes as the result of a dissemination of 
birdseed.  It is known as cannabin, cannabis Americana or cannabis 
Sativa.  Marihuana is the Mexican term for cannabis Indicia.  We 
seem to have adopted the Mexican terminology, and we call it 
marihuana, which means good feeling.201 
For Schedule I drugs and substances, the CSA prohibits their 
manufacture, distribution, or dispensation, as well as their possession 
with intent to manufacture, distribute, or dispense.202  Penalties 
include not only fines and imprisonment,203 but also criminal and civil 
forfeiture of property to the United States.204  
                                               
 199. Leary v. United States, 395 U.S. 6, 50 (1969) (citing lower court testimony of 
Dr. Richard Schultes, Director, Harvard Botanic Museum). 
 200. United States v. Moore, 330 F. Supp. 684, 686–87 (E.D. Pa. 1970) (citing 
Congressional legislative history, state court decisions, and scientific authorities for support). 
 201. Id. at 686 (quoting Taxation of Marihuana:  Hearings Before the Comm. on Ways and 
Means on H.R. 6385, 75th Cong. 18 (1937) (statement of H.J. Anslinger, Commissioner 
of Narcotics)).  It is unclear where Anslinger got the idea that “marihuana” meant “good 
feeling.”  The decision was affirmed by the U.S. Court of Appeals for the Third Circuit, 
United States v. Moore, 446 F.2d 448 (3d Cir. 1971), and certiorari was denied by the 
U.S. Supreme Court, Moore v. United States, 406 U.S. 909 (1972) (mem.).  Subsequent 
federal court decisions were consistent.  See, e.g., United States v. Gaines, 489 F.2d 690, 
690–91 (5th Cir. 1974) (affirming trial court’s refusal to instruct jury that the statutory 
definition of marihuana only included Cannabis sativa L.); United States v. King, 485 F.2d 
353, 360–61 (10th Cir. 1973) (holding a government chemist’s testimony amply 
sufficient for prima facie case that the substance in defendant’s possession was marijuana 
as defined in the statute, even though the chemist did not describe the marijuana as 
Cannabis sativa L.); United States v. Rothberg, 351 F. Supp. 1115, 1118 (E.D.N.Y. 1972), 
aff’d, 480 F.2d 534 (2d Cir. 1973) (rejecting defendants’ argument that government had 
to prove the marijuana in question was Cannabis sativa L., rather than a different strain). 
 202. 21 U.S.C. § 841(a)(1) (2012). 
 203. § 841(b). 
 204. §§ 853(a), 881(a).  Criminal forfeiture can occur where individuals have 
violated CSA provisions punishable by more than one year in prison.  § 853(a). 
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The CSA specifically authorizes the Attorney General to add or 
remove items from the Schedules, including moving items from one 
Schedule to another.205  Any changes must be guided by the CSA’s 
process, which includes requesting a scientific and medical evaluation 
and recommendation from the Secretary of Health and Human 
Services.206  Responsibility for the evaluation and recommendation has 
been delegated, in turn, to the FDA.207  The FDA must consider certain 
listed factors:  the drug’s actual or relative potential for abuse, scientific 
evidence of its pharmacological effect (if known), the state of current 
scientific knowledge regarding the drug, the drug’s history and 
current pattern of abuse, the scope (and duration and significance) of 
abuse, its psychic or physiological dependence liability, the risk (if any) 
it presents to public health, and whether it is an “immediate precursor” 
of another controlled substance.208  The Secretary must recommend a 
specific Schedule (or removal, if appropriate), and this 
recommendation is binding as to scientific and medical matters.209 
After the Secretary provides a recommendation, the Attorney General 
must use formal rulemaking to issue a final decision.210  If the Secretary 
recommends that a drug not be controlled, the Attorney General may 
not control the drug.211  Where the United States is a signatory to a 
treaty, convention, or protocol establishing controls over a particular 
drug or substance, the Attorney General must add that drug or 
substance to what is deemed the most appropriate Schedule.212  This is 
particularly relevant where cannabis remains controlled under the 
Single Convention on Narcotic Drugs.213  The FDA must alert the 
Attorney General when a NDA involves a drug that has a “stimulant, 
depressant, or hallucinogenic effect on the central nervous system,” and 
                                               
 205. § 811(a). 
 206. § 811(b). 
 207. See generally 21 C.F.R. § 1308; see also Controlled Substance Staff Functional Roles, 
FDA, https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsand 
Tobacco/CDER (last visited Feb. 5, 2019). 
 208. 21 U.S.C. §§ 811(b)–(c).  A drug or substance that is an immediate precursor of 
another listed drug or substance may be placed in the same or higher Schedule.  § 811(e). 
 209. § 811(b). 
 210. § 811(a). 
 211. § 811(b). 
 212. § 811(d). 
 213. United Nations Single Convention on Narcotic Drugs, 1961, art. 28, Mar. 20, 
1961, 18 U.S.T. 1407, 520 U.N.T.S. 240 (establishing an international treaty to regulate 
drugs, including cannabis). 
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the drug appears to have abuse potential.214  Any non-narcotic substance 
approved by the FDA to be sold over the counter shall be excluded from 
scheduling by regulation promulgated by the Attorney General.215 
In 2009, in light of the increasing number of states enacting medical 
marijuana laws, the DOJ issued a memo (the “Ogden Memo”) that 
deprioritized prosecution of individuals engaged in medical cannabis 
production, distribution, or use, provided they were compliant with 
state laws and did not otherwise pose any enhanced risks.216  In the 
wake of Colorado’s and Washington’s respective initiatives to state-
legalize recreational cannabis, the DOJ took a cautious response.  
Rather than taking any direct action against the states or officials 
within them tasked with implementing the recreational systems, the 
DOJ instead issued an internal guidance memo (the “Cole Memo”) to 
U.S. attorneys.217  It recommended that U.S. attorneys use a set of drug 
enforcement priorities in deciding where and how to allocate limited 
government resources to cannabis prosecutions.218  The guidance was 
particularly directed to attorneys in states with “robust” state cannabis 
regulatory regimes.219  The eight priorities are: 
(1) preventing the distribution of marijuana to minors; 
(2) preventing revenue from the sale of marijuana from going to 
criminal enterprises, gangs, and cartels; 
(3) preventing the diversion of marijuana from states where it is 
legal under state law in some form to other states; 
(4) preventing state-authorized marijuana activity from being used 
as a cover or pretext for the trafficking of other illegal drugs or other 
illegal activity; 
(5) preventing violence and the use of firearms in the cultivation 
and distribution of marijuana; 
                                               
 214. § 811(f). 
 215. § 811(g)(1). 
 216. Memorandum from Deputy Attorney Gen. David W. Ogden on Investigations 
& Prosecutions in States Authorizing the Medical Use of Marijuana to Selected United 
States Attorneys (Oct. 19. 2009), https://www.justice.gov/sites/default/files/o 
pa/legacy/2009/10/19/medical-marijuana.pdf. 
 217. Memorandum from Deputy Attorney Gen. James M. Cole on Guidance 
Regarding Marijuana Enforcement to All United States Attorneys (Aug. 29, 2013) 
[hereinafter Cole Memo], https://www.justice.gov/iso/opa/resources/30520138291 
32756857467.pdf. 
 218. Id. 
 219. Id. (noting that a “robust” regulatory system would address the same priorities 
the DOJ addresses in enforcement, including prohibiting access to minors and 
preventing illicit trade that funds criminal enterprises). 
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(6) preventing drugged driving and the exacerbation of other 
adverse public health consequences associated with marijuana use; 
(7) preventing the growing of marijuana on public lands and the 
attendant public safety and environmental dangers posed by 
marijuana production on public lands; and 
(8) preventing marijuana possession or use on federal property.220 
State regulatory regimes, such as that of Washington State, were set 
up expressly to avoid tripping any of these eight prosecution priorities, 
which also appeared in an earlier memo issued by Cole.221  However, 
in 2018, Attorney General Sessions rescinded the Cole Memo and 
other related guidance documents, and thus all participants in state-
legal cannabis systems are now subject to the regular discretion of their 
local U.S. Attorney to prosecute federal crimes.222  At the same time, 
the so-called Rohrabacher-Blumenauer Amendment, an appropriations 
bill rider that has been reapproved for the past few years,223 prohibits the 
DOJ from using any congressionally-appropriated funds for cannabis 
prosecutions for businesses or individuals operating under robust state 
medical cannabis regulatory systems.224  Notwithstanding this 
prohibition, the DOJ continued its prosecution of a California 
dispensary until a federal judge recently rebuked the DOJ’s theory of 
why its actions were not technically a use of appropriated funds.225  While 
this ruling might seem to be a major victory for regulated cannabis 
businesses, the DOJ’s willingness to go to court to protect its ability to 
prosecute cannabis CSA violations, regardless of both the guidance of 
                                               
 220. Id. 
 221. See generally WASH. REV. CODE ANN. § 69.51A (West 2015). 
 222. See Memorandum from Attorney Gen. Jefferson B. Sessions, III on Marijuana 
Enforcement to United States Attorneys (Jan. 4, 2018), https://www.justice.gov/opa/ 
press-release/file/1022196/download. 
 223. See Pub. L. No. 115-141, § 538, 132 Stat. 348 (2018); Pub. L. No. 115-31, § 537, 
131 Stat. 135, 228 (2017); Pub. L. No. 114-112, § 542, 129 Stat. 2242, 2332 (2016); Pub. 
L. No. 114-113, § 542, 129 Stat. 2242, 2332 (2015); Pub. L. No. 113-235, § 538, 128 Stat. 
2130, 2217 (2014). 
 224. See Consolidated Appropriations Act, Pub. L. No. 115-141, § 538 (2018) 
(providing that no funds from the Act may be used to prevent the states listed in the 
Amendment from implementing their own laws legalizing, to whatever extent, the 
medical use of cannabis). 
 225. United States v. Marin All. for Med. Marijuana, 139 F. Supp. 3d 1039, 1040, 
1044 (N.D. Cal. 2015) (attacking the “contradiction inherent in the [DOJ’s] assertion 
that enjoining any one medical marijuana dispensary . . . does not impede California’s 
implementation of its medical marijuana laws”).  The United States entered a notice 
of appeal in December 2015 but moved to dismiss its appeal the following spring. 
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the Cole Memo and the congressional appropriations bills, suggests that 
the DOJ is not quite ready to give up cannabis enforcement. 
In a much-publicized development, Congress “legalized” hemp in 
2018 by changing the definitions of marihuana and THC in the CSA.226  
First, this reveals the dubious position of those who assert hemp as some 
kind of separate cousin species to cannabis. The Agriculture 
Improvement Act227 effectively defines hemp as Cannabis sativa with 
THC concentration of not more than 0.3 percent on a dry weight 
basis.228  Second, the descheduling of “hemp” and Commissioner 
Gottlieb’s response underscore this Article’s thesis that descheduling 
cannabis will not result in the free production, marketing, and 
distribution that proponents have claimed.  Instead, the FDA will 
continue to regulate any product containing ingredients such as THC and 
CBD that are themselves currently regulated as drugs, as well as any 
medical claims made by a producer of any products, regardless of whether 
those products or their ingredients are scheduled under the CSA.  
III.   FDA REGULATION RELEVANT TO MEDICAL CANNABIS 
The FDA regulates a wide variety of medical and consumer products 
sold in the United States—not just foods and drugs, but also dietary 
supplements, medical devices, cosmetics, and tobacco products.229  
The agency’s authority to regulate an item is triggered when that item 
satisfies a definition in the primary statute implemented by the agency, 
the FDCA.230  For instance, if an item meets the definition of “drug” in 
§ 201(g) the FDCA, the FDA has jurisdiction over the item and applies 
its rules and policies relating to drugs.231 
Two threshold points about the FDA’s jurisdiction are important to 
understand.  First, the statutory definitions for the various regulated 
categories—such as “drug” and “dietary supplement”—do not always 
align with common usage of the terms in question.  Their meanings 
have been fleshed out by the agency and courts, leading to rules that 
                                               
 226. See Agriculture Improvement Act of 2018, Pub. L. No. 115-334. 
 227. Pub. L. No. 115-334 (2018). 
 228. Id. 
 229. What Does FDA Regulate?, FDA, https://www.fda.gov/aboutfda/transparency/ 
basics/ucm194879.htm (last visited Feb. 5, 2019). 
 230. 21 U.S.C. §§ 301–399h (2012). 
 231. § 321(g)(1).  Throughout this Article, statutory references in the text use the 
provisions as numbered in the FDCA, rather than as numbered the U.S. Code.  Section 
201(g) of the FDCA is codified at 21 U.S.C. § 321(g). 
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might not be evident from looking at the statute alone.232  And the 
definitions do not take the same approach to classifying items.  For 
instance, one definition might consider the form of the item, another 
the actual use of the item, and another the claims made about the 
item.233  Complicating matters further, some definitions overlap.  It is 
possible for a single item to be both a cosmetic and a drug, for instance, 
and regulated under both sets of authorities.234 
Second, the FDA has authority only with respect to products shipped in 
interstate commerce.  Congress enacted the FDCA pursuant to its power 
to regulate commerce among the states,235 and the statutory provisions 
governing agency jurisdiction therefore focus on products that will be 
shipped in interstate commerce as well as those that have already been 
shipped in interstate commerce.236  The agency also takes the position 
that it may regulate products containing components (such as 
ingredients) previously shipped in interstate commerce, and the courts 
have generally deferred to the agency on this point.237  Most medical 
                                               
 232. See, e.g., Meserey v. United States, 447 F. Supp. 548, 553 (D. Nev. 1977) 
(explaining that “[r]egardless of the actual physical effect of the product, once it is 
established that its intended use brings it within the drug definition, it will be deemed 
a drug for purposes of the Act”); United States v. Frank, 189 F. 195, 199 (S.D. Ohio 
1911) (“[I]f any substance or mixture is intended to be used for the cure, mitigation, 
or prevention of disease of either man or other animals, it is nevertheless a drug 
whether it is recognized in the Pharmacopoeia . . . or not.”). 
 233. See United States v. Hazel Bishop, Inc., 409 F.2d 734, 739 (2d Cir. 1969) 
(“Regardless of the actual physical effect of a product, it will be deemed a drug for purposes 
of the Act where the labeling and promotional claims intended to show uses that bring it 
within the drug definition.”); Meserey, 447 F. Supp. at 553 (explaining that “[r]egardless of 
the actual physical effect of the product,” once the product’s intended use is established as 
one that falls within the statute, it will be deemed a drug covered by the FDCA). 
 234. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?), FDA, https://www.fda.gov/cosmetic 
s/guidanceregulation/lawsregulations/ucm074201. (last visited Feb. 5, 2019) (“[A] 
shampoo is a cosmetic because its intended use is to cleanse the hair. An antidandruff 
treatment is a drug because its intended use is to treat dandruff. Consequently, an 
antidandruff shampoo is both a cosmetic and a drug.”). 
 235. United States v. Walsh, 331 U.S. 432, 434 (1947) (“The Federal Food, Drug, 
and Cosmetic Act rests upon the constitutional power resident in Congress to regulate 
interstate commerce.”). 
 236. See, e.g., 21 U.S.C. § 331 (2012) (prohibiting certain acts, including the 
introduction of misbranded or adulterated foods, drugs, devices, cosmetics, or tobacco 
products into interstate commerce). 
 237. E.g., United States v. Regenerative Scis., LLC, 741 F.3d 1314, 1320–21, 1326 
(D.C. Cir. 2014) (affirming the FDA’s regulatory authority over the stem cell mixture 
at issue on the grounds that the mixture contained certain elements, specifically the 
antibiotic doxycycline, that were transported through interstate commerce prior to 
their incorporation into the mixture). 
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treatments and consumer products travel in interstate commerce, so the 
interstate commerce requirement generally does not meaningfully 
constrain the FDA’s authority.  After descheduling, however, some 
cannabis-based products could be made, sold, and used only within the 
borders of one state, without any component that traveled in interstate 
commerce.  In these cases, the FDA would have no jurisdiction.238 
A product containing or derived from cannabis, or containing 
components derived from cannabis, is most likely to be regulated by the 
FDA as a drug, food or food additive, or dietary supplement.  The 
category will depend on the product.  Because the product will contain 
plant-derived ingredients, the FDA may also consider it a “botanical 
product”—but this is a descriptive term, not a regulatory classification.239 
Section II.A, discusses regulation of cannabis-based products as 
drugs.  Next, Section II.B and Section II.C explain how FDA would 
regulate a food or a dietary supplement that contained cannabis or a 
cannabis constituent.  Section II.D considers the possibility that a 
product comprising cannabis or derived from cannabis might fall into 
a different FDA-regulated category or, indeed, outside the FDA’s 
purview altogether due to the statutory requirement for interstate 
                                               
 238. Cf. Patricia J. Zettler, Pharmaceutical Federalism, 92 IND. L.J. 845, 879 (2017) 
(“Because the FDA’s jurisdiction is limited to drugs that move in interstate commerce 
(including drugs with components that move in interstate commerce), medical 
marijuana laws could be written to avoid the FDA altogether by permitting only 
wholly intrastate production and sale of marijuana.”).  In this situation, however, state 
laws might authorize (or prohibit) sale.  As both Professor Zettler and Professor Noah 
have pointed out, various state laws authorized the local production and sale of laetrile 
for the treatment of cancer in the 1970s and 1980s, even though the FDA had not 
approved the treatment.  Id.; see also Lars Noah, State Affronts to Federal Primacy in the 
Licensure of Pharmaceutical Products, 2016 MICH. ST. L. REV. 1, 22–23 (noting that after 
the FDA “acted against [Laetrile] in the 1970s, numerous states legalized the use of 
this purported treatment for cancer”).  The interstate commerce limitation in the 
FDCA has similarly prompted the FDA to stay its hand with respect to purely intrastate 
sale of raw milk products.  See Pub. Citizen v. Heckler, 653 F. Supp. 1229, 1235 (D.D.C. 
1986) (explaining that the FDA declined to ban sales of raw milk because most raw 
milk products were marketed exclusively in intrastate commerce and the agency did 
not have adequate legal authority on the facts available at the time to prohibit 
intrastate marketing of raw milk); Requirements Affecting Raw Milk for Human 
Consumption in Interstate Commerce, 52 Fed. Reg. 29,509 (Aug. 10, 1987) (to be 
codified at 21 C.F.R. pt. 131). 
 239. CDER Small Bus. & Indus. Assistance, Botanical Drug Review, FDA/CDER SBIA 
CHRONICLES (Nov. 17, 2015), https://www.fda.gov/downloads/drugs/developm 
entapprovalprocess/smallbusinessassistance/ucm472934.pdf (“Botanical products 
may be classified as foods, dietary supplements, drugs, medical devices, or cosmetics, 
depending on their ‘intended use.’”). 
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commerce.  Part IV continues the discussion of the current statutory 
framework (as interpreted by the FDA) and the current regulatory 
framework (as applied by the FDA) and, in places, note positions that 
the FDA might take—without exploring whether this approach would 
in the end withstand legal challenge. 
A.   Medical Cannabis as “Drug” 
Explicit or implicit claims that a product containing cannabis (or a 
cannabis constituent) could treat disease, or even simply affect the 
functioning of the body, would turn that product into a “new drug” 
that requires premarket approval from the FDA.240  The research 
required to support premarket approval of a new drug is expensive and 
time consuming,241 and some cannabis-based products could present 
novel scientific and regulatory questions for the agency, potentially 
slowing the process and adding risk.  The agency has signaled its 
support for cannabis-based drugs and may be flexible with regulatory 
requirements in some situations, but there is no escaping the fact that 
the cost of taking a cannabis-based product through the FDA’s new 
drug approval paradigm could place this pathway out of reach for most 
entities providing medical cannabis today. 
1. Regulation of medical cannabis under the FDA’s new drug authorities 
Any product containing or made from cannabis would be deemed a 
“drug” by the FDA if it were associated with medical claims.242  Section 
201 of the FDCA defines a “drug” as any article (item) “intended for use 
in the diagnosis, cure, mitigation, treatment, or prevention of disease in 
man.”243  The term “drug” also includes any article “intended to affect 
the structure or function of the body of man” (unless it is a food).244  
Finally, anything intended as a “component” of a drug is also a drug.245  
Under this definition, the FDA’s authority is triggered by the “intended 
                                               
 240. See United States v. Cruez, 144 F. Supp. 229, 230, 235 (D. Ill. 1956) (holding that 
because the “defendant orally represented” that an herb tonic “was a remedy for treatment 
of arthritis,” the tonic was considered a drug and subject to regulation under the FDCA). 
 241. News Release, Cost of Clinical Trials for New Drug FDA Approval are Fraction 
of Total Tab, Johns Hopkins Bloomberg School of Public Health (Sept. 24, 2018) 
(describing study findings that FDA clinical trials cost a median of $19 million dollars, 
which makes up “one percent of the average total cost of developing a new drug”). 
 242. 21 U.S.C. § 321(g) (2012). 
 243. § 321(g)(1)(B). 
 244. § 321(g)(1)(C). 
 245. § 321(g)(1)(D). 
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use” of an item.  “Intended use” does not refer to the subjective intent 
of the company selling the product, nor does it refer to the purchaser’s 
intentions.246  Instead, intended use is measured objectively—generally 
on the basis of the claims made by the persons legally responsible for 
the product in interstate commerce.247  Thus, it usually turns on claims 
made in labeling, advertising, and other promotion.248 
Drug claims need not be explicit.  If a company implies its product 
can be used to treat disease, the FDA may conclude that the product is 
a drug.249  And the term “disease” should be understood broadly.  Any 
claim relating to treatment of a medical condition—for instance, 
easing the symptoms (such as muscle spasms) of multiple sclerosis, 
reducing nausea associated with chemotherapy, increasing appetite in 
patients with chronic illness such as HIV, or relieving pain and 
inflammation of arthritis—will be viewed as a drug claim by the FDA.250  
These claims turn the product into a drug even if the product does not 
work as described.251 
Any item is a “drug” for purposes of the FDA’s authority if it has the 
requisite intended use.252  The agency’s drug authority will apply 
                                               
 246. See Nat’l Nutritional Foods Ass’n v. Mathews, 557 F.2d 325, 334 (2d Cir. 1977) 
(“In determining whether an article is a ‘drug’ because of an intended therapeutic 
use, the FDA is not bound by the manufacturer’s subjective claims of intent but can 
find . . . intent on the basis of objective evidence.”). 
 247. 21 C.F.R. § 201.128 (2018) (stating that “intent is determined by such persons’ 
expressions or may be shown by the circumstances surrounding the distribution of the article”). 
 248. The claims need not be physically attached to the product (e.g., on the label).  
See Kordel v. United States, 335 U.S. 345, 350 (1948) (finding that “[o]ne article or 
thing is accompanied by another when it supplements or explains it”). 
 249. See, e.g., Patricia J. Zettler et al., Closing the Regulatory Gap for Synthetic Nicotine, 
59 B.C. L. REV. 1933, 1944 (2018) (noting that the FDA regulates smoking cessation 
aids as drugs based on the implied claims that they lower the risk of disease). 
 250. See United States v. Lane Labs–USA, Inc., 324 F. Supp. 2d 547, 569 (D.N.J. 
2004) (finding that “through its promotional material . . . [the defendant] promoted 
[its products] for the diagnosis, cure, mitigation, treatment, or prevention of diseases, 
namely cancer and HIV/AIDS,” and making them drugs under the FDCA); United 
States v. Cruez, 144 F. Supp. 229, 230, 235 (E.D. Ill. 1956) (holding that because the 
“defendant orally represented” that its herb tonic “was a remedy for treatment of 
arthritis,” it was considered a drug under the FDCA). 
 251. The definition of “drug” focuses on the item’s intended use, not its actual effect 
in the body. 
 252. This is not to say, however, that anything intended to treat a disease is a drug.  
FDA also regulates “devices,” which are similarly intended for use in the diagnosis, 
cure, mitigation, treatment, or prevention of disease or intended to affect the structure 
or function of the body.  21 U.S.C. §§ 321(h) (2012).  Such an item will be a device, 
rather than a drug, if (1) it is an “instrument, apparatus, implement, machine, 
contrivance, implant, in vitro reagent, or other similar or related article,” (2) it does 
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whether the product is composed of dried cannabis flower, derived 
from a cannabinoid (or terpenoid or flavonoid), extracted from the 
plant, or composed of synthetic compounds identical to (or similar to) 
these botanically-derived alternatives.  FDA authority will apply no 
matter what form the product takes—whether it is sold in a tin like 
chewing tobacco, sold dried for smoking, sold in an oil form for use 
with a diffuser, or baked into a cookie.  For instance, the FDA sent a 
warning letter to General Mills in May 2009, concluding that because 
the company promoted Cheerios® Toasted Whole Grain Oat Cereal 
for lowering cholesterol and thus for treatment, mitigation, and 
prevention of coronary heart disease, the breakfast cereal was also a 
“drug” and would be regulated as a drug.253  Drug claims will establish 
a drug’s intended use and turn the item into a drug, for FDA purposes. 
“Drug” status under the FDA framework would trigger a variety of 
regulatory requirements.  For instance the manufacturer would be 
required to comply with “current good manufacturing practices” 
(cGMP).254  The FDA’s cGMP regulations impose requirements relating 
to the creation and training of a quality control unit, design and features 
of any buildings and facilities used, design and maintenance of 
equipment used, production and process controls, and recordkeeping, 
among other things.255  Failure to comply with current cGMP would 
render the product adulterated and could expose the company to 
enforcement action, including criminal prosecution.256 
Also, the FDA would have jurisdiction over the product’s “labeling,” 
meaning any “written, printed, or graphic materials” associated with 
the product.257  If the agency concluded the product could be sold over 
the counter,258 the manufacturer would need to comply with the 
                                               
not “achieve its primary intended purpose through chemical action within or on the 
body,” and (3) it is “not dependent upon being metabolized for the achievement of its 
primary intended purpose.”  Id. 
 253. Warning Letter from FDA to General Mills (May 5, 2009), 
http://wayback.archive-it.org/7993/20170112195733/http://www.fda.gov/ICECI/E 
nforcementActions/WarningLetters/2009/ucm162943.htm. 
 254. 21 U.S.C. § 351(a) (2012) (deeming a drug “adulterated” if “the methods used 
in, or the facilities or controls used for, its manufacture, processing, packing, or 
holding do not conform to or are not operated and administered in conformity with 
current good manufacturing practice”). 
 255. See generally 21 C.F.R. pt. 211 (2018). 
 256. See 21 U.S.C. § 331(a), § 332, § 333. 
 257. § 321(m) (defining labeling as “all labels and other written, printed, or graphic matter 
(1) upon any article or any of its containers or wrappers, or (2) accompanying such article”). 
 258. See infra Section III.C. 
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agency’s nonprescription drug labeling regulations and, among other 
things, generally include a “Drug Facts” panel on the outside 
container.259  If the FDA instead concluded that prescriptions would be 
needed, the company would need to comply with the agency’s 
prescription drug labeling rules.260  The agency could also take 
enforcement action if any labeling—written, printed, or graphic 
materials—were “false or misleading in any particular.”  This would 
include taking action if the labeling omitted material information, 
such as the consequences from customary or usual use of the 
product.261  Again, these rules would apply simply because the product 
bore a medical claim and therefore became a “drug”—no matter what 
form the product took. 
The FDA would almost certainly also deem a cannabis drug to be a 
“new drug,” which is a separate statutory category requiring premarket 
approval.  A drug is a “new drug” unless two things are true:  (1) it is 
“generally recognized, among experts qualified by scientific training 
and experience to evaluate the safety and effectiveness of drugs, as safe 
and effective for use under the conditions prescribed, recommended, 
or suggested in the labeling thereof,” and (2) it has been marketed for 
a material time and to a material extent under those conditions.262  
Conventionally, this is referred to as being “generally recognized . . . as 
safe and effective” or “GRASE.”263  The FDA determines whether each 
product is GRASE, conducting the inquiry product by product, rather 
than active ingredient by active ingredient.264  And the inquiry is 
specific to the conditions described in that product’s labeling—its 
intended use, as well as its route of administration, dosage form, and 
strength.265  In other words, the specific drug product (not cannabis 
itself, or cannabis for a particular type of use, such as pain relief) must 
be GRASE.  If it is not, the product is a new drug, which means it cannot 
be shipped in interstate commerce without either (1) an approved NDA, 
                                               
 259. See 21 C.F.R. § 201.66(c). 
 260. See infra Section III.A.3. 
 261. 21 U.S.C. §§ 321(n), 352(a). 
 262. § 321(p). 
 263. Id. 
 264. See United States v. Generix Drug Corp., 460 U.S. 453, 459 (1983) (concluding that the 
term “drug” refers to “entire drug products, complete with active and inactive ingredients”). 
 265. 21 U.S.C. § 321(p) (defining a drug as a new drug if it is not GRASE “under 
the conditions prescribed, recommended, or suggested in the labeling thereof”). 
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which permits commercial marketing, or (2) effective investigational 
new drug application (IND), which permits testing in humans.266  
The FDA has consistently treated cannabis-based drugs as “new 
drugs” under the FDCA.  For instance, in the 1970s, the agency 
permitted INDs for the use of cannabis to treat a variety of ailments, 
including refractory glaucoma and anorexia associated with AIDS.267  
Although the IND regulatory mechanism normally governs clinical 
trials, the INDs permitted here were for compassionate use programs.  
Unlike clinical trials, these programs were not intended to generate 
information for purposes of new drug approval.  They were instead 
designed primarily to permit treatment of a patient’s disease or 
condition.268  While these early “treatment INDs” are no longer active, 
the FDA has since permitted dozens of INDs for true clinical trials of 
cannabis and cannabis-based products.269  In addition, the FDA has 
approved three NDAs for synthetic cannabinoids as well as one NDA 
for a naturally derived cannabinoid drug product.270 
In view of these precedents, the FDA would likely conclude that any 
drug containing or derived from cannabis is a new drug.271  Although 
                                               
 266. § 355(a). 
 267. MACK & JOY, supra note 81, at 159–61. 
 268. The government established the program initially to settle a civil lawsuit 
brought by Robert Randall, who sought cannabis for treatment of his glaucoma.  The 
government eventually agreed to supply medical cannabis—in cigarette form—to 
several other people through the same mechanism.  Kuromiya v. United States, 78 F. 
Supp. 2d 367, 368 (E.D. Pa. 1999); see also Moira Gibbons, The Cannabis Conundrum:  
Medication v. Regulation, 24 HEALTH LAW. 1, 5 (2011).  The National Institute on Drug 
Abuse (NIDA), part of the National Institutes of Health (NIH), cultivated and 
distributed the cannabis.  MACK & JOY, supra note 81, at 160. 
 269. The program shut down in 1991, but the government continued to supply the 
thirteen patients that it had approved by that time.  Kuromiya, 78 F. Supp. 2d at 370; MACK 
& JOY, supra note 81, at 160.  For a discussion of current clinical trials, see infra Section IV.B. 
 270. See infra Section IV.A. 
 271. In November 2017, the FDA received a citizen petition asking it to confirm 
that cannabis and THC are not only drugs but also new drugs—that is, not generally 
recognized as safe and effective.  See Drug Watch Int’l, Inc. Citizen Petition, No. FDA-
2017-P-6692 (Nov. 21, 2017), https://www.regulations.gov/document?D=FDA-2017-P-
6692-0001.  The petition relies on the fact that, at the time of its filing, the FDA had 
approved three synthetic cannabinoid drugs under the new drug provisions.  Id. at 4.  
On July 2, 2018, the FDA denied the citizen petition, refusing to issue a “negative 
monograph specifically stating that unapproved new OTC marijuana and THC 
products are not GRAS/E and [] subject to” regulation, but nonetheless finding that 
“these products are ‘new drugs’” under the FDCA.  Response from FDA to Drug Watch 
Int’l, Inc., No. FDA-2017-P-6692-0042 (July 2, 2018), https://www.regulations.gov/ 
document?D=FDA-2017-P-6692-0042. 
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a drug may be exempt from the FDA’s new drug authorities, it is 
unlikely that either exemption would cover a drug containing or 
derived from cannabis.272  First, a particular product might be deemed 
GRASE and therefore not a new drug.  Since the 1960s, however, the 
FDA has interpreted the GRASE exemption to require “the same 
quantity and quality of scientific evidence that is required to obtain 
approval of an application for the product.”273  The Supreme Court has 
accepted the FDA’s approach, reasoning that any other approach would 
deprive the agency of jurisdiction over a drug that, if it were subject to 
the agency’s jurisdiction, could not be marketed.274  And again, the new 
drug inquiry is product by product and specific to the conditions of use 
described in the labeling. Extensive published research on medical 
cannabis uses, broadly speaking, will not satisfy the standard.  The 
agency would expect “substantial evidence” that a particular product was 
safe and effective for a particular use.275  In this case, the manufacturer 
might as well seek approval of a marketing application. 
Second, a product might be “grandfathered,” and therefore not a 
new drug.  Under the original grandfather clause, a drug product on 
the market before passage of the FDCA in 1938 was not a “new drug” 
if “its labeling contained the same representations concerning the 
conditions of its use.”276  When Congress amended the statute in 1962 
to require that new drug applications contain effectiveness data, it 
extended the grandfather clause, exempting any drug that was 
excluded prior to 1962, so long as its composition and labeling did not 
change.277  In effect, a drug that is not GRASE is nevertheless exempt 
from the new drug provisions if it was regulated under the Pure Food 
and Drugs Act of 1906 and if its labeling at the time contained the same 
representations as now concerning the conditions of its use.  It would 
be exceptionally difficult for a company to satisfy the documentation 
                                               
 272. It would still be a “drug” subject to the agency’s drug regulations, including (as 
noted) current good manufacturing practice and labeling requirements, and probably 
prescription status. 
 273. 21 C.F.R. § 314.200(e)(1) (2018).  This Article describes this evidentiary 
burden in the next Subpart. 
 274. See Weinberger v. Hynson, Westcott & Dunning, Inc., 412 U.S. 609, 631 (1973) 
(“[W]e cannot construe § 201(p) to deprive FDA of jurisdiction over a drug which, if 
subject to FDA regulation, could not be marketed because it had not passed the 
[FDA’s] ‘substantial evidence’ test.”). 
 275. Id. at 617–19. 
 276. 21 U.S.C. § 321(p) (2012). 
 277. Drug Amendments Act of 1962, Pub. L. No. 87-781, § 107(c), 76 Stat. 780, 789. 
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requirements that the FDA has put in place for grandfather status.278  
The agency requires evidence of “past and present quantitative 
formulas, labeling, and evidence of marketing.”279  And, like GRASE 
status, grandfather status is product-specific.280  The FDA has rejected 
arguments about cannabis products to date based on the sufficiency of 
the evidence presented.281 
                                               
 278. See 21 C.F.R. § 314.200(e)(2) (providing that “[a] contention that a drug 
product is exempt” under § 201(p) of the act or the § 107(c) amendments must be 
supported by sufficient evidence). 
 279. Id. 
 280. The FDA will not make decisions about grandfathering on a class-wide basis.  
See, e.g., Response from FDA to Alston & Bird LLP, No. FDA-2012-P-0189 (Nov. 12, 
2015), https://www.regulations.gov/document?D=FDA-2012-P-0189-0006 (denying 
petition to confirm grandfather status of cocaine hydrochloride, noting disagreement 
with petitioner’s premise “that a determination as to whether drug products are 
exempt from the new drug safety and effectiveness requirements . . . by virtue of the 
1938 grandfather clause can or should be made on a class-wide (i.e., non-product-
specific) basis,” and adding that “determinations with respect to ‘grandfather’ status 
are made on a product-specific basis”). 
 281. In 2000, the FDA rejected a petition arguing that various products prepared 
from “home-grown cannabis” were exempt from the “new drug” authorities under the 
grandfather clause.  See Klopper & Mikuriya Citizen Petition, No. FDA-1999-P-2922 
(formerly Docket No. 99-1865/CP1) (May 21, 1999).  The petitioners had described 
specific formulations, uses, and labeling on the market prior to the 1938 statute, 
including formulations marketed by Parke, Davis, & Company (which included 
“pressed flowering tops” sold by the ounce) for analgesic purposes, spasmodic 
disorders, and neuralgia; extracts sold by Eli Lilly & Company as analgesics and for 
migraines; “flowering top of the female plant” sold by Merck to increase the appetite; 
and the “dried flowering tops of the female plant” sold by Squibb for epilepsy.  Id.  The 
agency denied the petition because the petitioners had not presented evidence that 
the drug products for which they sought grandfather status were “the same drug 
products that were marketed” prior to 1938.  Response from FDA to Klopper & 
Mikuriya, No. FDA-1999-P-2922 (Dec. 29, 2000).  A grandfather argument must be 
supported by (among other things) an “exact quantitative formulation of the drug 
(both active and inactive ingredients).”  Id.  It must also be supported by documents 
to show that the labeling has not changed.  The FDA also took the position that 
because cannabis is a controlled substance and must bear a “C” designation in the 
labeling, the labeling has changed sufficiently to revoke grandfather status.  If cannabis 
were descheduled, the FDA could not deny grandfather status on this ground. 
A still-pending petition submitted in 2011 attempts to overcome the 
documentation hurdles with respect to two additional products:  bulk cannabis (in 
pressed, loose leaf, sifted, grounded, or powdered forms) and cannabis in tincture or 
liquid form as manufactured and labeled by the Lloyd Brothers Corporation.  See 
Mikuriya & McPike Citizen Petition, No. FDA-2011-P-0671 (Sept. 9, 2011), 
https://www.regulations.gov/document?D=FDA-2011-P-0671-0001.  The petitioners 
provide details about the Lloyd Brothers distilling process, details about the company’s 
marketing time line, and copies of the labels showing the percentage of alcohol present.  Id. 
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A company need not petition the agency asking for confirmation 
that its product is GRASE or grandfathered.  Instead, it may reach this 
conclusion on the basis of evidence in its possession and proceed to 
market.  If the company is correct, the product is a drug subject to the 
FDA’s drug authorities.  But the FDA is likely to disagree with this 
assessment for a drug containing or derived from cannabis, and a 
company that erred would face enforcement action—up to and 
including criminal prosecution.282  The Authors therefore assume that 
any commercial product containing or derived from cannabis that is 
intended for a medical use will require an approved NDA.283   
2. Pathway to market under the new drug authorities 
An NDA must describe the product, including its composition and 
how it is made, and demonstrate that the product is safe and effective 
when used as described in its labeling.284  An applicant describes the 
product and manufacturing process in the “[c]hemistry, 
manufacturing, and controls” (“CMC”) section of the NDA, and it 
substantiates the product’s safety and effectiveness with preclinical 
(animal and laboratory) and clinical (human) data.285 
                                               
 282. 21 U.S.C. § 333(a) (2012). 
 283. There is another possibility:  new drug status and enforcement discretion 
because the cannabis is undetectable.  The National Drug Code Directory on the 
FDA’s website lists numerous marketed homeopathic drugs that list cannabis sativa as 
an ingredient.  See National Drug Code Directory, FDA, https://www.accessdata.fda.gov/ 
scripts/cder/ndc (last visited Feb. 5, 2019).  Home Sweet Homeopathics, for instance, 
appears to market a homeopathic medicine for migraine containing “cannabis sativa 
30c.”  Id. (select “labeler” from the drop down menu; then search for “Home Sweet 
Homeopathics”).  BioEnergetics, Inc. appears to market a homeopathic medicine for 
allergies containing cannabis sativa pollen.  Id. (select “labeler” from the drop down 
menu; then search for “BioEnergetics, Inc.”).  The practice of homeopathy assumes 
that disease symptoms can be cured by small doses of substances that would cause 
similar symptoms in healthy people.  The cannabis in a homeopathic product labeled 
as containing diluted cannabis is likely to be undetectable.  Homeopathic medicines 
are nevertheless “drugs” and, indeed, likely all “new drugs” that require preapproval.  
The FDA has historically exercised enforcement discretion, unless safety issues arose.  
See generally FDA, DRUG PRODUCTS LABELED AS HOMEOPATHIC:  GUIDANCE FOR FDA STAFF 
AND INDUSTRY (2017), https://www.fda.gov/downloads/drugs/guidancecompliance 
regulatoryinformation/guidances/ucm589373.pdf; CPG Sec. 400.400 Conditions Under 
Which Homeopathic Drugs May be Marketed, FDA, https://www.fda.gov/iceci/com 
pliancemanuals/compliancepolicyguidancemanual/ucm074360.htm (last updated 
Mar. 20, 2015).  It is unlikely to exercise this discretion if the cannabis-derived active 
ingredient can be detectable. 
 284. 21 C.F.R. § 314.50(d)(1). 
 285. § 314.50(d)(1), 314.50(d)(5)(iv). 
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Some new drugs containing, or derived from, cannabis would qualify 
as botanical drugs, in which case they might benefit from the agency’s 
emerging and more flexible approach to botanical NDAs.286  The FDA 
has published guidance to encourage the development of botanical 
drugs,287 and in 2003 it created a Botanical Review Team (BRT) to 
assist in review of botanical NDAs.288  The guidance describes greater 
flexibility with respect to some application requirements, and the BRT 
appears to be pivotal in ensuring the agency exercises this flexibility.289  
Using this more flexible approach, the FDA has now approved two 
botanical drugs:  Veregen (sinecatchins) for the treatment of genital 
and perianal warts, and Mytesi (crofelemer) for the symptomatic relief 
of non-infectious diarrhea in adult patients with HIV/AIDS on anti-
retroviral therapy.290 
                                               
 286. A botanical NDA proposes a drug containing plant-derived ingredients.  
According to agency officials, interest in botanical drugs has been increasing.  Between 
1982 and 2007, the agency received more than 350 requests to conduct clinical trials 
and requests for meetings about clinical trials.  Shaw T. Chen et al., New Therapies from 
Old Medicines, 26 NATURE BIOTECH. 1077, 1077 (Oct. 2008). 
 287. See generally FDA, BOTANICAL DRUG DEVELOPMENT:  GUIDANCE FOR INDUSTRY 
(2016) [hereinafter BOTANICAL GUIDANCE]. 
 288. A reviewer from the BRT provides a “pharmacognosy review” which, among 
other things, evaluates the identity of the plant used in the botanical drug product, 
evaluates the applicant’s raw material characterization and control, and evaluates 
previous human experience with the botanical product.  The botanical NDA is 
otherwise reviewed by the same FDA scientific staff within the Office of New Drug 
Products (OND) as any other NDA.  Chen, supra note 286, at 1077–78.  See generally 
FDA, CTR. DRUG EVALUATION & RES., OFFICE OF PHARM. QUALITY, MAPP 5210.9 REV 1, 
MANUAL OF POLICIES AND PROCEDURES:  REVIEW OF BOTANICAL DRUG PRODUCTS (2016) 
[hereinafter REVIEW OF BOTANICAL DRUG PRODUCTS]. 
 289. See REVIEW OF BOTANICAL DRUG PRODUCTS, supra note 288, at 9 (discussing the BRT’s role). 
 290. FDA, CTR. FOR DRUG EVALUATION & RES., APPROVAL PACKAGE FOR:  APPLICATION 
NO. 202292ORIG1S000 (2012) [hereinafter FULYZAQ APPROVAL PACKAGE], 
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202292Orig1s000Appr
ov.pdf (approving Fulyzaq); FDA, CTR. FOR DRUG EVALUATION & RES., APPROVAL 
PACKAGE FOR:  APPLICATION NO. 21-902 (2006) [hereinafter VEREGEN APPROVAL 
PACKAGE], https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021902s000_ 
approv.pdf (approving Veregen).  The names of these products have changed since 
their initial approval.  In June 2007, FDA approved a supplemental NDA to reflect a 
change in the nonproprietary name for Veregens from kunecatechins to sinecatchins.  
See FDA, CTR. FOR DRUG EVALUATION & RES., APPROVAL OF NDA 21-902/S-001, (June 1, 
2007), https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/021902s 
001ltr.pdf.  In March 2018, FDA approved a supplemental NDA to reflect a change in 
the proprietary name of Fulyzaq to Mytesi.  See FDA, CTR. FOR DRUG EVALUATION & 
RES., APPROVAL OF NDA 202292/S-006 (Mar. 6, 2018), https://www.accessdata.fda.gov/ 
drugsatfda_docs/appletter/2018/202292Orig1s006ltr.pdf.  The text of this Article 
uses the current names rather than the names at the time of initial approval. 
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FDA officials cite the agency’s work on botanical drug development 
as evidence that the agency “actively” supports the development of 
drugs from cannabis.291  But there are two reasons to be cautious.  First, 
the botanical NDA framework does not apply to drugs containing 
highly-purified substances simply derived from naturally occurring 
sources.292  Many commonly-used drugs contain active ingredients 
derived from plant sources and subsequently are highly processed and 
purified.293  The FDA gives the example of paclitaxel, originally derived 
from an extract of the yew tree.294  The agency does not consider these 
botanical drugs, and they do not benefit from the flexibility enjoyed by 
the companies that developed Veregen and Mytesi.295  Likewise, a 
highly processed and purified drug derived from an extract of the 
cannabis plant does not enjoy the same flexibility that attaches to drugs 
the FDA deems botanical.  As a result, the traditional new drug 
development and approval paradigm described below will apply to 
some drug products derived from cannabis.296  The more flexible 
                                               
 291. Douglas C. Throckmorton, Meeting Presentation, FDA Regulation of Marijuana:  
Past Actions, Future Plans (April 12, 2016), https://www.fda.gov/downloads/AboutFD 
A/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM498077.pdf. 
 292. BOTANICAL GUIDANCE, supra note 287, at 1. 
 293. See Kate Wong, Mother Nature’s Medicine Cabinet, SCIENTIFIC AMERICAN (Apr. 9, 2001), 
https://www.scientificamerican.com/article/mother-natures-medicine-c  (providing commons 
examples such as aspirin). 
 294. BOTANICAL GUIDANCE, supra note 287, at 2.  Paclitaxel was originally made from the 
bark of Taxus brevifolia, the Pacific yew tree.  Success Story:  Taxol, NATIONAL CANCER INST., 
https://dtp.cancer.gov/timeline/flash/success_stories/S2_taxol.htm.  Eventually a 
starting material could be extracted from other Taxus trees, including the common 
Taxus baccata (European yew).  Id.  This starting material was collected from plants 
cultivated in public and private parks and gardens as well as plantations in Europe.  
E.g., FDA, CTR. FOR DRUG EVALUATION & RES., NDA 20-262/S-026, ENVIRONMENTAL 
ASSESSMENT AND FINDING OF NO SIGNIFICANT IMPACT FOR TAXOL (PACLITAXEL) INJECTION 
(Nov. 6, 1997), https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020262 
s026s027s028_taxol_chemr_EA_phrmr.pdf. 
 295. Veregen is made from the dried leaves of Camellia sinensis, a green tea plant, 
grown on specific farms.  FDA, CTR FOR DRUG EVALUATION & RES., APPLICATION NO. 21-
902, BOTANICAL REVIEW (Sept. 15, 2006) [hereinafter VEREGEN BOTANICAL REVIEW], 
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021902s000_botanicalr.
pdf.  The drug substance in Mytesi—crofelemer—is extracted from Croton lechleri, also 
known as dragon’s blood or tree’s blood, harvested from the wild in South America.  
FDA, CTR FOR DRUG EVALUATION & RES., APPLICATION NO. 202292ORIG1S000, SUMMARY 
REVIEW (Dec. 14, 2012) [hereinafter FULYZAQ SUMMARY REVIEW], https://www.acce 
ssdata.fda.gov/drugsatfda_docs/nda/2012/202292Orig1s000SumR.pdf. 
 296. As this Article discusses in Part IV, the FDA recently approved a drug 
containing a highly purified extract of cannabis, and although the agency did not 
deem the drug a botanical, it invited the BRT to participate in review of the 
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approach to development and approval of botanical drugs—also 
described below—may apply to others. 
Second, agency documents relating to approval of Veregen and 
Mytesi illustrate that although the FDA may be willing to take a more 
flexible approach with respect to certain portions of the NDA, there is 
a potential for significant disputes between the BRT and the usual 
reviewers in the Office of New Drug.297  This disagreement may require 
resolution by agency leadership.  The need for leadership involvement 
could make it risky to count on the exercise of flexibility for a cannabis-
based botanical NDA and important to engage with the agency early 
regarding plans to file a botanical NDA. 
a. Chemistry, manufacturing, and controls 
The CMC section must describe and provide data on the 
composition, manufacture, and specifications of both the drug 
substance (active ingredient) and the finished drug product (that is, 
in its final form for the patient).298  Describing the active ingredient 
means describing its physical and chemical characteristics and its 
stability; explaining how it is made (or isolated and purified, for 
instance); describing the controls used during manufacturing; and 
laying out the specifics that are needed to ensure its identity, strength, 
quality, and purity.299  Describing the product also includes listing the 
components used in its manufacture (and identifying their 
manufacturer and specifications), describing the manufacturing 
procedures and in-process controls used, and laying out the 
specifications needed to ensure the product’s strength, quality, purity, 
potency, and bioavailability.300 
The primary challenges for a botanical NDA are uncertainty about 
the botanical drug’s active constituents, heterogeneity of the drug 
substance, and inconsistency from batch-to-batch.301  These issues will 
complicate preparation and review of the CMC section of the NDA.302  
                                               
application.  See EPIDIOLEX PRODUCT QUALITY REVIEW(S), infra note 571.  But it does 
not appear from the review documents that the applicant needed, or that the FDA 
exercised, the same sort of flexibility with respect to application requirements as it 
applied when approving Veregen and Mytesi. 
 297. FULYZAQ SUMMARY REVIEW, supra note 295; VEREGEN APPROVAL PACKAGE, supra note 290. 
 298. 21 C.F.R. § 314.50(d)(1)(i)(2018). 
 299. § 314.50(d)(1). 
 300. § 314.50(d)(1)(ii)(a). 
 301. BOTANICAL GUIDANCE, supra note 287, at 4. 
 302. 21 C.F.R. § 314.50(d)(1)(i). 
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The FDA’s guidance document indicates that “therapeutic consistency” 
can be supported using a totality of the evidence approach,” if the 
applicant submits information relating to the botanical raw material, 
quality control through chemical testing and manufacturing control, 
and biological assays or even clinical data.303  Quality control of the drug 
substance may consider factors such as strength by dry weight, chemical 
identification of active constituents (if known) or chemical constituents, 
quantification of active constituents (if known) or chemical 
constituents, and tests for residual pesticides.304  A biological assay 
would need to reflect the drug’s known or intended mechanism of 
action.305  If the active constituents are not known or quantifiable, it 
may be important to develop an assay to assess batch potency and 
activity relative to a reference standard.306  The chemistry section 
should also include a thorough review of past human experience with 
the raw materials and known constituents.307 
The application of a “totality of the evidence” for botanical drugs 
means that some drugs that would not pass a traditional CMC review 
may survive review with the support of the Botanical Review Team.308  
The primary chemistry reviewer in the Office of New Drugs 
considering Mytesi, for instance, concluded that issues relating to the 
identity, strength, purity, and quality of the drug substance and drug 
product precluded approval.309  The botanical reviewer, by way of 
contrast, argued that these concerns stemmed from a “strict reading” 
of the regulations and definitions of “identity,” “active ingredient,” and 
“purity” from a “pure small molecule drug perspective.”310  He argued 
that the regulations should be interpreted in a way that would 
                                               
 303. Id.; see also Botanical Drug Review, supra note 239, at 2 (noting that the FDA will 
use a “totality of the evidence” approach, in order to overcome limitations in the ability 
to characterize the active ingredient (or mixture) and in order to respond to concerns 
about heterogeneity and batch-to-batch variability).  Describing the raw material 
includes explaining the agricultural and collection practices used. BOTANICAL 
GUIDANCE, supra note 287, at 4. 
 304. BOTANICAL GUIDANCE, supra note 287, at 10–11. 
 305. Id. at 4. 
 306. Id. at 10. 
 307. Id. at 7–8. 
 308. Botanical Drug Review, supra note 239 (indicating that the CMC documentation 
for a botanical drug may be different from that for a synthetic or highly purified drug). 
 309. FULYZAQ SUMMARY REVIEW, supra note 295, at 4; see also FDA, CTR. FOR DRUG 
EVALUATION AND RES., MEMORANDUM:  BOTANICAL SECONDARY REVIEW OF NDA 202292 
8–11 (2012), https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202292Or 
ig1s000BotanicalR.pdf. 
 310. FULYZAQ SUMMARY REVIEW, supra note 295, at 2. 
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“accommodate the complex nature of botanical drug substance.”311  
For example, he wrote, “the ‘identity’ of botanicals must include, in 
addition to the standard chemical analyses, the source of raw materials 
and other non-CMC data—e.g., identification of species, geographic 
location of harvesting, processing, and bioassay, if available.”312  The 
Division Deputy Director agreed with the botanical reviewer’s view that 
“botanical new drugs can rarely have CMC specifications as precise as 
those of pure chemical drugs,” and “it is especially difficult to 
determine for botanical drugs with unknown number and identities of 
active ingredients (such as crofelemer) whether the future marketing 
batches will have the same therapeutic effects as that observed in 
clinical trials.”313  Ultimately, the Director of the Center for Drug 
Evaluation and Research made the call, concluding—possibly in light 
of the “urgent need” for the product, which was intended for 
treatment of diarrhea in patients with HIV/AIDS—that “all of the 
CMC characterization” was not needed.314  This history suggests that 
the agency’s willingness to be flexible in any particular case may 
depend a great deal on the views of a single botanical reviewer.  It could 
also depend on the support of agency leadership, who may focus on 
broader questions of public health. 
b. Preclinical and clinical data 
An NDA also contains several sections establishing the product’s 
safety and effectiveness.315  Generating the data in these sections 
requires a stepwise process beginning with laboratory and animal 
studies, (“preclinical” or “nonclinical” research), followed by several 
phases of human (“clinical”) trials that culminate in pivotal trials 
establishing effectiveness.316 
                                               
 311. Id. 
 312. Id. The botanical reviewer played a key role in pushing the agency’s thinking 
further.  For instance, he proposed a variety of ways to address uncertainty about batch-
to-batch variability that did not appear in the 2004 version of the guidance document 
then in effect.  These included “pre-CMC” steps (such as controlling collection of raw 
materials to eco-geographic regions with good agricultural and collection practices) 
and “post-CMC” evidence (such as clinical evidence that therapeutic effect is not 
affected by batch-to-batch variation).  Id. at 4–5. 
 313. Id.  at 4. 
 314. Id. at 12. 
 315. 21 C.F.R. § 314.50(d)(2)–(5)(2018). 
 316. FULZYAQ SUMMARY REVIEW, supra note 295, at 5–6. 
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The general goal of preclinical research is to collect the data 
necessary to support the safety of early clinical trials.317  In practice, the 
FDA expects both pharmacology tests, which consider how the drug 
works on various physiological systems and how the body processes the 
drug, and toxicology tests, which assess the drug’s short-term and long-
term adverse effects.318  The applicant submits its preclinical data in an 
IND.  The amount of newly generated preclinical data needed for a 
botanical IND will depend on the human experience with the 
botanical drug to date.319  But the FDA expects rigorous data on the 
nonclinical pharmacology and toxicology of the precise drug 
substance being developed, which means that anecdotal reports about 
the safety and effectiveness of cannabis—even if based on decades of 
illicit use or even reports of lawful medical use prior to enactment of 
the CSA—will not suffice. These data could reduce the amount of 
nonclinical testing required by the FDA, but they will not replace it.320 
After the FDA permits an IND to go into effect, the company may 
conduct human testing.321  The agency expects the pre-approval 
clinical testing process to advance through stages, from small groups 
of healthy volunteers, at the outset, to large multi-site trials in patients, 
designed and executed to provide statistically robust proof of safety 
and efficacy.322  The agency’s regulations describe three phases of 
trials, but marching through three sequential, non-overlapping phases 
of testing is not required and may not always be the most effective or 
efficient way to proceed.323  The final pivotal trials are designed to 
                                               
 317. Id. at 9. 
 318. 21 C.F.R. § 312.23. 
 319. Id. 
 320. The recently-enacted 21st Century Cures Act does not change this.  See generally 
Pub. L. No. 114-255, 130 Stat. 1033 (2016).  Congress directed the FDA to evaluate the 
potential use of “real world evidence” in approval decisions, but only in decisions to 
approve new indications for already approved drugs.  See 130 Stat. at 1096–98.  
Moreover, this new provision of the statute does not alter the standard of approval, 
including the “substantial evidence” standard.  Id. 
 321. The Drug Development Process, Step 3:  Clinical Research, FDA, https://www.fda.gov 
/forpatients/approvals/drugs/ucm405622 (last visited Feb. 5, 2019). 
 322. Id. 
 323. § 312.21.  Phase 1 trials generally involve administering the investigational 
drug to a very small number of healthy individuals primarily to gather safety data, such 
as safe dosage for future tests.  A company might use patients rather than healthy 
volunteers, however, if the drug is very potent or toxic and use in healthy volunteers would 
raise ethical issues.  Phase 2 trials are designed to gather additional short-term safety data 
and dose range findings, but also effectiveness data.  They usually involve a small number 
of patients, perhaps as many as several hundred. Phase 3 studies are designed to determine 
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establish that the drug satisfies the statutory approval standard:  
“substantial evidence” of effectiveness.324  Substantial evidence means 
evidence consisting of “adequate and well-controlled” clinical trials, on 
the basis of which qualified experts could “fairly and responsibly” 
conclude that the drug has the effect claimed.325 
The FDA’s regulations flesh out the characteristics of an “adequate 
and well-controlled” trial.326  Such a trial has a protocol with a clear 
statement of objectives and a summary of the proposed method of 
analysis.327  It should use a design that permits a valid comparison with 
a control to provide a quantitative assessment of the drug’s effect, and 
the effect should be measured in a way that is well-defined and 
reliable.328  Subjects should be selected in a way that ensures they have 
the disease or condition being studied, and they should be assigned to 
treatment and control groups in a way that minimizes bias and ensures 
the arms are comparable.329  Additional measures should be taken to 
minimize bias on the part of the subjects as well as other participants 
in the trial, such as the investigators conducting the trial.330  Finally, 
the study report should include an appropriate statistical analysis of 
the results, sufficient to assess the drug’s effects.331  
                                               
whether the drug is safe and effective for the target indication and to more precisely 
identify any drug-related adverse effects.  They typically involve several hundred to several 
thousand patients and multiple sites, often in multiple countries.  Id. 
 324. 21 U.S.C. § 355(f) (2012). 
 325. § 355(d).  The FDA generally expects two adequate and well-controlled trials, 
however, Congress amended the FDCA in 1997 to confirm that the agency may 
approve a drug on the basis of one, combined with “confirmatory evidence.”  See Food 
and Drug Modernization Act of 1997, Pub. L. No. 105-115, 111 Stat. 2296, 2313. 
 326. See 21 C.F.R. § 314.126; see also Lietzan, supra note 46, at 51–54 (2018). 
 327. § 314.126(b)(1). 
 328. § 314.126(b)(2). 
 329. § 314.126(b)(3). 
 330. § 314.126(b)(4). 
 331. § 314.126(b)(7).  The gold standard approach is a randomized, double-blind, 
placebo-controlled hypothesis-testing trial pursuant to a written protocol with a 
prespecified data analysis plan.  E.g., John Concato et al., Randomized, Controlled Trials, 
Observational Studies, and the Hierarchy of Research Designs, 342 NEW ENGLAND J. MED. 1887 
(2000); Laura E. Bothwell et al., Assessing the Gold Standard—Lessons from the History of 
RCTs, 374 NEW ENGLAND J. MED. 2175 (2016).  That said, the substantial evidence 
standard can be surprisingly flexible when circumstances necessitate flexibility.  The 
FDA has approved new drugs on the basis of a single trial, on the basis of a single study 
in fewer than 10 patients, on the basis of studies without blinding or controls, and—
indeed—without any efficacy testing in humans.  See, e.g., Frank J. Sasinowski & 
Alexander J. Varond, FDA’s Flexibility in Subpart H Approvals:  Assessing Quantum of 
Effectiveness Evidence, 71 FOOD & DRUG L.J. 135, 139–41 (2016) (studying nineteen 
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The clinical data requirements for approval of a botanical drug do 
not differ from the clinical data requirements for a non-botanical 
drug.332  Phase 3 trials of a botanical drug, including a drug containing 
cannabis, would have the same purpose and design requirements as 
any other phase 3 trials.  Clinical development of botanical drugs does, 
however, face some special issues, and clinical development of a 
cannabis-based botanical drug would face these issues. 
First, a botanical drug substance can differ in its characteristics over 
the course of a drug development program.333  For instance, changes 
in the agricultural and collection practices for the raw material, or 
changes in the manufacturing process as result of process optimization, 
may lead to changes in drug substance composition.334  Preclinical and 
clinical testing results that use earlier versions of the drug substance 
generally cannot be used in a marketing application without 
“bridging” studies that compare the versions.335 
Second, a botanical drug substance may vary in chemical 
composition from batch-to-batch.  The FDA will expect an applicant to 
explore the impact of batch-to-batch variability on the therapeutic 
effect of the botanical drug product and, in particular, to support an 
argument that expected variations will not cause a meaningful 
difference in therapeutic effect.336  The agency has suggested using 
multiple batches in phase 3 trials, which may help an applicant 
understand (1) which variations are clinically relevant and (2) if they 
are clinically relevant, the range of variability that can be tolerated to 
maintain the product’s identity, safety, and efficacy.337 
Third, depending on the route of administration and therapeutic 
goal, it may be difficult to design an adequately blinded clinical trial 
with objective endpoints.338  In some cases, it may be necessary to use a 
botanical in the control drug in order to mask the presence (or 
                                               
approvals granted by the FDA through its accelerated approval process for diseases 
and illnesses other than cancer and AIDS). 
 332. See, e.g., VEREGEN BOTANICAL REVIEW, supra note 295, at 2 (2006) (“For clinical 
data to support marketing approval, there should be no difference between botanical 
and non-botanical drugs.”). 
 333. Other drugs evolve during development, but the FDA has flagged this as an 
issue for botanical drugs in particular. 
 334. BOTANICAL GUIDANCE, supra note 287, at 6. 
 335. Id. 
 336. Id. at 15–16. 
 337. Id. 
 338. Id. at 12. 
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absence) of the active drug.339  Senior leadership at the agency has also 
questioned whether blinding is possible if an investigational cannabis-
based drug is administered through combustion (smoking) and have 
expressed concern about the subjectivity of the endpoints needed for 
many therapeutic goals of cannabis-based products.340  Subjective 
endpoints can reduce the reliability of positive results from a trial and 
can lead the FDA to reject marketing applications.341 
Finally, there is an open question of whether and how the FDA’s 
combination drug regulation will apply.342  Under this regulation, the 
sponsor of a drug product containing two active components must 
demonstrate that each component makes a contribution to the total 
effect that the combination is represented to have.343  Traditionally, if 
both ingredients are directed to the same sign or symptom, the FDA 
expects a “factorial” study, which demonstrates that the combination 
has a larger treatment effect than either active ingredient alone.344  The 
agency has proposed to consider fresh or physically processed material 
derived from a single part of a single species of a plant as a single 
botanical raw material.345  Thus a botanical drug product derived from 
a single part of a plant would not be subject to the fixed combination 
drug regulation.346  In contrast, a botanical product composed of 
multiple and easily separable parts of a single species of plant (e.g., 
flowers and bark of a woody plant) would continue to be subject to the 
combination drug requirements.347  The agency has proposed waiving 
this regulation for a traditional botanical drug composed of multiple 
raw materials in a fixed ratio, at least if there are so many active 
ingredients that factorial studies to assess the contribution of each 
would be infeasible.348  Other botanical drug products would be 
                                               
 339. Id. 
 340. See Marijuana Trials Should Aim for Higher Standard:  Superiority to Marinol, FDA’s 
Temple Suggests, PINK SHEET (Feb. 24, 1997). 
 341. FDA, GUIDANCE FOR INDUSTRY, INVESTIGATORS, AND REVIEWERS:  EXPLORATORY 
IND STUDIES 11 (2006). 
 342. See generally 21 C.F.R. § 300.50 (2018). 
 343. § 300.50(a). 
 344. Fixed-Combination and Co-Packaged Drugs:  Applications for Approval and 
Combinations of Active Ingredients Under Consideration for Inclusion in the Over-
the-Counter Monograph, 80 Fed. Reg. 79,776, 79,785 (Dec. 23, 2015) (to be codified 
at 21 C.F.R. pts. 300, 330, and 610). 
 345. Id. at 79,780. 
 346. Botanical Drug Review, supra note 239, at 2. 
 347. Id. 
 348. 80 Fed. Reg. at 79,787. 
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deemed fixed combination drugs even though derived from a single 
botanical raw substance.349 
c. Route of administration 
State-regulated medical cannabis today is mostly inhaled (vaporized 
or combusted), although increasing amounts are administered orally 
(for instance, in gel caps and oils) or even topically.350  A company 
developing a medical cannabis product for FDA approval could in 
theory consider any route of administration.  A drug’s route of 
administration can affect its dosing as well as its safety and 
effectiveness;351 however,  the route of administration will dictate some 
data requirements.352  As discussed in Section IV.A, the four approved 
cannabinoid drugs are administered orally.353  Other routes of 
administration may face additional hurdles at the agency. 
The prospects for inhaled products, in particular, are unclear.  
Generally, inhaled drug products fall into three categories:  metered 
dose inhalers, dry powder inhalers, and nebulizers.354  Some ongoing 
medical cannabis clinical research involves inhaled products; many 
involve combustion (smoking), but at least one involves a metered 
dose inhaler.355  But the agency has expressed skepticism.  When 
discussing medical cannabis, FDA leadership recently indicated the 
                                               
 349. Id. at 79,781. 
 350. Mary Barna Bridgeman & Daniel T. Abazia, Medicinal Cannabis:  History, Pharmacology, 
and Implications for the Acute Care Setting, 42 PHARMACY & THERAPEUTICS 180, 183 (2017). 
 351. This is known to be true of cannabis in particular.  Id. (“The method of 
administration can impact the onset, intensity, and duration of psychoactive effects; 
effects on organ systems; and the addictive potential and negative consequences 
associated with use.”). 
 352. If a drug is meant to be inhaled, for instance, the FDA requires inhalation 
toxicity studies and may require carcinogenicity studies.  FDA, NONCLINICAL SAFETY 
EVALUATION OF REFORMULATED DRUG PRODUCTS AND PRODUCTS INTENDED FOR 
ADMINISTRATION BY AN ALTERNATE ROUTE:  GUIDANCE FOR INDUSTRY AND REVIEW STAFF 6 
(2015). 
 353. See infra Section IV.A. 
 354. Shuguang Hou et al., Practical, Regulatory and Clinical Considerations for 
Development of Inhalation Drug Products, 10 ASIAN J. PHARM. SCI. 490, 491, 495–96 (2015) 
(defining metered dose inhalers as a suspension- or solution-based formulation of 
drugs propelled by hydrofluoroalkane propellants; dry powder inhalers as “a blend of 
micronized drug powder with larger carrier particles”; and nebulizers as a drug 
“formulated in aqueous solution or suspension, which is atomized into fine droplets 
via an external nebulization source”). 
 355. NCT02729623, The Pharmacokinetics, Safety, and Ease of Use of a Portable Metered-
Dose Cannabis Inhaler, CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show/ 
NCT02729623 (last updated July 25, 2016). 
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agency prefers that inhaled drugs be intended to treat the lungs.356  
Most drugs approved for delivery through the lungs are intended to 
treat the lungs in some fashion.357  The agency’s resistance to 
inhalation could be overcome, however, with solid data on the 
effectiveness of this route of administration—such as evidence that 
inhalation leads to more consistent dosing than oral delivery.358 
Inhalation by combustion would face a higher hurdle.  Agency 
officials have consistently expressed skepticism that combustion of 
cannabis would allow delivery of a consistent dose.359  The FDA would 
expect an applicant to address the risk of pulmonary cancer and other 
respiratory tract diseases, such as chronic obstructive pulmonary disease, 
particularly if the combustible product were intended for chronic use.  
This could entail long-term safety studies before approval, and—
depending on the intended use—some findings might preclude 
                                               
 356. Brenda Sandburg, Gottlieb on Medical Marijuana:  Smoking is Not Effective Way to 
Deliver API, PINK SHEET (Apr. 19, 2018), https://pink.pharmaintelligence. 
informa.com/PS122944/Gottlieb-On-Medical-Marijuana-Smoking-Is-Not-Effective-
Way-To-Deliver-API (quoting Scott Gottlieb, the Commissioner of Food and Drugs, as 
saying, “We generally would prefer not to deliver drugs through the lung unless we 
were treating the lung in some fashion”). 
 357. Id.  For instance, Proventil-HFA (albuterol sulfate) and Flovent (fluticasone 
propionate) are marketed in pressurized metered dose inhalers for treatment of 
bronchospasm and asthma, respectively.  Shuguang, supra note 354, at 493.  Tobi 
Podhaler (tobramycin) is marketed as a powder for inhalation, which a patient self-
administers for management of cystic fibrosis with Pseudomonas aeruginosa, using a 
proprietary device.  Id. at 493, 497.  AstraZeneca markets Pulmicort Respules 
(budesonide) for asthma in a suspension (liquid) for use with a nebulizer, which turns 
the liquid into a mist for inhalation into the lungs.  Id. at 493. 
 358. Some research suggests that inhaled THC reaches its peak level in the body 
“nearly instantaneously” due to direct absorption by the capillaries in the lungs, 
leading to more consistent levels of the drug than an oral formulation.  MACK & JOY, 
supra note 81, at 143, 203. 
 359. Researching the Potential Medical Benefits and Risks of Marijuana, FDA (2016) 
[hereinafter Researching Marijuana], https://www.fda.gov/newsevents/testimony/ 
ucm511057 (“When the Institute of Medicine (IOM) reviewed the clinical use of 
marijuana, it identified the problems associated with obtaining consistent dosing using 
smoked products and recommended that clinical trials involving marijuana should be 
conducted with the goal of developing safe, alternative delivery systems . . . .”); 
Sandburg, supra note 356 (quoting Commissioner Gottlieb that “the best way to deliver 
an active pharmaceutical ingredient is in a measured dose in a form where you can 
purify the ingredient and you know what you are getting and you can demonstrate 
dose effect and you can provide a reliable treatment to a patient,” which “generally is 
probably not going to come from something that is smoked”). 
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approval.360  Although the FDA permits numerous clinical trials of smoked 
cannabis for medical conditions, the agency’s view seems to be that “the 
purpose of clinical trials of smoked cannabis would not be to develop 
cannabis as a licensed drug but rather to serve as a first step toward the 
development of non-smoked rapid-onset cannabinoid delivery systems.”361 
Cannabis-based drugs presented in dosage forms that are not 
intended for inhalation (especially combustion) are less likely to raise 
complex regulatory issues and less likely to meet resistance from the 
agency.  But each route of administration and dosage form will present 
issues for consideration.  Topically administered drugs in solution or 
gel form, for instance, may present safety issues if physical contact with 
others can transfer the active ingredient.362  Concerns about transfer 
could lead to additional premarket testing requirements and, if 
appropriate, special safety controls after approval.363  The agency’s 
                                               
 360. See Ethan Russo et al., Current Status and Future of Cannabis Research, CLINICAL 
RESEARCHER 58, 59 (Apr. 2015) (“Meanwhile, although cannabis smoking may not be 
epidemiologically linked to lung cancer, it is responsible for chronic cough, sputum, 
and cytological changes, which render smoked cannabis an impossible candidate for 
approval as a prescription product in most jurisdictions.”).  Because the approval 
decision requires benefits and risks to be considered together, it is likely that even 
these risks would be acceptable to the agency for some uses. 
 361. Researching Marijuana, supra note 359.  If the agency permitted an inhalable 
cannabis-based product, the product might be considered a “combination product” 
(combining a drug and device).  The phrase “combination product” includes a drug 
and device that are physically combined and produced as a single entity (such as a 
patch that delivers an active ingredient), as well as a drug and device that are packaged 
together (such as a nebulizer and suspension).  21 C.F.R. § 3.2(e) (2018).  In this case, 
the company would need to consider both drug and medical device regulatory issues.  
As a practical matter, the analysis is unlikely to change.  A combination product’s 
“primary mode of action”—the single mode of action that provides its most important 
therapeutic action—dictates which part of the FDA will review the premarket 
submission.  21 U.S.C. § 353(g)(1)(C) (2012).  The Center for Drug Evaluation and 
Research (CDER) would almost certainly take the lead on premarket review of a 
cannabis-derived drug product.  Combination products are typically regulated under 
the marketing authorization associated with the component that provides the primary 
mode of action, meaning that this product would probably still require only an NDA.  
See 21 U.S.C. § 353(g)(1)(D).  In some cases, though, the agency will require a second 
premarket submission tied to the second constituent part.  An alternative in this case 
would be to use a device that the FDA has already approved or cleared for the market. 
 362. See, e.g., MEDICATION GUIDE:  ANDROGEL (2016), https://www.rxabbvie 
.com/pdf/androgel1_62_medguide.pdf (advising users to wash their hands “right 
away” after application). 
 363. For instance, testosterone in gel form is approved for treatment of men with a 
testosterone deficiency but it can rub off on women and children, causing early 
puberty in a child.  Companies developing topical testosterone products are generally 
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guidance documents and precedents are key to understanding what 
might be required in any particular case, but it is safe to say that orally 
administered products in traditional dosage forms (tablet, capsule, and 
solution) are the least likely to face unexpected regulatory hurdles. 
3. Approval and risk management 
Approval of a new drug represents the FDA’s conclusion that the 
benefits of the drug outweigh its risks when the drug is used in 
accordance with its approved labeling.364  The agency would make 
several additional risk management decisions when approving a 
cannabis-based drug. 
First, the FDA would likely designate a cannabis-derived drug 
product as a prescription product.  Prescription status is required for 
any drug that is “not safe for use except under the supervision of” 
licensed prescribers because of its “toxicity or other potentiality for 
harmful effect, or the method of its use, or the collateral measures 
necessary to its use.”365  Although the FDA considers these and related 
factors when deciding whether to switch a drug from prescription to 
nonprescription status,366 as a practical matter, almost every new drug 
                                               
required to conduct transfer studies, and the drugs are approved with special risk 
management measures.  For instance, Androgel® (testosterone) is distributed with a 
“Medication Guide” that instructs patients to apply the drug to areas of their shoulders, 
upper arms, and abdomen that will be covered by a t-shirt and to wash their hands 
immediately.  See id. 
 364. See 21 C.F.R. § 314.50(d)(5)(viii) (requiring NDAs to discuss “why the benefits 
exceed the risks under the conditions stated in the labeling”); see also United States v. 
Rutherford, 442 U.S. 544, 555 (1979) (“[T]he [FDA] generally considers a drug safe 
when the expected therapeutic gain justifies the risk entailed by its use.”); FDA, 
CRITICAL PATH OPPORTUNITIES REPORT R-8 (March 2006), http://wayback.archive-
it.org/7993/20180125142845/https://www.fda.gov/downloads/ScienceResearch/Sp
ecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/UCM077254.p
df (suggesting approval once “uncertainty” about benefit-risk balance has been 
“reduced to an acceptable level”). 
 365. 21 U.S.C. § 353(b).  If cannabis and THC were rescheduled rather than 
descheduled, the CSA would require that the product be sold only on prescription.  
See 21 C.F.R. § 1306.11 (requiring a written prescription for the distribution of any 
Schedule II substance); § 1306.21 (requiring a prescription for the distribution of any 
Schedule III, IV, or V substance). 
 366. The FDA considers a variety of factors, such as the ability of patients to self-
diagnose and follow treatment instructions, public health considerations, such as 
whether a prescription requirement would be an impediment to timely treatment in 
emergency situations, and possibly even social policy.  See generally Peter Barton Hutt, 
A Legal Framework for Future Decisions on Transferring Drugs from Prescription to 
Nonprescription Status, 37 FOOD DRUG COSM. L.J. 427 (1982). 
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is first approved today as a prescription drug.367  The agency might also 
be reluctant to permit a cannabis-based drug to be available over the 
counter if others are limited to prescription status—particularly if the 
prescription products are intended for treatment of serious conditions 
and generally require a physician’s involvement.  Some active 
ingredients are available in both prescription and nonprescription 
form,368 but the possibility that patients needing medical attention 
might self-treat with the nonprescription cannabis-based product 
would give the agency pause. 
Second, as a prescription drug, a cannabis-based drug—whether 
edible, inhaled, ingested, or applied topically—would require FDA-
approved labeling for prescribers.  Agency regulations specify the 
format and content of this labeling, which is meant to summarize and 
distill the safety and effectiveness information in the marketing 
application so that prescribers can make informed judgments about 
treatment.369  In addition to information about the preclinical and 
clinical studies supporting approval, the labeling must describe the 
overall adverse reaction profile of the drug based on the entire safety 
database, as well as clinically significant adverse reactions and other 
safety hazards.370  The labeling must present information about “drug 
abuse” and “dependence,” even if the drug is not controlled, describe 
clinically significant interactions with other prescription medicines (as 
well as nonprescription drugs, foods, and dietary supplements), discuss 
use in special populations such as pregnant and breastfeeding women, 
and advise about the signs and symptoms of overdose and 
recommended treatment of overdose.371 
Third, in some cases, the FDA might decide that the risks associated 
with the product require the adoption of special risk management 
measures.  The agency could, for example, require the company to 
distribute patient labeling, a “Medication Guide,” explaining the key 
risks associated with the drug and any special measures that should be 
taken (such as avoiding driving and consumption of alcohol) when 
using the drug.372  If the FDA concludes that the drug’s benefits 
                                               
 367. Id. at 428. 
 368. Examples include ibuprofen and fluticasone propionate. 
 369. See 21 C.F.R. § 201.57; Requirements on Content and Format of Labeling for 
Human Prescription Drug and Biological Products, 71 Fed. Reg. 3,922 (Jan. 24, 2006) 
(to be codified at 21 C.F.R. pts. 201, 314, and 601). 
 370. 71 Fed. Reg. at 3,922. 
 371. Id. at 3,994. 
 372. 21 C.F.R. §§ 208.1, 208.20. 
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outweigh its risks only with special risk management measures in place, 
it will require the company to implement a “risk evaluation and 
mitigation strategy.”373  In particular, if necessary to mitigate a specific 
serious risk listed in the drug’s labeling, the agency can impose use and 
distribution restrictions.374  These might include limiting the drug to 
prescribers with special training or requiring that all patients be 
entered in a registry.375  Particularly if the agency had concerns about 
dependence or misuse of a cannabis-based drug product, it might 
impose access restrictions.  Descheduling of cannabis, THC, and 
cannabimimetics would not preclude this. 
Nevertheless, the risks and benefits of a new drug are never fully 
understood at the time of approval.  This would be true of any 
cannabis-based new drug product, despite the long history of medical 
and non-medical use of cannabis.376  The FDA’s concern is the safety 
and effectiveness of the particular dosage form, strength, patient 
population, and use at issue.  Risk management, which includes 
monitoring and responding to risk, is therefore the dominant feature 
of postmarket regulation of new drugs.377  The FDA may require a 
company to conduct postmarket testing, as a condition of approval, to 
assess known risks or even to assess signals that emerged during 
premarket testing.378  Both approved botanical drugs were subject to 
postmarket testing obligations.379  And regardless of whether the 
agency imposed postmarket testing as a condition of approval, any 
company that held an approved NDA for a cannabis-based drug 
product would be required to evaluate and report any adverse events 
of which it became aware.380  These reports, in turn, could lead to 
                                               
 373. Risk Evaluation and Mitigation Strategies (REMS), FDA, https://www.fda 
.gov/Drugs/DrugSafety/REMS/default.htm (last updated Feb. 2, 2018). 
 374. 21 U.S.C. § 355-1(f)(3) (2012). 
 375. §§ 355-1(f)(3)(A), (F). 
 376. Russo, supra note 54, at 1614. 
 377. 21 U.S.C. § 355-1. 
 378. See § 355(o)(3). 
 379. For instance, the FDA required Salix Pharmaceuticals, which holds the NDA 
for Mytesi, to conduct two rodent carcinogenicity studies.  See FDA, CTR. DRUG 
EVALUATION & RES., NDA APPROVAL:  NDA 202292, https://www.accessdata.fda.gov/ 
drugsatfda_docs/appletter/2012/202292Orig1s000ltr.pdf (last visited Feb. 5, 2019).  
The company also committed to an in vitro and an in vivo study in humans to further 
explore the pharmacodynamics of crofelemer, as well as additional analytical work and 
additional work on its bioassays.  Id. 
 380. See 21 C.F.R. § 314.80 (2018). 
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labeling changes or more significant requirements, such as new studies 
or access restrictions.381 
The Poison Prevention Packaging Act of 1970 (PPPA)382 would also 
apply to cannabis-derived drug products and might require the 
manufacturer to adopt special packaging.383  The PPPA applies to any 
food or drug customarily produced or distributed for sale for 
consumption or use by individuals in or about the household.384  The 
Consumer Product Safety Commission’s implementing regulations 
require that any prescription drug intended for oral administration be 
packaged in accordance with its “special packaging” standards.385  The 
general idea is that the packaging must be reasonably convenient for 
adults to open and yet designed so that young children cannot easily 
obtain the contents.386  Thus, the company would have to use packaging 
that provided a specified degree of child resistance, confirmed using 
testing procedures also specified in the regulations.387  At the same time, 
the packaging would need to satisfy “ease of adult opening” standards, 
which must be similarly tested in both senior adults and younger adults 
according to the agency’s testing standards.388 
4. Consequences of using the new drug pathway 
The new drug research and development process is notoriously 
expensive and risky.  For a new chemical entity, it can take ten to twelve 
years and cost more than $1 billion.389  Prior and longstanding use of 
cannabis for medical and non-medical purposes may reduce some of 
the risk, for instance, by identifying promising uses and suggesting the 
appropriate dosing.  Also, the agency’s flexibility with botanical NDAs 
may reduce some of the cost, where it applies.  Pursuing new drug 
approval for medical cannabis after descheduling could, however, still 
cost hundreds of millions of dollars.  This will put the process out of 
                                               
 381. 21 U.S.C. §§ 355(o)(3)–(4); 21 C.F.R. § 201.57(c)(6)(i). 
 382. Pub. L. No. 91-601, 84 Stat. 1670 (codified at 15 U.S.C. §§ 1471–77). 
 383. § 1472. 
 384. § 1471(2). 
 385. 16 C.F.R. § 1700.14(a)(10). 
 386. § 1700.14. 
 387. §§ 1700.15, 1700.20. 
 388. § 1700.15. 
 389. Joseph A. DiMasi et al., Innovation in the Pharmaceutical Industry:  New Estimates of 
R&D Costs, 47 J. HEALTH ECON. 20, 25–27 (2016) (estimating average out-of-pocket cost 
per approved compound of $1.4 billion and total preapproval cost of $2.56 billion); Erika 
Lietzan, The Myths of Data Exclusivity, 20 LEWIS & CLARK L. REV. 91, 107–08 (2016) 
(discussing range of estimates for the length of time and cost of developing a new drug). 
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reach for most entities currently providing medical cannabis.390  Yet 
avoiding the new drug approval process is not an option; medical 
claims on any product in interstate commerce will trigger the FDA’s 
new drug authorities and require an approved NDA.391 
Even well-established biopharmaceutical companies might eschew 
development of cannabis-based products.  It is not clear a cannabis-
based product would enjoy enough exclusivity in the market for a 
company to recoup its investment and earn a profit.  U.S. law provides 
exclusivity (as an incentive for new drug research) through two 
mechanisms—patent protection and regulatory exclusivity—but the 
value of these for cannabis-based drugs is unclear.392  Patent protection 
would preclude any other company from making, using, or selling the 
patented invention for a fixed period of time.393  But a company could 
not patent the cannabis plant itself, and it may not be possible to patent 
the medical uses of cannabis that have been known for years.394  It may 
be possible to patent genetically engineered cannabis plants, methods 
of cultivating the plants, and methods of manufacturing cannabis-
based products.  Newer methods of treatment and delivery devices, 
among other things, may also be patentable.395  And regulatory 
exclusivity will prevent submission, or in some cases approval, of other 
applications at the FDA for a fixed period of time.396  Patent protection 
and regulatory exclusivity could motivate the larger companies to invest 
                                               
 390. See Alex Halperin, What Will Rescheduling Marijuana Mean for the Pot Industry?, 
ROLLING STONE (Apr. 20, 2016), https://www.rollingstone.com/culture/culture-
news/what-will-rescheduling-marijuana-mean-for-the-pot-industry-203124 (“If the 
federal government determines that medical marijuana must be subjected to FDA 
approval, companies would have to enter a process that can take years to complete and 
cost more than $1 billion per product.  Few, if any, cannabis companies in the U.S. 
have the resources for that, which might open the door for Big Pharma to muscle in 
and take over the business.”). 
 391. See supra Section III.A.1. 
 392. Lietzan, supra note 46, at 56 (2018). 
 393. See 21 U.S.C. §§ 355(c)(3)(E), 355(j)(5)(F). 
 394. See 35 U.S.C. § 102(a)(1) (preventing a person from obtaining a patent if the 
product was “described in printed publication, or in public use, or otherwise available 
to the public” before the patent was filed). 
 395. See generally Gretchen L. Temeles et al., IP Protection and the Cannabis Industry:  
Strategies and Trends, LEGAL INTELLIGENCER (April 2, 2018, 2:10 PM), 
https://www.law.com/thelegalintelligencer/2018/04/02/ip-protection-and-the-cann 
abis-industry-strategies-and-trends (describing cannabis-related patents to date). 
 396. E.g., 21 U.S.C. § 355(j)(5)(F)(ii) (prohibiting submission of a generic drug 
application for five years after approval of a new chemical entity, meaning an active 
moiety not previously approved in an NDA); 21 U.S.C. § 360cc (providing seven years 
of “orphan drug” exclusivity for drugs approved for treatment of rare diseases). 
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in the research and development needed for approval of a cannabis-
based product. These companies could, however, be concerned about 
competition from cannabis-based products that are labeled for other 
conditions or, indeed, that are marketed without medical claims at all.  
Without a reasonable assurance of actual exclusivity in the marketplace, 
these companies might pursue other projects instead. 
B.   Medical Cannabis as (or in) Food 
Cannabis as it is currently sold and used is unlikely to qualify as food 
in itself, and an extract from cannabis presented as a single-ingredient 
product would similarly not qualify.  Rather than focusing on intended 
use as it does for drugs, the FDCA defines food by its actual use.  Food, 
thus, is any “article[] used for food or drink for man.”397  The FDA 
interprets this to mean any item consumed primarily “for taste, aroma, 
or nutritional value.”398 
Arguably, neither cannabis nor a single-ingredient cannabis extract 
product would satisfy this test.  There is, however, some evidence that 
cannabis seeds, leaves, and other parts of the plant were historically 
eaten as food, whether by themselves or in combination with other 
foodstuffs.399  Seed cakes were popular in the ancient world, and oil 
seems to have been consumed just like other plant oils.400  Further, 
these uses would not have decarboxylated the THC or CBD contained 
in the raw plant materials (unless the foods were cooked or baked), 
which means the strongest and most notable effects of cannabis were 
probably not obtained.401  This suggests that ancient populations may 
have valued cannabis components for their nutritive value.  If true seed 
cakes and other cannabis-based foods were re-introduced to the 
market and consumed primarily for their nutritive value, as was 
apparently the case in the ancient world, the FDA might apply its food 
authorities.402  Among other things, the food would be adulterated if it 
                                               
 397. 21 U.S.C. § 321(f)(1). 
 398. Nutrilab, Inc. v. Schweiker, 547 F. Supp. 880, 883 (N.D. Ill. 1982), aff’d, 713 
F.2d 335 (7th Cir. 1983). 
 399. See supra Section I.B. 
 400. See e.g., Zuardi, supra note 64, at 154. 
 401. Id. at 154, 156. 
 402. For instance, as discussed in note 430, the agency permits the use of hulled hemp 
seed, hemp seed protein powder, and hemp seed oil in certain foods, provided these 
ingredients meet certain specifications.  In some cases, however, there is a risk the FDA 
would resist the characterization as food (or a food ingredient) and deem the product 
an unlawfully marketed dietary supplement, for reasons discussed in Section IV.B. 
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was “ordinarily . . .  injurious” to health or if it contained a pesticide 
residue that exceeded an established tolerance, or for which no 
tolerance had been established.403 
As discussed in this part, however, there are also substantial 
impediments to simply adding cannabis, or an extract from cannabis, 
to a conventional food such as a cookie, candy, or beverage.  These 
impediments include the rule that foods cannot contain new drugs 
(the drug exclusion rule) and the fact that, as a single ingredient 
among many, cannabis (and a cannabis constituent) would probably 
be deemed a “food additive” requiring premarket approval. 
1.  The drug exclusion rule:  the 301(ll) problem 
It is unlawful to include either dronabinol (9-THC) or CBD in a 
conventional food because these substances now appear in products 
regulated as new drugs.404  As discussed later in this Article, the FDA 
has approved two NDAs for dronabinol and an NDA for CBD.405  
Under the drug exclusion rule of § 301(ll) of the FDCA, a food 
containing a substance that is an active ingredient of an approved drug 
product—or an active ingredient of a product in clinical trials that 
have been made public—cannot be shipped in interstate commerce.406  
Although there are ways to avoid the drug exclusion rule, these are not 
promising for cannabis-based foods. 
                                               
 403. 21 U.S.C. §§ 342(a)(1)–(2), 348(a) (2012).  Pesticide issues could be significant.  
There are no pesticides approved for use on cannabis plants.  Jenna H. Bishop, Note, 
Weeding the Garden of Pesticide Regulation:  When the Marijuana Industry Goes Unchecked, 65 
DRAKE L. REV. 224, 226 (2017).  At the same time, studies “overwhelmingly reveal that 
growers are choosing to use unapproved and unregulated pesticides.”  Id.  But these 
problems are not insurmountable.  Indeed, the responsible segments of the industry are 
well aware that pesticide issues need to be addressed for all cannabis products, not just 
those that might be positioned as conventional food. 
 404. Even if there were no drug exclusion, the FDA might take the position that 
intentionally adding dronabinol or CBD to a food product in amounts known to affect 
the body constitutes evidence that the product is intended to address disease or affect 
the structure or function of the body.  Cf. Zettler, supra note 249, at 1965 (discussing 
a warning letter to distributor of “Magic Power Coffee,” which contained an analogue 
of sildenafil, the active ingredient of Viagra). 
 405. See infra Section IV.B.1. 
 406. 21 U.S.C. § 331(ll).  The FDA focuses on the whether the food is or contains a 
substance that is the same active moiety as the new drug in question.  The source of 
the substance does not matter.  Thus, for instance, the rule applies even if the 
substance derives from a plant classified as “hemp” and exempt from the Controlled 
Substances Act pursuant section 12619 of the Agriculture Improvement Act of 2018, 
Pub. L. 115-334 (amending 21 U.S.C. §§ 802(16), 812(c)).  See Statement on Signing 
of the Agriculture Improvement Act, supra note 49. 
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First, § 301(ll) contains an exception for a substance marketed in 
food before the drug in question was approved or the trials started.407  
But the agency requires that the substance be overtly marketed in the 
food, for instance with references in the label.408  The FDA would 
probably refuse to consider marketing in violation of federal law, 
including the CSA.409  Moreover, the FDA has already concluded that 
“THC” and CBD must be excluded from foods in interstate 
commerce.410  That said, it has invited evidence and arguments to the 
contrary.411  In addition, its claim about “THC” may be overbroad.  The 
agency has approved products containing dronabinol, which is a 
synthetic 9-THC, but cannabis also contains several variants of 8-
THC.412  These are also referred to as “THC” but may not be barred by 
the drug exclusion rule. 
Second, the drug exclusion rule “precludes only the specific active 
ingredients already present in new drugs.”413  “A company can avoid the 
drug exclusion by adding a different cannabinoid (or terpenoid or 
flavonoid) from cannabis—rather than dronabinol or CBD—to its 
food.”414  But it will be important to do so overtly—“calling out the precise 
cannabinoid in the food label”—as soon as possible after descheduling.415  
“As soon as one of these other cannabinoids is the subject of a publicly 
known clinical trial, it will be too late to add it to a food.”416 
                                               
 407. § 331(ll)(1). 
 408. E.g., FDA, DIETARY SUPPLEMENTS:  NEW DIETARY INGREDIENT NOTIFICATIONS AND 
RELATED ISSUES:  GUIDANCE FOR INDUSTRY 44 (2016) [hereafter NDI GUIDANCE]; FDA 
Response to Biostratum, Inc., No. FDA-2005-P-0259 (formerly Docket No. 2005P-
0305/CP1) (Jan. 12, 2009), https://www.regulations.gov/document?D=FDA-2005-P-
0259-0004 (explaining that the “relevant inquiry” for determining whether a substance 
prohibited by the drug exclusion rule is whether a company was also marketing the 
substance alone as a food or dietary “by . . . making claims about the [substance] or 
otherwise highlighting its presence in the product”). 
 409. Alice Mead, The Legal Status of Cannabis (Marijuana) and Cannabidiol (CBD) 
Under U.S. Law, 70 EPILEPSY & BEHAVIOR 288, 290 (2017). 
 410. FDA and Marijuana:  Questions and Answers, FDA (June 25, 2018), https://www. 
fda.gov/newsevents/publichealthfocus/ucm421168 [hereafter Marijuana Q&A]. 
 411. Id. 
 412. See MARIJUANA AND MEDICINE, supra note 92, at 24–25. 
 413. Erika Lietzan, Cannabis and the Often Overlooked Drug Exclusion Rule, OBJECTIVE 
INTENT BLOG (Sep. 18, 2018), https://objectiveintent.blog/2018/09/19/cannabis-
and-the-often-overlooked-drug-exclusion-rule. 
 414. Id. 
 415. Id. 
 416. Id. 
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Third, a company might be able to “avoid the drug exclusion rule by 
manufacturing and selling conventional food products with 
dronabinol or CBD purely within the confines of a single state.”417  To 
be sure, the FDA has asserted jurisdiction over medical treatments 
involving substances prepared purely on premises or within a state 
when it can identify a component (raw material) that had been 
shipped in interstate commerce.418  But doing so rests on the phrasing 
of an enforcement provision that would not apply here.  The FDA 
generally proceeds under § 301(k) of the statute, which prohibits 
misbranding or adulteration after an item has been shipped in 
interstate commerce.419  But § 301(ll) is drafted differently, prohibiting 
interstate shipment of a food after addition of a new drug.420  It is not 
clear that the FDA could act under § 301(ll) with respect to a food 
made with dronabinol or CBD and sold within the same state, even if 
it contained a component (which is also a “food”)—such as flour—that 
had been shipped in interstate commerce. 
2. Regulation as a food additive:  the 402(a) problem 
Even if a company avoided the drug exclusion rule (for instance, by 
adding a new cannabinoid, terpenoid, or flavonoid to its food), it 
would still need to grapple with the FDA’s food additive rules.  
Generally speaking, every ingredient in a food sold in interstate 
commerce is a food additive, subject to preapproval requirements, 
unless an exception applies.421  The FDCA defines “food additive” as 
“any substance the intended use of which results or may reasonably be 
expected to result, directly or indirectly, in its becoming a component 
                                               
 417. Id. 
 418. See United States v. Regenerative Scis. LLC, 741 F.3d 1314, 1320–21 (D.C. Cir. 
2014); see also Complaint for Permanent Injunction, United States v. California Stem 
Cell Treatment Ctr., No. 5:18-CV-1005 (C.D. Cal. 2018), 2018 WL 2144859; Warning 
Letter from FDA to Dr. Drew Varano (Apr. 5, 2010), https://wayback.archive-
it.org/7993/20170112062943/http://www.fda.gov/ICECI/EnforcementActions/Wa
rningLetters/2010/ucm207651.htm. 
 419. See 21 U.S.C. § 331(k) (2012) (prohibiting any act with respect to a food or 
drug that (1) is done while the article is held for sale after shipment in interstate 
commerce and (2) renders the article adulterated or misbranded). 
 420. See § 331(ll) (preventing the introduction into interstate commerce of a food 
to which a drug has already been added). 
 421. See § 321(s) (providing exceptions for substances that are generally recognized 
as safe, as well as certain pesticide chemicals, color additives, new animal drugs, and 
dietary supplements). 
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or otherwise affecting the characteristics of any food.”422  Even food itself 
becomes a food additive if it is used as a component in another food. 
A company wishing to add a non-excluded cannabis constituent (other 
than dronabinol or CBD) to a conventional food would need to obtain 
approval of a food additive petition unless it determined that an 
exception applied.423  A petition, in turn, must contain information about 
the additive itself (its “chemical identity and composition”), information 
about the manufacturing process and facility, and the controls used to 
ensure that the additive’s composition is consistent.424  It must also 
contain data on the technical effects of the food additive, as well as data 
from safety studies.425  Generating these data and securing the FDA’s 
approval of a food additive petition can take six years or longer.426 
The key exception carves out a substance “generally recognized, 
among experts qualified by scientific training and experience to 
evaluate its safety, as having been adequately shown . . . to be safe 
under the conditions of its intended use.”427  Put another way, if the 
cannabis constituent were generally recognized as safe (GRAS) under 
the specific conditions of use intended, meaning safe at a particular 
level in a particular type of food, it would not be considered a food 
additive.  A company could determine on its own that a particular 
cannabis constituent was GRAS for use in the particular food the 
company marketed.428  Federal law does not require a company to seek 
the FDA’s approval, or even the agency’s agreement, that the product is 
                                               
 422. Id. 
 423. See § 348(b); see also Determining the Regulatory Status of a Food Ingredient, FDA, 
https://www.fda.gov/food/ingredientspackaginglabeling/foodadditivesingredients/
ucm228269 (last updated Sept. 20, 2018). 
 424. See 21 C.F.R. § 171.1(b) (2018). 
 425. Id. 
 426. Inst. of Med.:  Food Forum, Enhancing the Regulatory Decision-Making 
Approval Process for Direct Food Ingredient Technologies 2, 29 n.230 (1999). 
 427. 21 U.S.C. § 321(s). 
 428. A substance is GRAS if shown safe using “scientific procedures” or, if it was used 
in food before January 1, 1958, shown safe “through experience based on common use 
in food.”  21 C.F.R. § 170.30(a).  The FDA interprets this to require “common knowledge 
throughout the scientific community knowledgeable about the safety of substances 
directly or indirectly added to food that there is reasonable certainty that the substance 
is not harmful under the conditions of its intended use.”  Id. 
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GRAS.429  But if the agency disagreed with the company’s judgment call,430 
the ingredient would be an unapproved food additive, which would mean 
the conventional food containing this ingredient was adulterated under 
§ 402(a) of the FDCA.431  A company that shipped or received the food in 
interstate commerce could face enforcement action, up to and including 
criminal prosecution.432  Even if the food itself was not shipped in 
interstate commerce, the FDA could take enforcement action if another 
ingredient was shipped in interstate commerce.433 
3. No claims could be made 
If a company avoided the drug exclusion issue and § 402(a), it might 
be able to add a cannabis constituent to a conventional food.  But 
                                               
 429. The FDA has created a formal process for voluntary GRAS notifications.  See 
generally 21 C.F.R. §§ 170.203–170.285.  This does not result in regulatory certainty; the 
agency will typically respond only that it has “no questions at this time.”  
 430. The agency has published various lists of substances it recognizes as GRAS.  
Although the lists are not meant to be exhaustive, they do not include cannabis.  See 
21 C.F.R. pts. 182, 184, 186.  In December 2018, however, the FDA issued three “no 
questions” letters in connection with voluntary GRAS notifications relating to the use 
of hulled hemp seed, hemp seed protein powder, and hemp seed oil in various foods.  
Hemp seeds are the seeds of the Cannabis sativa plant, and the specific ingredients that 
were the subject of the GRAS notifications contained only trace amounts of THC and 
CBD.  See FDA Responds to Three GRAS Notices for Hemp Seed-Derived Ingredients for Use in 
Human Food, FDA (Dec. 20, 2018), https://www.fda.gov/Food/NewsEvents/Con 
stituentUpdates/ucm628910 (describing the FDA’s response to GRAS Notice Nos. 
GRN 000765, 000771, 000778).  As a result, these constituents can be marketed in the 
specified foods without food additive approval. 
 431. Section 402(a) of the FDCA deems a food adulterated if it contains a food 
additive that is unsafe within the meaning of 21 U.S.C. § 348.  See 21 U.S.C. 
§ 342(a)(2)(C)(i); see also § 348 (declaring a food additive unsafe unless it complies 
with a food additive regulation). 
 432. See §§ 331(a), (c).  To be sure, the FDA has not acted against foods containing 
cannabis that are sold in recreational cannabis law states.  As mentioned above, this is 
probably because the sales are illegal under the CSA in the first instance.  Robert J. 
MacCoun & Michelle M. Mello, Half-Baked—The Retail Promotion of Marijuana Edibles, 372 
NEW ENG. J. MED. 989, 990 (2015); see also Paul R. Larkin, Marijuana Edibles and “Gummy 
Bears,” 66 BUFF. L. REV. 313, 349–56, 359 (2018) (discussing three reasons the FDA may 
have refrained from acting, including that the agency chose to avoid getting embroiled 
in disputes over the proper role of the federal government with respect to state cannabis 
laws and an overly broad reading of the Rohrabacher-Blumenauer Amendment). 
 433. The agency would reason that the food—for instance, a cookie—was 
adulterated by the addition of an unapproved food additive subsequent to the 
interstate shipment of one of its components—the flour.  See 21 U.S.C. § 331(k); see 
also Complaint for Permanent Injunction ¶ 13, 15, 47–49, 55, United States v. Cal. 
Stem Cell Treatment Ctr., No. 5:18-CV-1005, (C.D. Cal. 2018), 2018 WL 2144859. 
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federal law would not permit the company to make any claims about 
the food relating to the presence of the cannabinoid. 
First, the FDA would not permit a “structure/function” claim (such 
as “helps maintain a calm disposition”) relating to the cannabis 
constituent.  While the agency freely permits structure/function claims 
on dietary supplements,434 it permits these claims on conventional 
foods only if the claimed effect is achieved through the “nutritive 
value” of the food or nutrient.435  In a related context, the agency 
defines “nutritive value” to mean the item’s “value in sustaining human 
existence by such processes as promoting growth, replacing loss of 
essential nutrients, or providing energy.”436  Thus although the FDA 
will permit structure/function claims referring to the role of well-
known nutrients such as calcium and vitamin C, it would probably not 
permit a structure/function claim relating to non-nutritive effects of 
cannabis constituents.437  It might be possible to make a 
structure/function claim for a food containing cannabis constituents with 
nutritive value (such as seeds and leaves in a hemp cake), but the FDA 
would permit only claims about effects related to the nutritive benefit. 
Second, the FDA would not permit any claim relating to the 
treatment, prevention, or cure of a disease, such as cancer.  A disease 
claim will always turn a substance into a drug and usually also trigger 
the requirement to hold an approved NDA.438  It would not matter that 
the commercial product was presented to consumers as a conventional 
food.  A product can fall into more than one regulatory category and 
be regulated under both sets of rules at the same time.439  A 
conventional food containing cannabis, with a disease claim relating 
to the cannabis, would be regulated as both a food and a drug. 
Third, even though there is a special exception for “health claims” 
on foods and dietary supplements, the FDA would probably not permit 
a health claim on a conventional food based on the presence of a 
                                               
 434. See supra Section IV.B. 
 435. Food Labeling; Requirements for Nutrient Content Claims, Health Claims, 
and Statements of Nutritional Support for Dietary Supplements, 62 Fed. Reg. 49,859, 
48960 (Sept. 23, 1997) (to be codified at 21 C.F.R. pt. 101). 
 436. 21 C.F.R. § 101.14(a)(3) (2018). 
 437. It might be possible to challenge the FDA’s approach to structure/function 
claims on conventional foods as inconsistent with the statute, but exploring this 
argument is beyond the scope of this Article. 
 438. See supra notes 250, 288 and accompanying text. 
 439. See, e.g., supra note 240 and accompanying text. 
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cannabis constituent in this food.440  A health claim characterizes the 
relationship of a substance to a disease or health-related condition.441  
The agency’s regulations provide that a health claim must satisfy 
certain basic eligibility requirements before it can even be 
considered.442  A typical health claim for a conventional food relates to 
decreased dietary level of a substance (such as lower saturated fat).443  
For example, the agency has authorized “diets low in sodium may 
reduce the risk of high blood pressure, a disease associated with many 
factors” on a food that satisfies the agency’s nutrient content 
requirements for “low sodium” food.444  If a health claim is based on the 
presence of a substance other than decreased dietary levels, the substance 
must be used in the conventional food for a traditional food purpose.445  
                                               
 440. Moreover, the agency’s permission is necessary.  There are three ways this can 
happen.  First, the agency may expressly authorize a claim, in a regulation, if it finds 
that the claim is supported by the “totality of publicly available scientific evidence” and 
that there is “significant scientific agreement” among qualified experts that the claim 
is supported by this evidence.  21 U.S.C. § 343(r)(3)(B); 21 C.F.R. § 101.14(c).  
Second, a series of First Amendment rulings require the agency to exercise 
enforcement discretion with respect to claims that do not rise to this statutory 
standard, if appropriate disclaimers have been added.  E.g., Pearson v. Shalala, 164 
F.3d 650, 653–54, 657 (D.C. Cir. 1999).  The FDA expects a company to submit a 
petition for a qualified health claim, however, with the scientific data supporting the 
proposed claim. See Guidance for Industry:  Interim Procedures for Qualified Health Claims 
in the Labeling of Conventional Human Food and Human Dietary Supplements, FDA (July 
2003), https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegu 
latoryInformation/LabelingNutrition/ucm053832.htm#intro.  Third, another federal 
agency with responsibility for human nutrition research or for protecting public health 
might publish an authoritative statement concerning the relationship between the 
substance and a disease or health-related condition.  The FDA has the opportunity to 
modify or even prohibit a claim published by another agency.  See Guidance for Industry:  
Notification of a Health Claim or Nutrient Content Claim Based on an Authoritative Statement 
of a Scientific Body, FDA (June 11, 1998) [hereinafter Health Claim Guidance], 
https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInf
ormation/LabelingNutrition/ucm056975. 
 441. 21 U.S.C. § 343(r)(1)(B).  The FDA defines a “disease or health-related 
condition” in this context as “damage to an organ, part, structure, or system of the 
body such that it does not function properly (e.g., cardiovascular disease), or a state of 
health leading to such dysfunctioning (e.g., hypertension).”  21 C.F.R. § 101.14(a)(5). 
 442. See Health Claim Guidance, supra note 440. 
 443. 21. C.F.R. § 101.14(b)(2). 
 444. § 101.74. 
 445. § 101.14(b)(3) (“The substance must . . . contribute taste, aroma, or nutritive 
value, or any other technical effect listed in § 170.3(o) of this chapter, to the food and 
must retain that attribute when consumed at levels that are necessary to justify a claim”); 
see also Food Labeling; General Requirements for Health Claims for Food, 58 Fed. Reg. 
2,478, 2,499 (Jan. 6, 1993) (to be codified at 21 C.F.R. pts. 20 and 101).  Permitted 
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In effect, the substance must contribute taste, aroma, or nutritive value.446  
The FDA probably would not permit a health claim on conventional food 
based on the presence of a cannabinoid because the cannabinoid would 
not be serving one of these traditional food purposes.  It is conceivable 
the agency would permit a health claim about another cannabis 
constituent grounded in the nutritive value of that constituent. 
4. Risk of the FDA invoking new drug authorities 
The path forward for a food containing a cannabis constituent 
requires solving the drug exclusion issue (for instance, by ensuring the 
food contains only constituents that have not been studied or approved 
in new drugs, which excludes at least dronabinol and CBD), avoiding 
§ 402(a) (through approval of a food additive petition or a GRAS 
determination), and making no claims relating to the medical benefits 
of cannabis in the food (though perhaps making health claims tied to 
nutritive benefits, with the agency’s permission).  But there would still 
be a non-trivial risk that the FDA would classify the product as a drug. 
The FDA’s regulations state that a product’s intended use is 
determined by the expressions of the person legally responsible for its 
labeling, but it may also be shown “by the circumstances surrounding 
the distribution of the article.”447  These include the circumstance that 
the item is, with this person’s knowledge, “offered and used for a 
purpose for which it is neither labeled nor advertised.”448  In 1980, the 
United States Court of Appeals for the D.C. Circuit added that the 
intended use of a product is determined “from its label, accompanying 
labeling, promotional claims, advertising, and any other relevant 
source.”449  The full impact of the language in the regulation and court 
decision is unsettled.  But the FDA concluded that balloons filled with 
nitrous oxide (laughing gas) and distributed in the parking lot of a 
rock concert at RFK Stadium were “drugs” even though the sellers 
made no claims about the intended use of the balloons.450  A federal 
                                               
“technical effects” in food include use as an anti-caking agent, curing or pickling agent, 
emulsifier, or leavening agent, among other things.  21 C.F.R. § 170.3(o). 
 446. 21 C.F.R. § 101.14(b)(3). Nutritive value, in this context, means “value in 
sustaining human existence by such processes as promoting growth, replacing loss of 
essential nutrients, or providing energy.”  § 101.14(a)(3). 
 447. § 201.128. 
 448. Id. 
 449. Action on Smoking & Health v. Harris, 655 F.2d 236, 239 (D.C. Cir. 1980) 
(emphasis added) (quoting Hanson v. United States, 417 F. Supp. 30, 35 (D. Minn 1976)). 
 450. United States v. Travia, 180 F. Supp. 2d 115, 116, 118–19 (D.C. Cir. 2001). 
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district court agreed with the FDA that the balloons were intended to 
affect the structure or function of the body, reasoning that “the sellers 
did not need to label or advertise their product, as the environment 
provided the necessary information between buyer and seller.”451  If 
the agency were concerned about the safety of conventional foods 
containing cannabis constituents, it might invoke this theory and argue 
that the products were drugs.  This would, in turn, trigger the agency’s 
new drug authorities and render the products illegal.  But it would be 
a controversial position for the agency to take. 
If a company managed to move forward with a conventional food 
containing a cannabis constituent, the agency’s regulations and 
policies relating to food would apply.452  In addition to the pesticide 
residue issue already flagged, these would include a variety of 
affirmative labeling requirements.453  For example, unless an 
exemption applied, the company would need to provide nutrition 
information in the form of a “Nutrition Facts” box.454  In addition, the 
agency’s many regulations implementing the FDA Food Safety 
Modernization Act455 would also apply.  Thus, among other things, unless 
an exemption applied, the company would need to establish and 
                                               
 451. Id. at 119. 
 452. These rules therefore apply to any foods containing the hemp seed derived 
food ingredients for which FDA issued GRAS response letters in December 2018.  See 
supra note 430. 
 453. See 21 U.S.C. §§ 343(i)(1)–(2), 343(q).  Products marketed as imitations of 
well-known products that do not themselves contain cannabis or one of its constituents 
would likely draw warning letters, on the theory that the labeling was misleading, 
particularly if children were the primary consumers of the imitated products.  § 343(a).  
Examples might include “Rasta Reeses” (packaged to resemble Reese’s Peanut Butter 
Cups), “Keef Kat” (KitKat), and “Buddafinger” (Butterfinger), all currently on the 
market.  See MacCoun, supra note 432, at 990.  The FDA recently took action against 
vendors of e-cigarette liquids that were labeled to look like children’s juices and 
candies, on the theory that the products were misbranded, because their labeling 
and/or advertising was false or misleading—in that they imitated other products.  E.g., 
Warning Letter from FDA to NEwhere Inc. d/b/a Mad Hatter Juice (May 1, 2018), 
https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm618146. 
 454. 21 U.S.C. § 343(q)(1); Food Labeling; Serving Sizes of Foods that Can 
Reasonably be Consumed at One Eating Occasion; Dual-Column Labeling; Updating, 
Modifying, and Establishing Certain Reference Amounts Customarily Consumed; 
Serving Size for Breath Mints; and Technical Amendments, 81 Fed. Reg. 34,000, 
34,000 (May 27, 2016) (to be codified at 21 C.F.R. pt. 101).  Numerous exemptions 
apply, including for foods produced by very small businesses, food sold in small 
packages, and foods served in restaurants (including bakeries) for immediate 
consumption on the premises.  21 C.F.R. § 101.9(j). 
 455. Pub. L. No. 111-353, 124 Stat. 3885 (2011). 
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implement a food safety system that includes hazard analysis and risk-based 
preventive controls (HARPC).456  Further, any facility that manufactures, 
processes, packs, or holds food for consumption—including one that is 
HARPC-exempt—must comply with cGMP for food.457 
C.   Medical Cannabis in Dietary Supplements 
Dietary supplements are considered a type of food, but they are 
defined separately in the FDCA and subject to slightly different rules.  
As a result, there is a narrow path forward for marketing dietary 
supplements containing cannabis constituents.458  There are at least 
four significant constraints to keep in mind. 
First, a dietary supplement cannot lawfully contain either 
dronabinol or CBD.  The FDCA imposes a “drug exclusion” for dietary 
supplements, just as it does for conventional foods.459  A substance 
cannot be classified as a “dietary supplement” if it has been approved 
as a new drug or if it has been authorized for investigation as a new 
drug, the clinical trials have started, and the trials are public 
knowledge.460  The FDA already takes the position that this exclusion 
means THC and CBD cannot be added to dietary supplements.461  
There are options for avoiding the exclusion rule similar to those 
                                               
 456. 21 C.F.R. § 117.126; Current Good Manufacturing Practice, Hazard Analysis, 
and Risk-Based Preventive Controls for Human Food, 80 Fed. Reg. 55,908, 55,911 
(Sept. 17, 2015) (to be codified in 21 C.F.R.).  This entails analyzing the hazards, 
designing and implementing the controls, monitoring the effectiveness of the 
controls, maintaining records of the monitoring, and establishing corrective actions 
for problems, which must be documented.  A small company that marketed its 
cannabis-containing conventional food directly to consumers could qualify for an 
exemption and modified HARCP requirements.  21 C.F.R. § 117.5(a). 
 457. 80 Fed. Reg. at 55,911; 21 C.F.R. §§ 117.10–117.110.  To give another example, 
if the FDA has issued a standard of identity for the food in question, the cannabis-
derived constituent could not be added to the food unless doing so was permitted by 
the applicable standard of identity.  21 U.S.C. § 343(g).   
 458. Dietary supplements may contain herbs or botanicals, as well as concentrates, 
metabolites, constituents, or extracts of herbs or botanicals, among other things.  21 U.S.C. 
§ 321(ff).  Cannabinoids would presumably qualify as extracts of an herb or other botanical. 
 459. § 321(ff)(3)(B). 
 460. Id. 
 461. Marijuana Q&A, supra note 410.  It has sent numerous warning letters to 
companies marketing cannabidiol in supposed dietary supplements, citing this 
provision.  See Warning Letters and Test Results for Cannabidiol-Related Products, FDA, 
https://www.fda.gov/newsevents/publichealthfocus/ucm484109 (last updated Nov. 
2, 2017) (providing examples of FDA warning letters sent out in 2017 regarding the 
marketing of products containing CBD). 
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discussed in the last part of this Article.462  For example, if the substance 
was marketed in dietary supplement or food form before the drug was 
approved or the trials started, the drug exclusion rule does not apply.463  
The agency does not think this exception applies, but it has invited 
evidence and arguments to the contrary.464  Other cannabis constituents, 
however, could presumably be presented in dietary supplements.  There 
may also be room to argue that the agency’s claim about “THC” is 
overbroad because it has approved only dronabinol (9-THC). 
Today, numerous companies sell hemp extracts that contain CBD, 
in interstate commerce.465  These products are positioned as dietary 
supplements and marketed illegally, as the FDA has explained in 
various Warning Letters.466  For instance, the agency issued a Warning 
Letter in October 2017 to Stanley Brothers Social Enterprises, which 
operates as “CW Hemp” and markets “Charlotte’s Web” through the 
internet.467  The FDA’s letter took the position that certain claims on 
the website (e.g., claiming the product’s “anti-tumoral” and “anti-
cancer” benefits) rendered Charlotte’s Web a “new drug” which may 
not be shipped in interstate commerce without an approved 
application.468  The company appears to have removed the drug claims 
from its website and promotional materials, focusing instead, for 
instance, on “a sense of calm and focus.”469  As of August 2018, 
however, it is still distributing Charlotte’s Web in interstate 
commerce.470  The company may be missing the second violation cited 
                                               
 462. See infra Part IV. 
 463. § 321(ff)(3)(B). 
 464. Marijuana Q&A, supra note 410. 
 465. See, e.g., Shop CBD, CHARLOTTE’S WEBTM HEMP EXTRACT, 
https://www.cwhemp.com/all-charlottes-web-cannabinoid-hemp-cbd-supplements 
(last visited Feb. 5, 2019). 
 466. The FDA issues a Warning Letter when it finds significant violations of the 
statute, which it defines as “violations that may lead to enforcement action if not 
promptly and adequately corrected.”  FDA, REGULATORY PROCEDURES MANUAL § 4-1-1 
(2018), https://www.fda.gov/downloads/iceci/compliancemanuals/regulatoryproc 
eduresmanual/ucm074330.pdf. 
 467. Warning Letter from FDA to Stanley Brothers Social Enterprises, LLC (Oct. 
31, 2017) [hereinafter Stanley Warning Letter], https://www.fda.gov/ICECI/ 
EnforcementActions/WarningLetters/2017/ucm583192.  Charlotte’s Web is a type of 
CBD manufactured by the Stanley Brothers.  See Our Company, CHARLOTTE’S WEBTM HEMP 
EXTRACT,  https://investors.cwhemp.com/our-company/default.aspx (last visited Feb. 5, 2019).  
 468. Stanley Warning Letter, supra note 467, at 3. 
 469. Charlotte’s Web Benefits:  What Charlotte’s Web Can Do For You, CHARLOTTE’S WEBTM 
HEMP EXTRACT, https://www.cwhemp.com (last visited Feb. 5, 2019). 
 470. Id. 
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in the Warning Letter because CBD has been the subject of new drug 
clinical trials (and in fact is now the subject of an approved new drug), 
and no company may distribute dietary supplements containing 
CBD.471  In other words, either the disease claim or the presence of 
CBD is sufficient to trigger enforcement action.  A Warning Letter does 
not commit the FDA to enforcement action, but the recent approval 
of a new drug containing CBD (discussed in Part IV) could prompt the 
agency to act without further notice.472   
Second, any dietary supplement containing a non-excluded 
cannabis constituent must be sold to consumers in a form intended for 
ingestion.473  This means a tablet, capsule, powder, softgel, liquid, or 
another ingestible form that is not represented as conventional food 
or as a meal replacement.474  Further, no dietary supplement can be 
represented for use as a conventional food or meal replacement.475  
This precludes putting a cannabis constituent in a conventional food 
(such as a brownie) that is then recharacterized as a dietary 
supplement.  It should be possible to market “edible” dietary 
supplements containing cannabis constituents, but it is important to 
avoid the appearance of a conventional food as well as the use of any 
terms (such as “beverage”) in the labeling that would cause the FDA to 
categorize the product represented as a conventional food.476  And 
because a dietary supplement must be intended for ingestion, it is not 
possible to present a cannabis-based product in a form that cannot be 
ingested—such as an inhaler, gel, or patch—and characterize that 
product as a dietary supplement.477 
                                               
 471. Stanley Warning Letter, supra note 467, at 2. 
 472. REGULATORY PROCEDURES MANUAL, supra note 466, § 4-1-1 (2018) 
(“violations . . . may lead to enforcement”) (emphasis added); see also infra Part IV. 
Indeed, after Congress removed hemp from the Controlled Substances Act in 
December 2018, the FDA issued a statement noting the “proliferation” of products 
containing cannabis-derived substances, reminding the public that it is unlawful to 
market CBD in dietary supplements, and promising to take any enforcement action 
needed.  See Statement on Signing of the Agriculture Improvement Act, supra note 49. 
 473. See 21 U.S.C. § 321(ff)(2)(A)(i) (2012). 
 474. Id.; see also § 350(c)(1)(B); United States v. Ten Cartons, Ener-B Nasal Gel, 888 
F. Supp. 381, 396 (E.D.N.Y. 1995). 
 475. § 321(ff)(2)(B). 
 476. See generally FDA, GUIDANCE FOR INDUSTRY:  DISTINGUISHING LIQUID DIETARY 
SUPPLEMENTS FROM BEVERAGES (2014), https://www.fda.gov/downloads/Food/Guid 
anceRegulation/GuidanceDocumentsRegulatoryInformation/DietarySupplements/
UCM381220.pdf. 
 477. See 21 U.S.C. §§ 321(ff)(2)(A)(i), 350(c)(1)(B). 
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Third, a company pursuing this strategy would probably need to 
submit a premarket notification to the FDA with results from 
premarket safety testing.  This is because a cannabis constituent 
(including a non-excluded cannabinoid) would probably be 
considered a “new dietary ingredient.”  If the substance had been 
marketed in dietary supplements before October 15, 1994, it would not 
be considered a new dietary ingredient.478  But the agency requires 
rigorous documentation of prior marketing—such as business records, 
mail-order catalogs, magazine advertisements, and sales contracts.479  It 
is unlikely that sufficient evidence would exist for any substance 
derived from cannabis, especially a cannabinoid other than 
dronabinol and cannabidiol.480  Any other dietary ingredient—one 
used in supplements for the first time after October 15, 1994—would 
be considered a “new dietary ingredient.”481 
Because a cannabis constituent would be a new dietary ingredient, 
there would be two bases for marketing it in a dietary supplement.  To 
begin with, a company could market a dietary supplement containing 
this new dietary ingredient if the dietary ingredient was previously 
present in the food supply “as an article used for food in a form in 
which the food has not been chemically altered.”482  The FDA 
interprets this to mean the ingredient was marketed in the same 
chemical form as a distinct conventional food or conventional food 
ingredient.483  A new cannabis constituent (other than dronabinol or 
CBD) would probably not satisfy this standard. 
In the alternative, a company could market a dietary supplement 
containing this new dietary ingredient if there was a “history of use or 
other evidence of safety” establishing that, when used according to the 
directions in its labeling, the ingredient will “reasonably be expected 
                                               
 478. 21 U.S.C. §§ 350b(a), 350b(d).  Any dietary ingredient marketed prior to that 
date is considered an “old” dietary ingredient and does not require a premarket 
notification.  But it must have been marketed as a dietary ingredient, meaning in or as 
a dietary supplement. NDI GUIDANCE, supra note 408, at 14. 
 479. NDI GUIDANCE, supra note 408, at 17–18.  The FDA also might not accept 
evidence relating to illegal marketing. 
 480. The FDA would not consider an ingredient’s previous marketing as a 
conventional food or marketing for non-food use as evidence that the substance was an 
old dietary ingredient.  Id. at 19.  Changes in the manufacturing process since 1994 would 
turn the dietary ingredient into a new dietary ingredient, if they altered the identity of 
the ingredient or changed its properties or even its purity or impurities.  Id. at 21. 
 481. 21 U.S.C. § 350b(d). 
 482. § 350b(a)(1). 
 483. NDI GUIDANCE, supra note 408, at 23, 25–26. 
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to be safe.”484  This would allow the company to test its cannabinoid to 
support its use as a dietary ingredient in a dietary supplement.  In this 
case, the company would submit a “new dietary ingredient 
notification” (“NDI notification”) at least seventy-five days before it 
planned to introduce the supplement to the market, providing the 
basis for its conclusion that the supplement satisfies the statutory safety 
standard.485  Although preparing an NDI notification is not as 
expensive and time consuming as preparing a food additive petition 
(let alone a new drug application), the burden is still significant.486  
The company would need to provide detailed chemistry information 
and a description of its manufacturing process, including analytical 
testing and specifications used.487  For a botanical drug, the agency 
would expect to see information about the conditions of propagation 
and cultivation, as well as production methods.  For an extract of a 
botanical, the agency would require additional manufacturing 
information (including, for instance, measures taken to control 
adulterants such as pesticides and heavy metals).  The amount of safety 
data required from testing in animals and humans would depend on a 
variety of considerations, such as whether the supplement was 
intended for daily chronic or intermittent use, whether there was 
documented historical use and the nature of that use, and the 
information from that historical use.488  In the absence of any history, 
the agency would generally require a battery of studies, some of which 
could last up to two years.489 
Fourth, a dietary supplement containing a cannabis constituent 
could not be the subject of a disease claim or health claim.  Any claim 
that the supplement could mitigate, treat, prevent, or cure a disease 
would render the supplement an unapproved new drug subject to 
enforcement action.490  Also, as noted, the FDA may permit “health 
claims” on dietary supplements if the standards for their inclusion are 
satisfied.491  But the agency is unlikely even to consider a health claim 
                                               
 484. § 350b(a)(2). 
 485. Id.  It is not necessary to wait for formal approval.  Many companies wait for a “no 
objection” letter, but it is legally permissible to wait for seventy-five days and then, in the absence 
of a response from the agency, begin marketing.  NDI GUIDANCE, supra note 408, at 50. 
 486. See generally NDI GUIDANCE, supra note 408, at 55–95 (describing what must be 
included in the notification). 
 487. Id. at 55–56. 
 488. Id. at 67, 72. 
 489. Id. at 77. 
 490. See 21 U.S.C. §§ 321(g)(1), (p) (2012). 
 491. See supra note 440. 
2019]THE SURPRISING REACH OF FDA REGULATION OF CANNABIS 901 
 
for a cannabis constituent.  It defines a health claim as one that 
characterizes the relationship of a “substance” to a disease or health-
related condition and defines a food “substance” as a specific food or 
component of food.492  Whether the substance occurs naturally in food 
or has been added, however, it must serve a traditional food purpose—
taste, aroma, or nutritive value (or a technical role such as 
preservation)—at the levels necessary to justify the health claim.493  
Cannabinoids are unlikely to satisfy this standard, although 
terpenoids, flavonoids, and other cannabis constituents might have 
nutritive value and qualify. 
Taking these four limitations into account, there is a limited path 
forward for dietary supplements.  It should be possible to market a new 
(non-dronabinol and non-CBD) cannabis constituent in an ingestible 
form as a dietary supplement, provided that:  (1) the product is not 
represented as a conventional food, and (2) premarket safety testing 
and premarket notification requirements have been satisfied.494  A 
company could not make disease claims or health claims with respect 
to a cannabinoid constituent, but it could possibly make 
“structure/function” claims (and maybe, although this would require 
the agency’s permission, which we view as unlikely, a health claim 
grounded in nutritive value) for other cannabis constituents.495  Unlike 
structure/function claims for conventional foods, structure/function 
claims for dietary supplements need not be based on the nutritive 
value of the supplement.496  The FDA does, however, carefully police 
the line between permissible structure/function claims and 
impermissible disease claims.  For example, it would not be permissible 
to refer to the symptom of a disease (such as pain associated with 
arthritis), nor would it be permissible to suggest that the supplement 
is a substitute for an approved drug.  The agency would likely permit a 
claim such as “helps to maintain a healthy appetite,” but it might not 
permit a claim such as “helps to maintain a healthy appetite during 
                                               
 492. 21 C.F.R. §§ 101.14(a)(1)–(2) (2018). 
 493. Food Labeling; General Requirements for Health Claims for Food, 58 Fed. 
Reg. 2,478, 2,480 (Jan. 6, 1993) (to be codified at 21 C.F.R. pts. 20 and 101). 
 494. See supra notes 463–93 and accompanying text. 
 495. Regulations on Statements Made for Dietary Supplements Concerning the 
Effect of the Product on the Structure or Function of the Body, 65 Fed. Reg. 1,000, 
1,000 (Jan. 6, 2000) (to be codified at 21 C.F.R. pt. 101) (adopting regulations 
governing permissible structure/function claims for dietary supplements). 
 496. Food Labeling; Requirements for Nutrient Content Claims, Health Claims, 
and Statements of Nutritional Support for Dietary Supplements, 62 Fed. Reg. 49,859, 
49,860–61 (Sept. 23, 1997) (to be codified at 21 C.F.R. pt. 101). 
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treatment for cancer.”497  Any structure/function claim would require 
substantiation.  The FDA applies the same standard as the Federal 
Trade Commission, meaning it expects “competent and reliable 
scientific evidence,” which it explains means “tests, analyses, research, 
studies, or other evidence based on the expertise of professionals in 
the relevant area, that has been conducted and evaluated in an objective 
manner by persons qualified to do so, using procedures generally 
accepted in the profession to yield accurate and reliable results.”498 
D.    The Possibility of Non-Regulation, with Caveats 
The preceding parts of this Article did not exhaust the possible ways 
cannabis could be commercialized after descheduling.  We note a few 
additional possibilities below and explain how they would be handled 
(if at all) by the FDA.499 
First, the cannabis flower might simply be sold for recreational 
smoking.  Purely intrastate transactions (in which the cannabis is 
grown, sold, and smoked within one state) would not trigger the FDA’s 
jurisdiction.500  This is true even if the seller made claims about using 
the cannabis to treat a disease or other health conditions.501  There is 
a solid argument that interstate transactions of cannabis only for 
                                               
 497. The FDA’s regulations prohibit claims suggesting that a product “treats, 
prevents, or mitigates adverse events associated with a therapy for a disease, if the 
adverse events constitute disease.”  21 C.F.R. § 101.93(g)(2)(ix) (2018).  The agency 
gives the example of “helps individuals using antibiotics to maintain normal intestinal 
flora” (impermissible disease claim) and “helps maintain healthy intestinal flora” 
(permissible structure/function claim).  65 Fed. Reg. at 1,029.  If the FDA concluded 
loss of appetite (anorexia) were a medical condition, it would not permit the claim 
described in the text. 
 498. Guidance for Industry:  Substantiation for Dietary Supplement Claims Made Under 
Section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act, FDA (Dec. 2008), 
https://www.fda.gov/food/guidanceregulation/guidancedocumentsregulatoryinfor
mation/dietarysupplements/ucm073200. 
 499. Additional possibilities might be inclusion of cannabis or ingredients derived 
from cannabis in animal drugs or animal food or feed.  Some of the rules governing 
animal food and drugs are similar to those applicable to human food and drugs, but 
there are additional considerations.  For instance, a food additive in animal feed can, 
if there is a residue remaining in the edible tissue of the animal, become an indirect 
food additive in human food, triggering the human food additive rules, which are 
different from the food additive rules for animal feed. 
 500. 21 U.S.C. § 355(a) (2012) (“No person shall introduce or deliver for 
introduction into interstate commerce any new drug, unless an approval . . . is effective 
with respect to such drug.”). 
 501. §§ 331(a)–(d) (specifically limiting prohibited acts to those in interstate commerce). 
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recreational smoking also would not trigger the FDA’s jurisdiction.502  
But if the seller (in interstate commerce) made claims about treating 
a disease or about affecting the structure or functioning of the body, 
the FDA would deem the cannabis a drug.503  Thus, claims that smoking 
the cannabis would promote relaxation, mitigate insomnia, reduce 
anxiety, or maintain the appetite would turn the cannabis into a 
regulated drug.  In the absence of these claims, the agency might try 
to assert its drug authorities on the theory that the product’s design or 
the circumstances surrounding its use demonstrated its intended use 
as a drug.504  But doing so would be controversial. 
Second, the same analytical framework would apply if a cannabis oil 
were marketed as a consumer product—for instance an essential oil 
sold for aromatherapy or with a vaporizer that can generate a mist for 
inhaling.  Such a product would not qualify as a dietary supplement 
because it is not intended for ingestion.505  For FDA purposes, it is 
either a drug or it is nothing.  If the product is associated with a disease 
claim or a structure/function claim and moves in interstate commerce, 
then the FDA will treat it as a drug—whether it appears in a soap, 
lotion, massage oil, or bottle for vaporizing.  The agency does not 
prioritize enforcement with respect to structure/function claims (such 
as “helps you sleep”) on essential oils like lavender because the risk to 
consumers is negligible.  But its calculus would change for a cannabis 
                                               
 502. The FDA would have jurisdiction only if the intended use of the cannabis 
triggered the agency’s drug authorities under § 201(p).  And intended use usually turns 
on claims made in labeling, advertising, and other promotion.  See supra Section III.A. 
 503. See § 321(g) (defining “drug”). 
 504. See infra Section IV.A (discussing the government’s reasoning that nitrous 
oxide balloons distributed at a rock concert constituted “drugs” due to the 
circumstances surrounding their distribution).  The FDA might also try to rely simply 
on the company’s knowledge that consumers use its product for medical purposes.  See 
21 C.F.R. § 201.128 (2018) (“But if a manufacturer knows, or has knowledge of facts 
that would give him notice, that a drug introduced into interstate commerce by him is 
to be used for conditions, purposes, or uses other than the ones for which he offers it, 
he is required to provide adequate labeling for such a drug which accords with such 
other uses to which the article is to be put.”).  The “knowledge prong” of the intended 
use regulation has been controversial for more than sixty years, however.  It faces 
substantial opposition from regulated industries, and it is seldom used (at least, not 
without other evidence as well).  E.g., Medical Information Working Group Citizen 
Petition, No. FDA-2013-P-1079, at 17–19 (Sept. 3, 2013), http://www.miwg.org/sites/ 
default/files/7%20MIWG%20Citizen%20Petition%20%282013%29%2C%20Docket
%20No%20FDA-2013-P-1079.pdf. 
 505. See 21 U.S.C. § 321(ff)(2)(A)(i) (defining “dietary supplement” as “a product 
that is intended for ingestion”). 
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constituent product that actually affected the functioning of the body.  
The agency would likely take enforcement action if the manufacturer 
made drug claims.  It is also possible the agency would find an intended 
drug use even without claims—based on the company’s knowledge of 
actual use in the market or perhaps its design.506 
Third, a company might place a cannabis constituent in a cream or 
lotion (or another similar topically applied product) and position the 
product as a cosmetic.  An item is a “cosmetic” for FDA purposes if it is 
intended for “cleansing, beautifying, promoting attractiveness, or 
altering the appearance” or if it is a component of such an item.507  
Cosmetics are less heavily-regulated than food and drugs.508  As always, 
any disease or structure/function claim would turn this item into a 
drug, even if the item also satisfied the definition of cosmetic.509  Thus, 
a skin oil with a cannabis extract would be regulated as a cosmetic and 
as a drug if the labeling made a disease claim.  But if the company 
made no claims about the presence of the cannabis constituent and 
genuinely marketed the product for cosmetic purposes, the agency 
might leave the company alone.510  This could change if the cannabis 
constituent had an impact on the structure or function of the body; for 
instance, if it was systemically absorbed and biologically active.511  The 
FDA has occasionally asserted that it could infer a supposed cosmetic’s 
intended drug use from its active ingredients.512 
                                               
 506. 21 C.F.R. § 201.128; see also supra note 406 and accompanying text. 
 507. 21 U.S.C. § 321(i). 
 508. The FDCA prohibits various acts relating to cosmetic misbranding and 
adulteration, which allow the agency to take enforcement action in a variety of 
situations, including when a cosmetic contains a “deleterious substance which may 
render it injurious” when used as directed.  § 361(a). 
 509. See supra notes 435–37 and accompanying text. 
 510. If a company simply removed the drug claims from its product and attempted 
to position the resulting product as a cosmetic, without correcting consumer 
impressions and perhaps even with disclaimers, FDA might still find a drug intended 
use.  See United States v. Undetermined Quantities of an Article of Drug Labeled as 
“Exachol,” 716 F. Supp. 787, 791 (S.D.N.Y. 1989) (“Courts have recognized that where 
years later customers purchase a product in reliance on the therapeutic claims of the 
previous literature marketed with that product, the court may use such literature to 
determine the intent in marketing the product despite a later disclaimer”); see also 
Zettler, supra note 249, at 1958 n.143. 
 511. For a discussion of FDA regulation of structure/function claims, see supra 
notes 435–37 and accompanying text. 
 512. E.g., Warning Letter from FDA to Lifetech Resources LLC (Apr. 18, 2011), 
https://wayback.archive-it.org/7993/20170111100914/http:/www.fda.gov/ICECI/E 
nforcementActions/WarningLetters/2011/ucm251951.htm (stating that the 
“presence of the prostaglandin analog . . .  along with appearance claims such as 
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Finally, a company might add cannabis to a currently-marketed 
tobacco product or add a cannabis extract to that tobacco product—
for instance, a cigarette.  In this case, the cannabis (or extract) would 
be considered a tobacco additive.513  The tobacco product itself, now 
modified with a new additive, would be considered a “new tobacco 
product” subject to a premarket approval requirement unless an 
exemption applied.514  Separately, the FDCA provides that once an 
item satisfies the definition of “tobacco product,” it cannot be sold in 
combination with any other product regulated under the FDCA.515  Put 
another way, dual classification (as a tobacco product and a new drug, 
for instance) is not permissible.  This provision would be triggered if the 
company made any claims about the new ingredient that triggered a 
different FDA regulatory authority.516  The FDA gives the example of 
adding a mouthwash (which might be a drug or a cosmetic) to the 
ingredients of a cigarette and identifying the cigarette as containing 
mouthwash.517  Moreover, the definition of “tobacco product” excludes 
“an article that is a drug” under § 201 of the FDCA.518  As a result, if a 
company added cannabis or an extract to a cigarette and made 
structure/function claims, the product in question would be deemed a 
“drug” rather than a “tobacco product,” and would be a new drug 
marketed illegally without an approved NDA.  Indeed, the FDA might 
infer a drug intended use on the basis of the additive’s identity and actual 
use of the product—even in the absence of claims—with the same result. 
                                               
‘enhance the appearance of your lashes and brows’ . .  indicate that your products are 
intended to affect the structure or function of the body”); Cosmetic Products 
Containing Certain Hormone Ingredients; Notice of Proposed Rulemaking, 58 Fed. 
Reg. 47,611, 47 611 (Sept. 9, 1993) (to be codified at 21 C.F.R. pts. 700 and 701) 
(proposing a rule that would declare any cosmetic product containing more than a 
specified amount of pregnenolone acetate or progesterone was an unapproved new 
drug regardless of claims made). 
 513. 21 U.S.C. § 387(1). 
 514. §§ 387j(a)(1)–(2). 
 515. § 321(rr). 
 516. § 321(rr)(4). 
 517. FDA, DRAFT GUIDANCE FOR INDUSTRY AND FDA STAFF:  THE SCOPE OF THE 
PROHIBITION AGAINST MARKETING A TOBACCO PRODUCT IN COMBINATION WITH ANOTHER 
ARTICLE OR PRODUCT REGULATED UNDER THE FEDERAL FOOD, DRUG, AND COSMETIC ACT 4 
(Sept. 30, 2009), https://www.fda.gov/downloads/TobaccoProducts/Labeling/Rules 
RegulationsGuidance/UCM259896.pdf. 
 518. § 321(rr). 
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E.    Summary 
Any product containing a cannabis constituent will be regulated as 
a “new drug” by the FDA if the company responsible for the product 
makes claims about its medical uses and if the product (or any 
component of the product) crosses state lines.  This will, in turn, 
require the company to conduct a rigorous research program proving 
the product’s safety and effectiveness before the product can be 
launched in the market.  There is no reasonable pathway forward for 
conventional foods containing or comprising cannabis constituents if 
those foods (or any of their ingredients) cross state lines, with the likely 
sole exception of certain hemp seed ingredients that appear to be 
GRAS.  Any other cannabis constituent would need to be chemically 
distinct from those already under clinical investigation or approved as 
new drugs—such as dronabinol (synthetic 9-THC) and CBD—and 
either GRAS or an approved food additive.  It may be possible to 
market a cannabis product in traditional dietary supplement form 
(such as capsules) or another ingestible form (such as liquid drops) 
but, again, only if the cannabis constituents chemically distinct from 
those already under clinical investigation or approved as new drugs.  
Permitted dietary supplements could require several years of 
premarket safety testing and could not be marketed with medical 
claims, but it should be possible to claim that they support the healthy 
structure and functioning of the body.  The FDA derives its jurisdiction 
from statutory provisions, however, that expressly require the 
movement of products in interstate commerce.  This means the agency 
will not regulate cannabis grown, sold, and consumed entirely within 
the borders of a single state, even if that cannabis is sold with claims 
about treatment of disease.  So, too, with conventional foods and 
dietary supplements.  But if any ingredient (such as the gelatin used to 
make a capsule for a dietary supplement) travels in interstate 
commerce, the agency could—and likely would—assert its authority. 
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IV.   THREE PATHWAYS FOR FEDERAL LEGAL  
MEDICAL CANNABIS FOLLOWING DESCHEDULING 
Based on the analysis in Part III, the Authors believe that if cannabis 
and THC are descheduled, there are three pathways forward under 
FDA law for medical cannabis.   
A.    Medical Cannabis Providers Engaged in Purely Intrastate Operations 
The first pathway forward represents, in a sense, continuation of the 
traditional medical cannabis industry—sale of whole plant-based 
products, by small operations, to locally-based consumers.  Cannabis 
that is grown, sold, and used entirely within the borders of one state 
will not fall within the FDA’s jurisdiction.519  This is true even if the 
seller makes medical claims about the product and if those claims are 
made in media, such as on the internet, that are accessible outside the 
state.520  Not only does the FDA derive its power from the Commerce 
Clause, but the FDCA is drafted even more narrowly.521  It is not 
sufficient for the agency to find a connection with interstate 
commerce; it generally must also find that a product or component of 
the product traveled in interstate commerce.522   
But there are reasons to be cautious about this pathway.  To begin 
with, if the FDA is concerned about the claims made or about the safety 
of the product, it will strain to find a component that traveled in 
interstate commerce.  Any inactive ingredient will qualify.523  In 
addition, the agency takes the position that sale of a product in one 
state for consumer use in another state constitutes introduction of that 
product into interstate commerce.524  This will include not only online 
sales to residents of other states but in-person sales if the purchasers 
cross state lines.  Moreover, violation of the FDCA is a strict liability 
                                               
 519. See §§ 331(a)–(d) (specifically limiting prohibited acts to those in interstate commerce). 
 520. See generally § 331 (listing prohibited acts does not include making claims about 
a product in the media). 
 521. U.S. CONST. art. I, § 8, cl. 3. 
 522. 21 U.S.C. § 331. 
 523. § 321(f) (defining food to include any article “used for components” of 
another food); § 321(g) (defining a drug to include any “article intended for use as a 
component” of another drug). 
 524. Thus, for instance, the agency has taken enforcement action against dairy 
farms that sell raw milk (which cannot be sold in interstate commerce) to buyers 
residing in other states.  E.g., United States v. Organic Pastures Dairy Co., 708 F. Supp. 
2d 1005 (E.D. Ca. 2010) (enjoining dairy that sold raw milk to out-of-state customers). 
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offense;525 a seller’s ignorance of the purchaser’s out-of-state status 
would presumably be irrelevant.  This effectively places the burden on 
the medical cannabis business to ensure that transactions are purely 
intrastate.526  There is no real prospect for creative circumvention of 
the intrastate requirement, for instance through a “buyer’s club.”527  
The FDA is likely to view these as shams, much as it does interstate 
“cow-share” arrangements, which are an attempt to circumvent the 
prohibition on sale of raw milk in interstate commerce.528  Finally, the 
fact that the FDA has no jurisdiction over medical cannabis does not 
                                               
 525. See United States v. Park, 421 U.S. 658 (1975) (affirming the conviction of an 
individual unaware of the violation of law, following a jury instruction that stated “the 
individual is or could be liable under the statute, even if he did not consciously do wrong”). 
 526. This does not mean that advertising and promotion cannot reach persons out 
of state, including through the internet.  After all, the availability of medical cannabis 
in a state could prompt people to move into the state.  The FDA does not derive its 
statutory authority from the reach of advertising and promotion, but rather from the 
movement of products (or their components) in commerce. 
 527. Members of a buyer’s club pay membership dues to the organization, which 
provides items or services free of charge to its members.  The theory is that without 
purchasing transactions, shipments of products (such as a cannabis-derived drug or 
raw milk) from a club to its members across state lines do not constitute shipment in 
interstate commerce.  The FDA rejects this theory, reasoning that the FDCA does not 
“recognize an exception to . . . prohibited conduct based on the nature of the 
contractual arrangement between the distributor and consumer.”  E.g., Memorandum 
in Support of Government’s Motion for Summary Judgment, United States v. Allgyer, 
Civil Action No. 5:11CV02651 LS (Dec. 6, 2011), 2011 WL 7416103. 
 528. The sale of raw milk in one state for consumer use in another state constitutes 
introduction of raw milk into interstate commerce, in violation of FDA regulations.  See 
21 C.F.R. § 1240.61(a) (2018).  But more than half of the states in this country permit 
the sale of raw milk directly to consumers.  See State Milk Laws, NAT’L CONF. ST. 
LEGISLATURES (Aug. 29, 2016), http://www.ncsl.org/research/agriculture-and-rural-
development/raw-milk-2012.  Dairy farms in states that have legalized the sale of raw 
milk have attempted to avoid the prohibition on interstate shipments by establishing 
“cow-share” arrangements, pursuant to which consumers combine resources to 
purchase a cow.  Some states permit (intrastate) cow sharing arrangements, but the 
FDA views interstate cow sharing as a sham.  Cf. United States v. Allgyer, No. 11-02651, 
2012 WL 355261, at *3–5 (E.D. Pa. 2012) (enjoining a Pennsylvania dairy farm 
operator from delivering raw milk to individuals in other states who joined a buyer’s 
club that leased his cows).  Some dairy farms instead establish “farm-share” 
arrangements.  See Share Agreements:  Cowshares, Goatshare, Herdshares, 
Farmshares, REALMILK.COM (Nov. 26, 2003), http://www.realmilk.com/herdshares/ 
share-agreements.  In this case, the consumer shares ownership in the farm and 
receives profits in the form of raw milk.  The FDA would also view an interstate farm 
sharing arrangement as a sham. 
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mean that the product will be unregulated.  States such as Washington 
already regulate medical cannabis.529 
B.    Development of Pharmaceutical Products Containing  
Cannabis Constituents and Synthetic Cannabinoids 
The second pathway forward takes the classical Western approach of 
small molecule drug development for a product containing a cannabis 
constituent or a synthetic cannabinoid.  Indeed, the FDA has already 
approved several new drugs containing synthetic cannabinoids as well 
as one new drug containing CBD.  These approvals shed some light on 
what this second pathway might look like after descheduling. 
1. Synthetic cannabinoids 
The pharmaceutical industry turned to synthetic cannabinoid 
products in the early 1980s, perhaps in part because scheduling of 
cannabis under the CSA made it difficult to secure botanical raw 
materials for naturally-derived products.  Unimed Pharmaceuticals, 
later acquired by Solvay (now AbbVie), brought the first synthetic 
cannabinoid to market.  
Marinol capsules contain synthetic 9-THC, assigned the 
nonproprietary (generic) name “dronabinol.”530  Each capsule 
contains dronabinol dissolved in sesame oil with other inactive 
ingredients.531  Oral delivery of dronabinol presented manufacturing 
                                               
 529. See, e.g., WASH. REV. CODE § 69.51.080 (2018). 
 530. The nomenclature conventions of the International Union of Pure and 
Applied Chemistry (IUPAC) guide the generation of the chemical name for a drug. 
Under the FDCA, every drug also has an “established” name, which is a shorter simpler 
nonproprietary name and by convention appears in parenthesis after any brand name 
(typically trademarked) the manufacturer may have adopted for its product.  21 U.S.C. 
§ 352(e)(1) (2012); see also Use of Drug Name Terms Policy, FDA, https://www.fda.go 
v/drugs/developmentapprovalprocess/formssubmissionrequirements/electronicsub
missions/datastandardsmanualmonographs/ucm071638 (last updated Oct. 3, 2014).  
As a practical matter the established name is usually the drug’s “United States adopted 
name” (USAN) assigned by the USAN Council, a small group of individuals that 
includes a representative from the American Medical Association (AMA) as well as the 
FDA.  See USAN Council, AM. MED. ASS’N, https://www.ama-assn.org/about/united-
states-adopted-names/usan-council (last visited Feb. 5, 2019); Designated Names; 
Revocation of List of Official Names of Drugs, 49 Fed. Reg. 37,574 (Sept. 25, 1984) (to 
be codified at 21 C.F.R. pt. 299).  “THC” is an abbreviation for “tetrahydrocannabinol.”  
Dronabinol is the established name for 9-THC. 
 531. MACK & JOY, supra note 81, at 202; see also FDA, MARINOL PACKAGE INSERT § 11 
(Aug.  28, 2017), https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/0186 
51s029lbl.pdf. 
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and development challenges.  For instance, only a small fraction of the 
dronabinol present in a capsule reaches its target in the body, in part 
because it is not water soluble.532  In addition, dronabinol takes effect 
slowly, reaching its full effect in two to four hours after dosing.533  
These issues have led researchers to explore other routes of 
administration, including inhalation and sublingual products 
(administered under the tongue).534  To date, however, this research 
has not borne fruit.535  One complicating factor may have been that a 
faster onset of action, though desirable from a therapeutic potential, 
is associated with a higher potential for misuse.536 
Approval and commercial launch of Marinol took an unusually long 
time, but the factors driving delay would not affect a new cannabis-
derived drug after descheduling.  The FDA initially approved Marinol 
in May 1985 for “treatment of the nausea and vomiting associated with 
cancer chemotherapy in patients who have failed to respond 
adequately to conventional anti-emetic treatment.”537  The company 
supported approval with pivotal effectiveness data from 454 cancer 
patients who received a total of 750 courses of treatment.538  But the 
FDA took nearly four years to approve the NDA.539  After Unimed filed 
its NDA in June 1981, the agency took three years to issue an 
approvable letter, which it subsequently rescinded.540  The agency did 
not issue a final approval letter until the summer of 1985.541  Today, an 
                                               
 532. MACK & JOY, supra note 81, at 143. 
 533. Id. at 203. 
 534. Id. at 206. 
 535. See generally id. at 205–06. 
 536. Id. 
 537. Unimed’s Marinol Is Headed out of Group C and into the Marketplace, PINK SHEET 
(Jun. 10, 1985) [hereinafter Marinol into the Marketplace], https://pink.pharmaintelli 
gence.informa.com/PS008469/unimeds-marinol-is-headed-out-of-group-c-and-into-
the-marketplace. 
 538. FDA, MARINOL LABEL, NDA 18-651/S-025 AND S-026 6 (June 21, 2006), 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018651s025s026lbl.pdf.  
In these patients, the drug’s effectiveness varied, with the greatest benefit seen in 
patients receiving cytotoxic therapy with MOPP for Hodgkin’s lymphoma and non-
Hodgkin’s lymphoma.  Id. 
 539. Marinol into the Marketplace, supra note 537. 
 540. Unimed’s Marinol NDA Will Be Resubmitted, PINK SHEET (Nov. 12, 1984) 
[hereinafter Marinol Resubmitted], https://pink.pharmaintelligence.informa.com/ 
PS007485/unimeds-marinol-nda-will-be-resubmitted. 
 541. Marinol into the Marketplace, supra note 537.  While the NDA was pending, the 
National Cancer Institute—which had been deeply involved in the development of 
dronabinol by conducting or funding much of the preclinical and clinical work that 
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NDA for a new cannabinoid would be subject to user fees and would 
receive an “action date” for the FDA decision, typically eight or twelve 
months from submission.542  The launch of Marinol was further 
delayed when the DEA took an unusually long time to reschedule the 
drug from Schedule I to Schedule II, but this would not be a 
consideration if cannabis and THC were descheduled.543 
Marinol has also faced challenges in the marketplace.  The drug can 
cause adverse psychiatric reactions, such as exacerbation of mania, 
depression, and schizophrenia, and cognitive impairment.544  These 
side effects are dose dependent and may be more common in elderly 
patients, who are more likely to be undergoing cancer treatment in the 
first instance.545  Other central nervous system adverse reactions 
commonly noted in clinical trials have included paranoid reactions, 
abnormal thinking, confusion, amnesia, depersonalization, and 
hallucinations.546  Combined with the access restrictions inherent in 
scheduling, these considerations may have limited the product’s sales for 
its initial indication—treatment of nausea and vomiting due to 
chemotherapy.547  Reglan (metoclopramide) was also approved for relief 
                                               
supported approval—distributed the drug for free to more than 25,000 patients.  MACK 
& JOY, supra note 81, at 143–44; Marinol Resbumitted, supra note 540. 
 542. See 21 U.S.C. § 379h (2012).  The FDA’s current goals are to act within ten 
months of the sixty-day filing date for a standard application and within six months of 
the sixty-day filing date for a priority application.  FDA, PDUFA REAUTHORIZATION 
PERFORMANCE GOALS AND PROCEDURES FISCAL YEARS 2018 THROUGH 2022 4 
https://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/
UCM511438.pdf. 
 543. Roxane Will Begin Marketing Unimed’s Marinol in Early May, PINK SHEET (Apr. 7, 
1986), https://pink.pharmaintelligence.informa.com/PS009947/roxane-will-begin-
marketing-unimeds-marinol-in-early-may.  The delay at DEA stemmed in part from a 
related petition at the agency and the Administration’s initial plan, which was opposed 
by the American Medical Association, to deem off-label prescribing a violation of the 
Controlled Substances Act.  DEA Schedule II Prescribing Limitations for Dronabinol, PINK 
SHEET (Feb. 3, 1986), https://pink.pharmaintelligence.informa.com/PS009616/dea-
schedule-ii-prescribing-limitations-for-dronabinol; Marinol DEA Scheduling, PINK SHEET 
(Dec. 16, 1985), https://pink.pharmaintelligence.informa.com/PS009414/Marinol-
DEA-scheduling. 
 544. MARINOL PACKAGE INSERT, supra note 531, § 5.1. 
 545. Id.  §§ 5.1, 8.5; MACK & JOY, supra note 81, 143. 
 546. MARINOL PACKAGE INSERT, supra note 531, § 6.1. 
 547. MACK & JOY, supra note 81, at 144–45.  Indeed, the company estimated that 
rescheduling Marinol would increase sales 15 to 20 percent, and DEA did so in July 
1999.  Id.; see also Roxane/Unimed Marinol Now Refillable Following DEA Down-Scheduling, 
PINK SHEET (July 12, 1999), https://pink.pharmaintelligence.informa.com/PS034 
484/RoxaneUnimed-Marinol-Now-Refillable-Following-DEA-DownScheduling. 
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of nausea and vomiting due to chemotherapy and remained the standard 
of care despite significant side effects.548  And sales of Marinol for nausea 
and vomiting declined after the FDA approved Zofran (ondansetron) in 
January 1991 for essentially the same indication.549  Sales improved after 
the FDA-approved Marinol in December 1992 for treatment of anorexia 
associated with weight loss in patients with AIDS.550 
The other synthetic cannabinoid faced challenges in the market as 
well.  The FDA approved Eli Lilly’s Cesamet (nabilone) at the end of 
1985, the same year it approved Marinol.551  Nabilone is a synthetic 
cannabinoid similar to 9-THC,552 and it was similarly approved for 
treatment of nausea and vomiting associated with cancer 
chemotherapy.553  Lilly withdrew the drug from the market in 1989 for 
“commercial reasons,” but Valeant purchased the drug from Lilly in 
                                               
 548. Glaxo’s Zofran (Ondansetron) Approved for Prevention of Chemotherapy-Induced 
Nausea and Vomiting with “1-B” Rating After 27-Month Review at FDA, PINK SHEET (Jan. 7, 
1991), https://pink.pharmaintelligence.informa.com/ps018594/glaxos-zofran-ond 
ansetron-approved-for-prevention-of-chemotherapyinduced-nausea-and-vomiting-with-
1b.  The FDA had initially approved Reglan (for a different use) in 1979.  Biocraft, 
Quantum Pharmics and Colmed Labs Clear Metoclopramide Generics, PINK SHEET (Aug. 5, 
1985), https://pink.pharmaintelligence.informa.com/PS008721/biocraft-quantum-
pharmics-and-colmed-labs-clear-metoclopramide-generics. 
 549. MACK & JOY, supra note 81, at 144. 
 550. Id.  The new use was protected by seven years of orphan exclusivity.  Id.; see also 
21 U.S.C. § 360cc (2012) (providing seven years of exclusivity for an approved drug 
that was designated under § 360bb for a rare disease or condition).  Unimed supported 
this new use with the results of a randomized, double-blind placebo-controlled study 
involving treatment of 139 patients for six weeks.  MARINOL PACKAGE INSERT, supra note 
531, § 14.1; see also Unimed’s Marinol (Dronabinol) Gains Indication for Anorexia in AIDS 
Patients, PINK SHEET (Jan. 4, 1993), https://pink.pharmaintelligence.informa.com 
/PS021983/unimeds-marinol-dronabinol-gains-indication-for-anorexia-in-aids-patients. 
 551. Lilly’s Cesamet (Nabilone) Launch Awaits DEA Scheduling, PINK SHEET (Jan. 6, 
1986) [hereinafter Cesamet Await Scheduling], https://pink.pharmaintelligence. 
informa.com/PS009486/lillys-cesamet-nabilone-launch-awaits-dea-scheduling.  The 
FDA took more than two years to approve the NDA.  See id. (indicating an advisory 
committee meeting in April 1983).  Through a series of corporate transactions, 
Cesamet is now marketed by Mylan.  Cesamet, INFORMA:  PHARMA INTELLIGENCE, 
http://drugprofiles.informa.com/drug_profiles/5266-cesamet (last visited Feb. 5, 2019). 
 552. The structural formula for dronabinol is C21H30O2.  See MARINOL PACKAGE 
INSERT, supra note 531,  § 11.  The structural formula for nabilone is C24H36O3.  Cesamet 
Label, NDA 18-677/S-011, U.S. FOOD & DRUG ADMIN. 3 (May 15, 2006), 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018677s011lbl.pdf. 
 553. Cesamet Await Scheduling, supra note 551. 
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2004 and relaunched in 2006.554  Its failure in the marketplace may 
have been attributable to its narrow therapeutic window.555 
Recently, the FDA approved a quasi-generic dronabinol in a new 
dosage form.  Generally, a generic drug must have the same route of 
administration, dosage form, and strength as the innovative drug it 
copies.556  The FDA has approved four generic dronabinol products 
presented in oral capsules at the same strength as Marinol.557  Insys 
Development Company chose to pursue an oral solution, however, 
which it believed would allow it to “convert a large portion of the 
market” from the generic dronabinol capsules to its product.558  The 
FDA concluded a “human abuse liability study” would be needed,559 
however, which meant the company could not use the generic 
approval pathway.  Thus Insys Development Company submitted its 
application under a statutory provision that permitted the company to 
rely on the Marinol NDA and add its own data.560  The company’s data 
revealed that its oral solution had a higher potential for misuse, and 
there were more psychiatric adverse events in the oral solution group 
                                               
 554. Valeant Returns Synthetic Cannabinoid to USA, PHARMATIMES (May 17, 2006), 
http://www.pharmatimes.com/news/valeant_returns_synthetic_cannabinoid_to_usa
_996830.  The FDA refused to approve the Valeant labeling until the company added 
“class-related” safety information—regarding psychotomimetic effect—to the package 
insert.  Lee Szilagyi, Valeant Cesamet Slated to Hit Market in ‘Next Several Weeks,’ PINK SHEET 
(May 16, 2006), https://pink.pharmaintelligence.informa.com/PS064159/Valeant-
Cesamet-Slated-To-Hit-Market-In-Next-Several-Weeks?vid=Pharma&process. 
 555. Di Marzo, supra note 133, at 2. 
 556. 21 U.S.C. § 355(j)(2)(A)(iii) (2012). 
 557. See FDA, CTR. FOR DRUG EVALUATION & RES., ANDA No. 078292, 
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process
&ApplNo=078292 (last visited Feb. 5, 2019); FDA, CTR. FOR DRUG EVALUATION & RES., 
ANDA No. 078501, https://www.accessdata.fda.gov/scripts/cder/daf/index.c 
fm?event=overview.process&ApplNo=078501 (last visited Feb. 5, 2019); FDA, CTR. FOR 
DRUG EVALUATION & RES., ANDA No. 079217, https://www.accessdata.fda.gov/scripts 
/cder/daf/index.cfm?event=overview.process&ApplNo=079217 (last visited Feb. 5, 
2019); FDA, CTR. FOR DRUG EVALUATION & RES., ANDA No. 201463, 
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process
&ApplNo=201463 (last visited Feb. 5, 2019). 
 558. Bridget Silverman, Keeping Track:  FDA Nixes Medicure’s Aggrastat for STEMI, 
Approves Insys’ Syndros, PINK SHEET (July 10, 2016), https://pink.pharmaintelligence. 
informa.com/PS118719/Keeping-Track-FDA-Nixes-Medicures-Aggrastat-For-STEMI-
Approves-Insys-Syndros. 
 559. FDA, CTR. FOR DRUG EVALUATION & RES., APPLICATION NO. 05525ORIG1S000, 
CROSS DISCIPLINE TEAM LEADER REVIEW 5–6 (May 20, 2016) [hereinafter INSYS GENERIC 
DRONABINOL TEAM LEADER REVIEW], https://www.accessdata.fda.gov/drugsatfda_ 
docs/nda/2016/205525Orig1s000CrossR.pdf. 
 560. See 21 U.S.C. § 355(b)(2). 
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than in the oral capsule group.561  These findings could make the 
agency more cautious about differences in dosage form and route of 
administration as other companies move forward with cannabinoid 
drug products.  The FDA approved Syndros in July 2016, and DEA 
scheduled the drug in March 2017.562  It is not clear whether the sales 
have lived up to the company’s expectations.563 
2. Naturally derived CBD 
On June 25, 2018, the FDA approved an NDA for Epidiolex® (CBD) 
for the treatment of seizures associated with Lennox-Gastaut syndrome 
(LGS) and Dravet syndrome (DS) in patients two years of age and 
older.564  Both are extremely rare seizure disorders that can lead to 
developmental delays and intellectual disabilities.565  Epidiolex’s 
approval marked the first FDA approval of a new drug derived directly 
from the cannabis plant and attracted attention in the popular press.566 
                                               
 561. INSYS GENERIC DRONABINOL TEAM LEADER REVIEW, supra note 559, at 52–53.  
This led to placement in Schedule II instead of Schedule III.  Id. at 53. 
 562. Schedules of Controlled Substances:  Placement of FDA-Approved Products of 
Oral Solutions Containing Dronabinol in Schedule II, 82 Fed. Reg. 14,815 (Mar. 23, 
2017) (to be codified at 21 C.F.R. pt. 1308). 
 563. Initially, many insurer formularies did not include the drug.  The company has 
also faced unrelated legal challenges, including suits relating to its marketing of a 
fentanyl spray and the arrest of its former Chief Executive Officer.  See Todd Campbell, 
Why this Marijuana Stock Crashed 18.5% in August, MOTLEY FOOL (Sept. 5, 2017, 9:31 
AM), https://www.fool.com/investing/2017/09/05/why-this-marijuana-stock-
crashed-185-in-august.aspx.  At the end of 2017 the company characterized the roll-
out of Syndros as “controlled,” and its first quarter 2018 reports indicated sales had 
been flat.  Insys Therapeutics Reports First Quarter 2018 Results, GLOBENEWSWIRE (May 8, 
2018), https://globenewswire.com/news-release/2018/05/08/1498834/0/en/INS 
YS-Therapeutics-Reports-First-Quarter-2018-Results.html; Insys Therapeutics Reports 
Fourth Quarter and Full Year 2017 Results, FINANZEN.NET (Mar. 8, 2018), 
https://www.finanzen.net/nachricht/aktien/insys-therapeutics-reports-fourth-quarte 
r-and-full-year-2017-results-6020165. 
 564. FDA, EPIDIOLEX PACKAGE INSERT § 1 (June 25, 2018), 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf. 
 565. Shelly B. DeAdder, The Legal Status of Cannabidiol Oil and the Need for 
Congressional Action, 9 BIOTECHNOLOGY & PHARMACEUTICAL L. REV. 68, 68–69 (2016); 
Michael Cipriano, Epidiolex Advisory Committee Appears to Be Covering U.S. FDA’s Bases, but 
Liver Injury Concerns Persist, PINK SHEET (Apr. 17, 2018), https://pink.pharmaint 
elligence.informa.com/PS122921/Epidiolex-Advisory-Committee-Appears-To-Be-Cov 
ering-US-FDAs-Bases-But-Liver-Injury-Concerns-Persist. 
 566. See, e.g., Debra Goldschmidt & Susan Scutti, FDA Approves First Cannabis-Based 
Drug, CNN (June 25, 2018, 2:02 PM), https://www.cnn.com/2018/06/25/health/fda-
approves-first-cannabis-drug-bn; John Hudak, Opinion, The FDA Just Opened the Door to 
Transforming Marijuana Policy, WASH. POST (June 27, 2018), https://www.washingtonpo 
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Although approving a drug derived from cannabis was 
unprecedented, it is important to understand what the approval does 
and does not represent.  Because the FDA had already approved a drug 
containing synthetic 9-THC and a drug containing a THC-like 
ingredient, the primary significance of Epidiolex’s approval was the 
natural, rather than synthetic, origins of the ingredients.567  Nor was it 
new for the FDA to approve a drug with botanical origins.  The agency 
had approved numerous new drugs with highly-processed active 
ingredients that derived from natural sources, as well as two botanical 
NDAs made from less-processed botanical raw materials.568  The active 
ingredient of Epidiolex is a highly purified extract produced from the 
cannabis plant.569  The FDA did not deem this drug substance a 
botanical.570  Consequently, it did not treat the application as a 
botanical NDA, nor did it exercise the flexibility with respect to 
chemistry, manufacturing, and controls that botanical drugs have 
needed in the past.571  Thus, the precedent is not as significant as it 
might seem at the surface. 
In many respects, the Epidiolex application was unremarkable.  CBD 
shares almost none of the pharmacological features of dronabinol,572 
and the FDA’s controlled substances staff concluded—on the basis of 
preclinical and clinical data—that it does not have misuse potential.573  
                                               
st.com/opinions/the-fda-just-opened-the-door-to-transforming-marijuana-policy/201 
8/06/26/aeb9b628-7978-11e8-aeee-4d04c8ac6158; Matthew Perrone, Medical 
Milestone:  U.S. Oks Marijuana-Based Drug for Seizures, CHI. TRIBUNE (June 25, 2018, 4:19 
PM), http://www.chicagotribune.com/business/ct-biz-fda-epidiolex-marijuana-seizu 
re-drug-20180625-story.html. 
 567. See supra Section IV.B.1. 
 568. See supra Section III.A.2. 
 569. EPIDIOLEX PACKAGE INSERT, supra note 564, § 11. 
 570. FDA, CTR. FOR DRUG EVALUATION & RES., APPLICATION NO. 210365ORIG1S000, 
SUMMARY REVIEW 9 (June 22, 2018),  https://www.accessdata.fda.gov/drugsatfda_docs 
/nda/2018/210365Orig1s000SumR.pdf (noting the FDA Office of Product Quality 
described the drug “as a highly-purified drug substance from a plant source”). 
 571. See generally FDA, CTR. FOR DRUG EVALUATION & RES., APPLICATION NO. 
210365ORIG1S000, PRODUCT QUALITY REVIEW(S) (June 4, 2018) [hereinafter EPIDIOLEX 
PRODUCT QUALITY REVIEW(S)], https://www.accessdata.fda.gov/drugsatfda_docs/ 
nda/2018/210365Orig1s000ChemR.pdf. 
 572. FDA, PERIPHERAL & CENTRAL NERVOUS SYSTEM DRUGS ADVISORY COMM., FDA 
ADVISORY COMMITTEE BRIEFING DOCUMENT 12 (Apr. 19, 2018) [hereinafter FDA 
BRIEFING DOCUMENT], https://www.fda.gov/downloads/AdvisoryCommittees/Comm 
itteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryC
ommittee/UCM604738.pdf. 
 573. FDA, PERIPHERAL & CENTRAL NERVOUS SYSTEM DRUGS ADVISORY COMM., FDA 
BRIEFING DOCUMENT:  NDA 210365 CANNABIDIOL 55 (Apr. 19, 2018) [hereinafter NDA 
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It does not attach to cannabinoid receptors or other neural receptors 
associated with misused drugs, and it did not induce overt behaviors 
like those induced by drugs like dronabinol.574  The NDA contained 
exactly what one would expect to see in any application for a drug 
intended to treat a serious but rare condition.575  The applicant 
demonstrated effectiveness through two randomized placebo-
controlled studies in LGS and one single randomized placebo-
controlled study in DS, together enrolling 516 patients.576  A signal of 
drug-induced liver injury emerged in the clinical trials and expanded 
access program, which necessitated a more detailed evaluation of liver 
safety prior to approval.577  The reviewers found that administration of 
the drug to the target population in controlled clinical trials, as well as 
in the expanded access program, was causally associated with 
elevations in liver enzymes consistent with drug-induced injury to liver 
cells.578  Actual cases of severe hepatocellular injury, however, did not 
occur.579  They were therefore unable to reach a conclusion on the risk 
for chronic liver injury.580  The advisory committee voted unanimously 
that the benefit-risk ratio of cannabidiol was favorable for treating 
                                               
210365 BRIEFING DOCUMENT], https://www.fda.gov/downloads/AdvisoryCommittees 
/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAd
visoryCommittee/UCM604736.pdf; see also supra notes 559–61 and accompanying text 
(noting research that found potential for abuse in dronabinol oral solution). 
 574. NDA 210365 BRIEFING DOCUMENT, supra note 573. 
 575. The company also benefitted from fast-track status and rolling review.  See FDA 
BRIEFING DOCUMENT, supra note 572, at 42.  Fast track is meant to “facilitate 
development and expedite review of drugs to treat serious and life-threatening 
conditions” so that drugs that meet unmet medical needs can more quickly reach 
consumers.  FDA, GUIDANCE FOR INDUSTRY:  EXPEDITED PROGRAMS FOR SERIOUS 
CONDITIONS—DRUGS AND BIOLOGICS 9 (2014), https://www.fda.gov/downloads/Drug 
s/Guidances/UCM358301.pdf.  The designation entitles the company to more 
frequent meetings with the agency to discuss the development plan and may allow the 
company to submit its application piecemeal as it completes each section (thus, a 
“rolling” submission).  Id. at 9–10.  The FDA will review the pieces as they arrive, rather 
than waiting for a complete application, which allows the applicant to address issues 
earlier and should, in theory, allow for earlier approval.  In this case, the agency agreed 
to fast track designation in June 2014, agreed to the rolling submission in July 2016, 
and received the final pieces of the NDA from the applicant in October 2017.  FDA 
BRIEFING DOCUMENT, supra note 572, at 42. 
 576. FDA BRIEFING DOCUMENT, supra note 572, at 43. 
 577. NDA 210365 BRIEFING DOCUMENT, supra note 573, at 7. 
 578. Id. at 51. 
 579. Id. 
 580. Id. at 52. 
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seizures associated with LGS and DS,581 and the FDA approved the 
NDA on June 25, 2018.582 
Three aspects of this approval nevertheless hold lessons for other 
companies. First, even though the Office of New Drug Products 
concluded that the drug substance was not a botanical, it invited the 
Botanical Review Team to provide a review of the quality control 
process for the botanical raw material.583  Although this could have 
been an anomaly, it is also possible BRT will be involved in review of 
other drugs containing highly purified extracts from cannabis.  As a 
general rule, and as suggested in Part III, the BRT’s involvement will 
work in an applicant’s favor as these reviewers are more familiar with 
the complexity of botanically sources and more inclined to be 
flexible.584  Further, the written memorandum from the review officer 
reflects the team’s current understanding of the cannabis plant (as well 
as its history of medical use).585  Among other things, the 
memorandum acknowledges the “competing schools of thought on 
cannabis taxonomy” and seems to adopt the monotypic (single species, 
with subspecies) perspective.586  The memorandum, though brief, now 
constitutes a sort of informal “precedent” within the agency, which 
subsequent new applicants should review. 
Second, a substantial expanded access program involved more active 
patients than had enrolled in the pivotal trials.587  The FDA began to 
                                               
 581. FDA, CTR. FOR DRUG EVALUATION & RES., SUMMARY MINUTES OF THE PERIPHERAL 
AND CENTRAL NERVOUS SYSTEM DRUGS ADVISORY COMMITTEE MEETING 4 (Apr. 19, 2018), 
https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials
/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM606745
.pdf.  FDA’s advisory committees are composed of outside experts from the scientific 
community, as well as industry and consumer representatives.  What is an FDA Advisory 
Committee?, FDA, https://www.fda.gov/AboutFDA/Transparency/Basics/ucm222191 
(last visited Feb. 5, 2019).  They provide the agency with independent advice on issues 
relating to drugs, food, and other products, but their recommendations are not 
binding on the agency.  Id.  See generally Erika Lietzan, Advisory Committees at FDA:  The 
Hinchey Amendment and “Conflict of Interest” Waivers, 39 J. HEALTH L. 415, 419–24 (2006) 
(providing an overview of the development of FDA advisory committees).   
 582. FDA, CTR. FOR DRUG EVALUATION & RES., NDA APPROVAL:  NDA 210365 (June 
25, 2018), https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/210365 
Orig1s000Ltr.pdf. 
 583. See EPIDIOLEX PRODUCT QUALITY REVIEW(S), supra note 571. 
 584. See Botanical Review Team (BRT), FDA, https://www.fda.gov/AboutFDA/Cente 
rsOffices/OfficeofMedicalProductsandTobacco/CDER/ucm090946 (last visited Feb. 5, 2019). 
 585. EPIDIOLEX PRODUCT QUALITY REVIEW(S), supra note 571, at 8–10. 
 586. Id. at 9 (noting the polytypic (multi-species) perspective, a competing school of 
thought). 
 587. FDA BRIEFING DOCUMENT, supra note 572, at 52–53. 
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authorize physician-initiated expanded access programs in May 2013, 
more than a year before the company began its clinical trials.588  
Although the company “exerted no control over these programs” (and 
“site physicians were responsible for specific treatment plans and 
actions”), it submitted, and the agency considered, the safety data as 
part of new drug approval.589  These data related to “684 patients with 
DS, LGS, and a variety of severe epilepsy conditions.”590  The adverse 
events in the expanded access program were generally consistent with 
those from the controlled trials, but interpretation of safety results 
from expanded access is always complicated by the lack of controls and 
the variability in investigators.591  Because cannabis-based drugs are 
likely to be studied in a variety of serious and life-threatening 
conditions, requests for expanded access are likely to be a feature of 
many premarket programs, and the safety data from this use will be an 
important part of the agency’s review of any resulting NDAs.592 
Third, it is unclear how the approval of Epidiolex will affect 
companies already marketing CBD, and the uncertainty points to one 
of the most difficult challenges that companies and policymakers 
would face if cannabis were descheduled.  The FDCA does not permit 
the marketing of a dietary supplement containing the active ingredient 
of a new drug.593  So it is a federal crime to market dietary supplements 
containing cannabidiol, and it was already a federal crime when GW 
Pharmaceuticals was testing its product in clinical trials.  The agency 
has cited violation of the drug exclusion rule in warning letters to 
companies marketing cannabidiol, and it specifically points to the 
clinical trials of Epidiolex.594  But many of these products remain on 
                                               
 588. Id. at 12, 42–43.  The company submitted its IND in March 2014 and started 
clinical trials in October 2014.  Id. at 42. 
 589. NDA 210365 BRIEFING DOCUMENT, supra note 573, at 14–15. 
 590. Id. at 33. 
 591. FDA BRIEFING DOCUMENT, supra note 572, at 99–100. 
 592. The new “Right to Try” law will not affect the FDA’s ability to consider the 
safety data from expanded access programs, if the data are material to the benefit-risk 
ratio of the drug.  See Trickett Wendler, Frank Mongiello, Jordan McLinn, and 
Matthew Bellina Right to Try Act of 2017, Pub. L. No. 115-176, 132 Stat. 1372 (codified 
at 21 U.S.C. § 360bbb-0a (2012)).  The Act provides that the FDA “may not use a 
clinical outcome associated with the use of an eligible investigational drug pursuant to 
this section” unless it finds that use of the clinical outcome “is critical to determining 
the safety of the eligible investigational drug.”  § 360bbb-0a(c)(1). 
 593. See supra Section III.C. 
 594. See Warning Letter from FDA to Green Roads of Florida LLC (Oct. 31, 2017), 
https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2017/ucm58318
8; Warning Letter from FDA to Natural Alchemist (Oct. 31, 2017),  
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the market.  Epidiolex received orphan drug exclusivity, which 
precludes the FDA from approving cannabidiol for the same uses for 
seven years.595  This is intended to provide GW Pharmaceuticals an 
opportunity to recoup its research and development costs in the 
marketplace through exclusive sales.596  If the company loses sales to 
inexpensive cannabidiol dietary supplements, however, it may not be 
able to recoup the research and development costs.  The 
manufacturers and distributors of the dietary supplements could not 
make claims about treatment of seizures associated with LGS and DS, 
but consumers could nevertheless purchase the products, particularly 
if the price differential is substantial.597 
GW Pharmaceuticals could reasonable urge the FDA to act against 
unlawfully marketed dietary supplements, which compete directly with 
its product and undermine its orphan exclusivity.  But when KV 
Pharmaceuticals effectively did the same thing—secured approval and 
orphan exclusivity for a treatment that had previously been available 
to patients in a cheap unapproved form and asked the FDA to take 
action against the unapproved versions—outraged insurers, patients, 
and physicians went to the Federal Trade Commission and Congress 
for relief.598  So it is unclear whether the manufacturer of Epidiolex 
will press the FDA to take action.  The FDA might take more formal 
action on its own initiative, but it would likely be concerned about the 
same backlash.599  Perhaps the parents of children with DS and LGS 
                                               
https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2017/ucm58320
5; Warning Letter from FDA to Stanley Brothers Social Enterprises, LLC (Oct. 31, 
2017),  https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2017/uc 
m583192; Warning Letter from FDA to That’s Natural! Marketing & Consulting (Oct. 
31, 2017),  https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2017 
/ucm583197. 
 595. See FDA, APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE 
EVALUATIONS:  38TH EDITION A-11 (Cumulative Supp. 2018), https://www.fda.gov/ 
downloads/Drugs/InformationOnDrugs/UCM086233.pdf. 
 596. See 21 U.S.C. § 360aa(b) (noting “there is reason to believe that some 
promising orphan drugs will not be developed unless changes are made . . . to provide 
financial incentives to develop such drugs”). 
 597. See supra Section III.A.1 (explaining that a product will be deemed a drug if it 
is associated with drug claims). 
 598. Cathy Kelly, Makena Pricing Prompts Multi-Pronged Appeals:  FDA, FTC—Bayh 
Dole?, PINK SHEET (Mar. 21, 2011), https://pink.pharmaintelligence.informa.com 
/PS053233/Makena-Pricing-Prompts-MultiPronged-Appeals-FDA-FTC-ndash-BayhDole. 
 599. The agency is most likely to act if companies make claims that present a public 
health risk, for instance, claims about treatment of serious or life-threatening 
conditions that might cause patients to forego proven therapies.  See, e.g.¸ Michael 
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will prefer the assurance of safety and effectiveness that comes with 
FDA approval, but others may not. Other companies considering 
cannabis-based drug products will watch GW’s pricing and sales 
closely.  Whether these companies move forward will depend in part 
on the complexity and burden of the NDA approval process for the 
particular drug they are developing and on the likely market 
conditions after approval.  If cannabis is descheduled, these companies 
will also need to consider the risk of investing hundreds of millions of 
dollars into a new drug product only to find that their target patient 
population self-medicates with recreational cannabis. 
3. Current conventional drug research and development 
The descheduling of cannabis and THC could lead to a rapid growth 
in research to develop new drugs from cannabis simply because 
researchers would no longer struggle to obtain raw materials.600  A 
review of the medical literature from 1948 through March 2015 
uncovered twenty-eight randomized clinical trials for uses other than 
those for which Marinol and Cesamet are approved, including chronic 
pain, neuropathic pain, multiple sclerosis, Parkinson’s disease, 
Crohn’s disease, amyotrophic lateral sclerosis (ALS), and neurogenic 
symptoms.601  Today, a review of the Clinical Trial Registry on the 
National Institutes of Health indicates more than a dozen ongoing 
clinical trials examining the therapeutic potential of cannabis.602  The 
                                               
Cipriano, Gottlieb:  Epidiolex Approval Covers One Specific Cannabidiol Medication, Not 
Marijuana, PINK SHEET (June 25, 2018), https://pink.pharmaintelligence.informa. 
com/PS123363/Gottlieb-Epidiolex-Approval-Covers-One-Specific-Cannabidiol-Medic 
ation-Not-Marijuana (quoting the FDA Commissioner saying that the agency will “prioritize 
enforcement going forward” by focusing on situations where patients face “particularly 
significant harm because there’s otherwise effective, available therapy for those patients”). 
 600. As discussed in Part I, researchers are currently limited to NIDA cannabis from 
the University of Mississippi.  See supra notes 161–65 and accompanying text.  Many 
trials on the NIH website are taking place in other countries, however, which may 
enable them to use other strains depending on the laws in those countries.  
ClinicalTrials.gov, U.S. NAT’L INST. HEALTH:  U.S. NAT’L LIBR. MED., 
https://clinicaltrials.gov/ct2/home (last visited Feb. 5, 2019) (listing, in a search for 
“cannabis,” 294 studies completed or active studies outside of the United States). 
 601. Kevin P. Hill, Medical Marijuana for Treatment of Chronic Pain and Other Medical 
and Psychiatric Problems:  A Clinical Review, 313 J. AM. MED. ASS’N 2474, 2474 (2015). 
 602. See ClinicalTrials.gov, supra note 600. This search captured trials that are 
currently recruiting or enrolling, or active but no longer recruiting.  Id.  The clinical 
trial registry on the NIH website must include any clinical trial of a new drug that 
occurs in the United States or under an IND (including under an IND but in a foreign 
country) and that is not a phase 1 trial.  42 C.F.R. § 11.22 (2017).  In practice, it 
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ongoing trials generally focus on CBD and THC, presumably 9-THC, 
rather than other cannabinoids.603  And, like the trials uncovered in 
the historical literature review, current research focuses primarily on 
treatment of pain or neurological or psychiatric conditions.604  For 
instance, many are examining the effectiveness of cannabis-based 
products in treating pain associated with cancer, low back pain, or 
osteoarthritis of the knee.605  Some are considering use of cannabis-
based products for treatment of Tourette Syndrome,606 tremor 
associated with Parkinson’s Disease,607 and multiple sclerosis.608  Others 
                                               
includes many phase 1 trials as well.  This Article discusses the ongoing clinical trials 
that relate to new therapeutic uses.  Many other trials listed on the registry relate to 
cannabis—for instance, examining its safety and pharmacology, and its effect on 
driving, on sperm production, or breast milk.  See ClinicalTrials.gov, supra note 600. 
 603. See ClinicalTrials.gov, supra note 600.  Other cannabinoids are, however, being 
studied.  For example, Schrot and Hubbard reported in 2016 that a mixture of 
cannabidiol and tetrahydrocannabivarin was being tested for treatment of diabetes 
and metabolic syndrome.  Richard J. Schrot & John R. Hubbard, Cannabinoids:  Medical 
Implications, 48 ANNALS OF MED. 128, 137 (2016). 
 604. See Hill, supra note 601. 
 605. See, e.g., NCT02460692, Trial of Dronabinol and Vaporized Cannabis in Neuropathic 
Low Back Pain, CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show/NCT0246 
0692 (last updated Oct. 19, 2018) (describing a Phase 2 trial of vaporized cannabis or 
dronabinol in patients with low back pain associated with nerve injury to determine 
whether these drugs reduce spontaneous and evoked pain more than placebo); 
NCT02324777, Cannabinoid Profile Investigation of Vapourized Cannabis in Patients with 
Osteoarthritis of the Knee (CAPRI), CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct 
2/show/NCT02324777 (last updated Apr. 5, 2018) (describing a Phase 2 trial of 
vaporized finely ground herbal cannabis to asses analgesic dose response in patients 
with osteoarthritis of the knee); NCT03339622, Safety and Efficacy of Smoked Cannabis for 
Improving Quality of Life in Advanced Cancer Patients, CLINICALTRIALS.GOV, 
https://clinicaltrials.gov/ct2/show/NCT03339622 (last updated Feb. 8, 2018) 
(describing a Phase 3 trial of an inhaled cannabis product (dried pellet smoked with 
a titanium pipe) to improve quality of life and reduce pain intensity in patients with 
uncontrolled cancer pain and incurable malignancy). 
 606. See, e.g., NCT03247244, Safety and Efficacy of Cannabis in Tourette Syndrome, 
CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show/NCT03247244 (last updated 
Oct. 19, 2018) (describing a Phase 2 trial considering the safety and effectiveness of 
vaporized medical cannabis in treatment of adults with Tourette Syndrome). 
 607. See, e.g., NCT02818777, A Study of Tolerability and Efficacy of Cannabidiol on Tremor 
in Parkinson’s Disease, CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show 
/NCT02818777 (last updated Apr. 28, 2017) (describing a Phase 1/2 trial assessing 
the tolerability and efficacy of cannabidiol oral solution in patients with tremor from 
Parkinson’s Disease). 
 608. See, e.g., NCT03186664, The Role of Sativex® in Robotic-Rehabilitation (SARR), 
CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show/NCT03186664 (last updated 
June 14, 2017) (detailing a trial of Sativex (nabiximols) to assess its role in improving 
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are studying cannabis in treatment of psychiatric conditions such as 
obsessive-compulsive disorder609 or post-traumatic stress disorder.610  
Several trials are examining its use in treatment of agitation associated 
with dementia,611 and one is considering oral cannabinoid formulations 
in the treatment of behavioral problems in children and youth with 
autism spectrum disorder.612 
Where this research would lead, however, remains to be seen. 
Descheduling will make it easier to develop drug candidates in the 
laboratory and to conduct clinical trials.  But much of the current 
research is sponsored by academic researchers rather than 
biopharmaceutical companies, and this could remain true after 
descheduling.  And in any case, whether the results would lead 
experienced companies to invest in full blown premarket clinical 
                                               
motor outcome when coupled with robotic neurehabilitation training in multiple 
sclerosis patients). 
 609. See, e.g., NCT03274440, Effects of Marijuana on Symptoms of OCD (ECOS), 
CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show/NCT03274440 (last updated 
Nov. 9, 2018) (discussing a Phase 1/2 trial of smoked marijuana in differing 
concentrations of CBD and THC in patients with obsessive-compulsive disorder 
(OCD)); NCT02911324, Cannabinoid Medication for Adults with OCD, 
CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show/NCT02911324 (last updated 
Feb. 7, 2018) (explaining a Phase 1 /2 trial of nabilone in patients with OCD). 
 610. See, e.g., NCT02759185, Study of Four Different Potencies of Smoked Marijuana in 76 
Veterans with PTSD, CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show/ 
NCT02759185 (last updated Nov. 7, 2018) (describing a Phase 2 trial of smoked 
cannabis in four variations with differing levels of THC and CBD in military veterans 
with post-traumatic stress disorder (PTSD)); NCT02517424, Evaluating Safety and 
Efficacy of Cannabis in Participants with Chronic Posttraumatic Stress Disorder, 
CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show/NCT02517424 (last updated 
Apr. 18, 2018) (describing a Phase 2 trial of different potencies of vaporized cannabis 
to evaluate its safety and effectiveness in treatment of chronic treatment-resistant post-
traumatic stress disorder). 
 611. See, e.g., NCT03328676, The Effect of Cannabis on Dementia Related Agitation and 
Aggression, CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show/NCT03328676 
(last updated Feb. 23, 2018) (reporting a Phase 2 trial of oral cannabis oil to investigate 
its effectiveness and safety for treatment of subjects with agitation related to dementia); 
NCT02351882, Safety and Efficacy of Nabilone in Alzheimer’s Disease, CLINICALTRIALS.GOV, 
https://clinicaltrials.gov/ct2/show/NCT02351882 (last updated Aug. 10, 2018) 
(evaluating a Phase 2/3 trial of nabilone to assess its safety and effectiveness in treating 
agitation in patients with moderate to severe Alzheimer’s Disease). 
 612. See NCT02956226, Cannabinoids for Behavioral Problems in Children with ASD 
(CBA), CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show/NCT02956226 (last 
updated Aug. 7, 2018) (describing a Phase 2 trial of two oral cannabinoid formulations 
to assess their safety, tolerability, and effectiveness for behavioral problems in children 
and youth with autism spectrum disorder). 
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programs, in light of the likely challenges maintaining an exclusive 
position in the marketplace to recover research and development 
costs, remains to be seen. 
C.    Dietary Supplements 
The prospects for marketing medical cannabis in dietary 
supplement form are more complex, and the pathway is riskier.  It is a 
misimpression that dietary supplements are mostly unregulated and 
that labeling a product as a “supplement” is enough to mostly bypass 
the FDA framework. The most important restriction is that no dietary 
supplement may contain a constituent of cannabis that already appears 
in an approved drug or in a drug that is the subject of clinical trials.  
Although it is theoretically possible to avoid this by proving the 
substance was marketed (overtly) in dietary supplements or food 
earlier, the FDA takes such a conservative approach to this exception 
that, in our view, pursuing the exception is unlikely to be productive. 
A company that chose to move forward with another constituent (in 
a dosage form for ingestion) would need to submit information and 
data to satisfy the statutory safety standard.  It would also need to wait 
for seventy-five days or (if it was risk averse) wait for the agency to issue 
a “no objection” letter.  The catch, however, is that time is of the 
essence; once a clinical trial of the same constituent has begun and is 
made public, the dietary supplement route is legally foreclosed—even 
if the supplement company is in the middle of its safety tests or waiting 
for the FDA’s response.  Once the seventy-five days lapse or the agency 
issues a no objection letter, the company could market the dietary 
supplement nationally, including with structure/function claims.  But 
the agency polices structure/function claims vigorously, and we 
believe it would be especially vigilant with respect to cannabis-derived 
dietary supplements.  Finally, the full scope of the drug exclusion may 
be the subject of some dispute with the agency.  That CBD is excluded 
is clear, but whether the FDA would attempt to treat all THCs as the 
same for purposes of drug exclusion remains to be seen. The dietary 
supplement pathway would be much less expensive than the new drug 
pathway, but its availability is much less clear. 
The competitive landscape for a dietary supplement would also be 
very different.  Although expensive to develop, an approved new drug 
would benefit from exclusivity in the marketplace, because the FDA 
would be precluded from approving generic copies for a time.  
Depending on the disease being treated, the agency might also be 
precluded from approving other versions that were not generic copies.  
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A dietary supplement containing a constituent of cannabis, by way of 
contrast, could very rapidly become one of many in the marketplace. 
And without the ability to make disease-related claims, it could be 
difficult for one company to differentiate its product from others. 
CONCLUSION 
After descheduling, all three pathways should be available for 
medical cannabis products.  The relative distribution of products 
among these three pathways will turn on a variety of factors.613  Fully 
exploring those factors and the likely distribution is beyond the scope 
of this Article, but this Article makes a few preliminary observations 
here based on the discussion in Parts III and IV. 
Given the approval of Epidiolex, the Authors would expect smaller 
pharmaceutical companies to explore the development of highly 
purified cannabis constituents for rare diseases that are poorly treated 
today.  This will be particularly true if insurance coverage and 
protection from competing drug approvals will ensure a profitably 
exclusive market position for some time.  The Authors also expect the 
pharmaceutical pathway would be pursued for any cannabis 
constituent that (based on preliminary research) seemed likely to be 
highly effective, particularly for a chronic or common condition 
because robust clinical evidence and the imprimatur of FDA approval 
could lead in this scenario to blockbuster status. 
At the same time, some patient groups and caregivers have a strong 
preference for products that they perceive as more “natural” and 
“holistic,” which is likely to maintain a market base for traditional 
cannabis dispensaries.  Thus, particularly in states that have legalized 
medical marijuana and that have patient populations accustomed to 
the availability of cannabis from dispensaries, intrastate-only medical 
cannabis operations might flourish.  Intrastate dispensaries might also 
emerge in areas where consumers embrace complementary and 
alternative medicine, as well as areas where consumers are more 
suspicious of federal regulation. 
Use of the dietary supplement pathway is harder to predict.  It is 
possible this pathway will be commercially advantageous only when 
structure-function claims can be made.  The challenge is that the 
constituents must be new (not yet tested in drug trials), and yet claims 
                                               
 613. See, e.g., Lester Black, Legal Weed Isn’t the Boon Small Businesses Thought It Would 
Be, FIVETHIRTYEIGHT (Dec. 29, 2017, 6:00 AM), https://fivethirtyeight.com/fea 
tures/legal-weed-isnt-the-boon-small-businesses-thought-it-would-be. 
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must be substantiated with competent and reliable scientific evidence.  
Time to market will be of the essence, because of the drug exclusion rule, 
so these dietary supplements may reach the market first without claims.  
This pathway might be more common in situations where the physiological 
benefits are uncertain.  Concerns about the pricing of prescription drugs 
and consumer preferences for self-medication with products perceived to 
be more “natural” could also drive up usage of this pathway. 
